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ABSTRACT 
 
The signal transducer and activator of transcription (STAT) and protein inhibitor of STAT 
(PIAS) system represent an elegant regulatory mechanism of transcriptional control IN 
mammalian cytokine signalling. Abnormal activation of the system is associated with 
immune disorders and a large group of diverse tumours. PIAS3 is a multiple domain protein 
with distinct functions involved in regulation of cytokine-mediated gene activation pathways. 
Its over-expression significantly inhibits cell growth and renders cancer cells more sensitive 
to drugs. The objective of this study was to structurally and biochemically characterise the 
function of the PIAS3 protein using in silico, in vivo and in vitro analysis approaches. The 
conservation pattern of the PIAS protein family and critical conserved residues in the PINIT 
(Proline, Isoleucine, Asparagine, Isoleucine, Tyrosine) domain were identified. The PINIT 
domain model was generated based on the PINIT domain structure of yeast PIAS3 
homologue Siz1 and structural determinants in the PIAS3-STAT3 interaction were evaluated. 
Guided by the in silico findings, in vivo analysis of the localisation of the PIAS3, mutant 
derivatives of PIAS3 (PIAS3-L97A, PIAS3-R99N, PIAS3-R99Q), PINIT and acidic domain 
was conducted. PIAS3 was completely localised in the nucleus while PIAS3 mutants 
appeared to exhibit diffuse cytoplasmic distribution. The PINIT domain was predominantly 
localised in the nucleus with some apparent perinuclear staining while the acidic domain 
exhibited a predominantly perinuclear staining pattern. Further analysis of the PINIT domain 
and the effect of the mutants on PIAS3-STAT3 interaction were assessed by in vitro analysis. 
Guided by in silico analysis, the PINIT domain and mutant derivatives of PINIT domain 
(PINIT-L97A, PINIT-R99N, and PINIT-R99Q) were heterologously expressed in 
Escherichia coli and subsequently purified using a combination of immobilized metal affinity 
and size exclusion based chromatography. The size and structural elements of the PINIT 
domain and its mutants were characterised. The 23 kDa PINIT domain was found to exist as 
a monomer in solution and its secondary structure was shown to consist of 66 % β-sheets by 
fourier transformed infrared spectroscopy consistent with the generated homology model. 
Using surface plasmon resonance spectroscopy (SPR) the PINIT domain was shown to bind 
to STAT3 in a specific concentration dependent manner. Recombinant PINIT-L97A, PINIT-
R99N and PINIT-R99Q mutants, which exhibited similar structural integrity to the wildtype, 
were found to abrogate binding to STAT3. These findings suggest that these residues form 
part of a potential binding surface for stat3. In conclusion, this study has provided evidence 
iii 
 
that the PINIT domain is an important determinant of PIAS3 interaction with STAT3 and that 
the interaction is mediated by defined conserved residues directly involved in the PINIT-
STAT3 interaction. 
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CHAPTER 1 
 
LITERATURE REVIEW, PROBLEM STATEMENT AND OBJECTIVES 
 
The signal transducer and activator of transcription (STAT)/protein inhibitor of STAT (PIAS) system 
represents an elegant system of control of mammalian cytokine signalling. Abnormal activation of 
transcriptional factors such as STAT proteins is associated with immune disorders and is found in a 
large group of diverse tumours. PIAS3 regulates cytokine–mediated gene activation pathways and its 
overexpression significantly inhibits cell growth and also renders cancer cells more sensitive to 
drugs. This review captures the historic and current literature of the system, with a focus on Janus 
kinase (JAK)–STAT signalling, STAT3 and its natural regulator PIAS3. Critique of the available 
structure/function data provides a view of the problems and current knowledge gap. 
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1.1 INTRODUCTION 
Signal transducers and activators of transcription (STAT) are a family of transcription factors 
that activate gene transcription in response to a number of different cytokines (O'Shea, 1997; 
Leonard and O'Shea, 1998; Hoey and Grusby, 1999). STAT proteins are expressed in diverse 
mammalian tissues and have been implicated in oncogenesis. The STAT protein family 
consists of several members all encoded by separate genes theorised to have diverged from a 
single gene through several consecutive duplications into three genetic loci (Copeland et al., 
1995). STAT proteins share six conserved structural regions that mediate cooperative binding 
to multiple DNA sites (Xu et al., 1996; Vinkemeier et al., 1996). The protein inhibitor of 
activated STAT (PIAS) protein family is a group of nuclear proteins that modulate 
transcriptional activities of various transcriptional factors. PIAS proteins are expressed in 
multiple human tissues (Chung et al., 1997) that includes lungs and kidneys (Wible et al., 
1998). PIAS are multidomain proteins with distinct functions (Chung et al., 1997; Levy et al., 
2006; Yagil et al., 2009; Borghouts et al., 2010). PIAS proteins exist as splice variants of 
different PIAS isoforms and homologues were identified in animal, plant and yeast species 
(Johnson and Gupta, 2001; Takahashi et al., 2001; Zhao and Blobel, 2005; Cheng et al., 
2006). Many different proteins, in particular transcription factors interact with members of 
the PIAS family (Shuai and Liu, 2005). Various regions of PIAS proteins are involved in 
different protein–protein interactions (Liao et al., 2000). The JAK (Janus kinase)–STAT 
pathway is activated by cytokine binding to its receptor and STAT is phosphorylated; these 
activation pathways are tightly controlled by positive and negative regulators such as the 
PIAS proteins. Uncontrolled cytokine signalling is associated with immune disorders and 
large group of diverse tumours (Brantley et al., 2008). The focus of this study is on the 
structural and molecular determinants of PIAS3-STAT3 interaction.  
1.2 THE STAT PROTEIN FAMILY  
The STAT protein family consists of seven members (STAT1, STAT2, STAT3, STAT4, 
STAT5α, and STAT5β AND STAT6) all encoded by separate genes (Darnell et al., 1994; 
Zhong et al., 1994). Due to the conserved nature of the family members, it is assumed that 
they have diverged from a single gene through several consecutive duplications into three 
genetic loci (Copeland et al., 1995). In humans, the STAT genes were mapped into distinct 
chromosomes (Copeland et al., 1995). STAT3, STAT5α and STAT5β were mapped to 
chromosome 17 (bands q11–1 to q22), whereas STAT1 and STAT4 were mapped to 
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chromosome 2 (bands q12 to q33) (Yamamoto et al., 2003). In mouse, STAT1 and STAT4 
were located on chromosome 1 (band 1 C1.1) (Schindler et al., 1992; Yamamoto et al., 2003) 
and STAT2 and STAT6 were located on chromosome 10 (band 10 D3) (FU et al., 1992; Quel 
et al., 1995). STAT3, STAT5α and STAT5β were mapped to chromosome 11 (band 11 D) 
(Zhong et al., 1994a; Copeland et al., 1995; Shi et al.,1996; Levy et al.,1998). Although the 
expression patterns of STAT protein family members vary during cell development and in 
multiple tissue types, nevertheless, they are highly sequence conserved (Akira et al., 1999).  
1.2.1 STRUCTURE AND FUNCTION OF STAT3 PROTEIN 
STAT proteins share six structural regions Figure 1.1. The STAT3 N–terminal domain (ND) 
consist of 130 residues that mediate cooperative binding to multiple DNA sites (Xu et al., 
1996; Vinkemeier et al., 1996). The 4–helix bundle coiled–coil domain (CCD) (residues 130 
to 320) is immediately followed by the eight–stranded β–barrel forming the DNA binding 
domain (DBD) with residues 400–500 conferring DNA–binding specificity; however this 
domain is not sufficient for optimal DNA binding (Horvath et al., 1995). The DNA binding 
β–barrel domain is linked to the SH2 domain by a small helical domain, formed by two 
helix–loop–helix modules, called the „connector‟ domain. This domain shows structural 
similarity to calcium–binding domains. However, the loops of the connector domain are 
longer and the connector domain shows no structural similarity to SH3 domains as was 
previously suggested through sequence identity (Becker et al., 1998). Residues 600–700 
share homology with SH2 domains (SH2) and mediate dimerisation as a result of 
phosphotyrosine recognition (Shuai and Liu. 2005) and the transcriptional activation domain 
(Figure 1.1B). The phosphorylated tyrosine is located at the C–terminus and the position 
varies with family member (Figure 1.1A). In addition, the C–terminus is important for 
transcriptional activation, which can be regulated by serine phosphorylation (Wen et al., 
1995; Akira, 1999).  
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Figure 1.1 Schematic illustrations of STAT family members, their domains and structural features. A) 
N–terminal domain (ND); 4–helix bundle coiled–coil domain (CCD); β–barrel; connector; Src homology 
domain 2(SH2) and the tyrosine residue (Y) phosphorylation site indicated by a number in each particular 
schematic STAT protein (adapted from Akira, 1999). B) Schematic representation of STAT3 functional 
features; the N–terminal domain (residues 1–130) that mediates cooperativity in binding to multiple DNA sites; 
residues 400–500 confer DNA–binding specificity; Residues 600–700 share homology with Src–homology–2 
(SH2) domains and mediate dimerization as a result of phosphotyrosine; the phosphorylated tyrosine is located 
around residue Tyr 705; the C–terminus is important for transcriptional activation (adapted from Becker et al., 
1998). 
These distinct functional domains within the STAT molecules were identified by sequence 
comparisons, biochemical assays and mutagenesis. Upon receptor activation, a single 
tyrosine residue (Y705 in STAT3) is phosphorylated (Akira, 1999; Shuai, 2006). 
Recombinant C–terminal fragment of STAT3β (residues 127 to 722) was phosphorylated at 
Tyr 705 causing it to dimerize and bind to specific DNA oligonucleotides, thus enabling the 
crystal structure of the STAT3β homodimer bound to DNA to be determined (Figure 1.2A) 
(Becker et al., 1998). Braunstein et al. (2003) reported that the C-terminal STAT3β fragment 
(residues 127–722) occurred as a monomeric species to a greater extent compared to full 
length STAT3. These findings showed that the full length dimer is mostly mediated by N–
terminal domain interactions. This conclusion was substantiated by the crystal structures of 
unphosphorylated STAT1 and STAT5 which showed that the core fragment (residues ~130 to 
~680) formed a reciprocal dimer involving CCD and DBD (Mao et al., 2005; Neculai et al., 
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2005). Although different STAT proteins have similar domains, each has its unique structure 
and biochemical features and these differences directly correlate with their specific biological 
functions where STAT1 is a tumour suppressor whereas STAT3 is an oncogene (potential 
tumour promoter). 
 
Figure 1.2 Three-dimensional representation of STAT3β homodimer–DNA complex and DB domain 
residues. A) STAT3β homodimer–DNA–complex showing the N–terminal 4–helix bundle (hot pink), the β–
barrel domain (orange), the connector domain in and the SH2 domain and phosphotyrosine–containing region in 
yellow. Views are shown along the DNA axis running vertically Rendered in JmoL (www.jmol.org) (adapted 
from Becker et al., 1998). B) Three dimensional representation of the residues and DNA phosphate groups 
involved in STAT3β–DNA–complex formation in the first DNA strand, atoms are coloured by element where 
oxygen atoms (red), nitrogen atoms (blue), sulphur atoms (yellow) are colour coded and the rest of the atoms are 
in grey. C) Three dimensional representation of the residues and DNA phosphate groups involved in STAT3β–
DNA–complex formation with the second DNA strand, atoms are coloured by element where oxygen atoms 
(red) nitrogen atoms (blue) are colour coded and the rest of the atoms are in grey The Figures were rendered in 
UCSF Chimera 1.5 (Goddard, et al., 2005). 
 
STAT3 has been suggested to associate with PIAS3 protein through its DB domain and the 
CCD (Chung et al., 1997; Borghouts et al., 2010). Furthermore, the STAT3 DB domain has 
been implicated in the regulation of nuclear export in resting cells (Zhiyuan and Kone, 2004). 
The crystal structure determined by Becker et al. (1998) showed that the DB domain 
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residues, His 332, Lys 340 and Gln 344 formed polar contacts to the phosphate group of one 
DNA strand while residues Met 331 and Val 343 formed hydrophobic interactions with its 
backbone sugars. The base specificity was determined by residues Asn 466 (Figure 1.2B). 
The other stand of DNA was bound by residues Arg 382, Val 432, Ser 465 and Gln 469 
(Figure 1.2C). 
 
1.3  LOCALISATION, CO–LOCALISATION OF PIAS3 AND INTERACTING 
PROTEINS  
The PIAS protein family is a group of nuclear proteins that modulate transcriptional activities 
of various transcriptional factors. In particular, PIAS3 regulates the transcriptional activity of 
STAT3 by inhibiting its DNA binding (Chung et al., 1997). Basal amounts of PIAS3 were 
found to be expressed in the nucleus of the majority of epithelial and endothelial cells (Wang 
and Banerjee, 2004). Also, 100/103 of samples examined by Wang and Banerjee (2004) 
showed that PIAS3 is expressed in a variety of human tumours including lung, breast, 
prostate, colorectal and brain cancer. The subcellular localisation of PIAS3 in the nucleus in 
both resting cells and stimulated cells have been shown in many studies (Kotaja et al., 2002; 
Duval et al., 2003; Sonnenblick et al., 2004; Man et al., 2006; Yamashina et al., 2006; Peng 
et al., 2010) (Table 1.1). However, the cytoplasmic localisation of PIAS3 has also been 
shown in both stimulated and unstimulated cells (Table 1.1), while the localisation in both 
nucleus and cytoplasm was shown in NIH3T3 mouse foetal fibroblast cells by the work of 
Rödel et al. (2000). Interestingly, live imaging of human pulmonary epithelial cells (A549 
and H520) by Dabir et al. (2009) revealed PIAS3 trafficking from the cytoplasm to the 
nucleus and back into the cytoplasm after 30 minutes of stimulating the cells with epidermal 
growth factor (EGF). The findings were consistent with that of Man et al. (2006), where 
T47D breast cancer cells were stimulated with progesterone and PIAS3 was subsequently 
observed in both the cytoplasm and nucleus with predominant nuclear staining. However, 
HeLa cervical cancer cells under the same treatment were found to have complete nuclear 
localisation of PIAS3 (Man et al., 2006). 
It has been suggested that localisation of the PIAS3 in the cytoplasm and nucleus is largely 
dependent on the associating proteins, and therefore, co–localise with these various proteins. 
Microphthalmia transcriptional factor (MITF) is a basic helix–loop–helix leucine zipper 
(bHLH–Zip) DNA–binding protein (Hodgkinson et al., 1993). MITF and PIAS3 co–localised 
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in the nucleus in resting cells (Sonnenblick et al., 2004). Glucocorticoid receptor–interacting 
protein 1 (GRIP1) is a transcriptional factor, a member of steroid receptor co-activator family 
and interacts with PIAS proteins. Substitution of the sumoylation sites in GRIP1 impaired its 
co–localisation resulting in diminished co–localisation with androgen receptor (AR) (Kotaja 
et al., 2002). Duplin is a negative regulator of β–catenin–dependent T–cell factor (Tcf) 
transcriptional activity in the Wnt signalling pathway and was identified as a PIAS3 binding 
protein(Yamashina et al., 2006). Co-expression of Myc–Duplin with Flag–PIAS3 in COS 
(CV-1 (simian) in origin and carrying the SV40 genetic material) cells resulted in nuclear co–
localisation of the two proteins in punctate structures. Furthermore, biochemical 
immunoprecipitation assay indicated that HA–Duplin indeed formed a complex with Flag–
PIAS3 in COS cells (Yamashina et al., 2006). Other PIAS family members were also 
evidently localised in nuclear punctate structures where they co–localised with their 
associating proteins. Of note is Dnmt3a, which is one of the three mammalian DNA 
methyltransferates that plays a crucial role in transcriptional silencing among other functions. 
GFP–PIAS1 and GFP–PIASxα were found co–localised with Dnmt3a in punctate structures 
exclusively in the nucleus of NIH3T3 cells (Ling et al., 2003). PIASxα, PIASxβ, PIAS1 and 
PIAS3, which interact with the small ubiquitin–related modifier SUMO–1 and its E2 
conjugate, Ubc9 (Kotaja et al., 2002), were all found co–localised with SUMO–1 in COS–1 
cell nuclei in punctate structures (Kotaja et al., 2002). Trim32, a RING domain ubiquitin–
protein isopeptide ligase interacts and co–localises with PIASy and promotes PIASy 
ubiquitination and degradation (Albor et al., 2006). PIASy was shown to predominantly 
localise to the nucleus (Zoumpoulidou et al., 2004; Albor et al., 2006) and treatment with 
MG132 (Z-Leu-Leu-Leu-al is an inhibitor of proteasome) showed a reduction of nuclear 
localisation and accumulation in cytoplamic granules (Albor et al., 2006). PIASy co–localise 
with Trim32 concentrated around the nucleus (Reymond et al., 2001; Albor et al., 2006). 
Progesterone receptor (PR) is critical in cell proliferation and differentiation and its 
transcriptional activity is modulated by multiple protein co-factors. Endogenous PR was 
found to localise mainly in the nucleus and cytosol in the absence of progesterone treatment 
of T47D cells while PIAS3 resided mainly in the nucleus, as punctate structures (Man et al., 
2006). Treatment of T47D cells with progesterone resulted in complete translocation of 
liganded–PR from cytoplasm to the nucleus where it co–localised with PIAS3 in the dot-like 
structures (Man et al., 2006). 
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Of significance to this study is the PIAS3–STAT3 association, which was first shown by 
protein immunoprecipitation with anti–PIAS3 from IL–6 treated M1 mouse myeloid 
leukemic cells (Chung et al., 1997). The PIAS3 was shown to freely interact with 
unphosphorylated and phosphorylated forms of STAT3 (Kotaja et al., 2002) and its 
movement from the cytoplasm to the nucleus has been shown to depend on the 
phosphorylated or unpohosphorylated state of STAT3 transcriptional factor (Dabir et al., 
2009). However, Chung et al, (1997) and Borghouts et al, (2010) suggested that the PIAS3–
STAT3 complex was only formed with the phosphorylated STAT3 as it translocated to the 
nucleus. It was shown that interleukin-6/interleukin-6 receptor (IL–6/IL–6R) treatment 
induced STAT3 to localise in the nucleus with MITF and PIAS3 whereas STAT3–Y705F 
was detected predominantly in the cytoplasm. However, STAT3–C (a constitutive form) 
showed co–localisation with PIAS3 and MITF in the nucleus (Sonnenblick et al., 2004). 
Cells transfected with mutant STAT3-Y705F and stimulated for 10 minutes showed very 
little nuclear PIAS3 compared to the cytoplasmic compartment (Dabir et al., 2009). The 
translocation of proteins, in particular STAT3, upon cytokine stimulation, is critical for the 
control of cell growth and proliferation. 
Table 1.1 Localisation of PIAS3 in various cell lines. 
Cell line Localisation References 
NIH3T3 mouse 
foetal fibroblast 
–predominantly 
nucleus 
–cytoplasm 
Rödel et al., 2000 
Hep3B human 
heptoma cells 
–predominantly 
nucleus 
–cytoplasm 
Dabir et al., 2009 
COS–1 –complete nucleus 
localisation 
 Chung et al., 1997; 
Duval et al., 2003 
HeLa cervical cancer 
cells 
–predominantly 
nucleus 
–cytoplasm 
Man et al., 2006 
A549 and H520 
human epithelial 
cells  
–nucleus Rödel et al., 2000 
T47D 
Human ductal breast 
epithelial tumour 
cells 
–nucleus Man et al., 2006 
M1 cells 
mouse myeloid 
leukemic cells 
–predominantly 
nucleus 
–cytoplasm 
Chung et al., 1997 
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1.4  JAK–STAT SIGNALLING PATHWAY REGULATION 
 
JAK (Janus kinase)–STAT3 pathway is activated when a cytokine binds to its receptor 
leading to receptor phosphorylation. This site will then act as a docking site to recruit latent 
cytoplasmic STAT3. The STAT3 is phosphorylated by JAK and subsequently dimerises and 
leaves the receptor to translocate to the nucleus where it directs gene activation (Darnell et 
al., 1994; Levy et al., 2002). The JAK–STAT3 pathway can also be activated by growth 
factor receptors and certain kinases including IL–6, 10, FGFR (fibroblast growth factor), 
HGFR (hepatocyte growth factor also known as MET), VEGFR (VEGF receptor), EGF 
(epidermal growth factor), and PDGF (platelet–derived growth factor) (Darnell et al.,1994). 
Also, oncoproteins such as Src (sarcoma) and Abl (Abelson murine leukemia viral oncogene) 
are activators of STAT3 in the JAK–STAT3 signalling pathway. The cytokine IL–6 is a 
major systematic mediator of the acute phase response to infection and injury, which includes 
increased production of acute phase plasma proteins by the liver (e.g. fibrinogen, c–reactive 
proteins, α1–antichymotrysin) and enhanced immune function, increased B–cell 
differentiation and T–cell activation (Sehgal et al., 1989; Mickiewicz et al., 1995, 1998). IL–
6 binds to the α–chain of the gp130 receptor to form a binary complex thereby inducing 
dimerisation of gp130. This dimerisation induces the activation of JAK family tyrosine 
kinases, (primarily JAK1, also JAK2 and Tyk) (Darnell et al., 1994, Heinrich et al., 1998) 
associated with the cytoplasmic tail of gp130, by tyrosine phosphorylation of the JAK kinases 
thus leading to their activation. Six discrete docking sites are created on the gp130 receptor 
by activated JAK kinases. These sites are proposed to recruit monomeric STAT3 in the 
cytoplasm via the SH2 domain of STAT3 (Heinrich et al., 1998). The event is followed by 
tyrosine phosphorylation of STAT3 (Tyr705) and subsequent dimerization and translocation 
into the nucleus allowing the dimeric STAT3 to bind target DNA motifs and modulate gene 
expression (Heinrich et al., 1998). 
JAK–STAT3 signalling pathway is down-regulated at various steps (Shuai, 2000, 2006). 
SOCS (suppressor of cytokine signalling) can inhibit the JAK–STAT signalling pathway by 
inhibiting the tyrosine kinase activity of JAKs. Also, STAT signalling can be negatively 
regulated by PTPase (protein tyrosine phosphatase) by deactivating JAKs and STATs. In 
particular, protein tyrosine phophatase TC45 deactivates STAT1 by dephosphorylation of 
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STAT1 in the nucleus (Hoeve et al., 2002). PIAS proteins regulate the JAK–STAT pathway 
by inhibiting STAT transcriptional activation activity (Shuai and Liu. 2005; Shuai, 2000). 
PIAS proteins bind specifically to phosphorylated STAT dimers in the nucleus and prevent it 
from binding target DNA and thereby inhibiting STAT3–mediated gene activation. There is a 
specific PIAS inhibitor for each STAT signalling pathway (Liao et al., 2000). The regulation 
of the JAK–STAT3 signalling pathway is largely influenced by levels of either STAT3 or 
PIAS3 expression in any given cells. Furthermore, it is known that STAT protein arginine 
methylation (Mowen et al., 2001) affects the JAK–STAT pathway. Methylation of STAT1 
prevented its association with PIAS1 resulting in increased amount of STAT1 available for 
DNA binding and gene induction. 
 
 
Figure 1.3 Schematic representation of canonical JAK–STAT pathway activation. Cytokine binds to the 
cytokine receptor at the cell surface (1) and activates JAK by phosphorylation (2). The activated JAK kinases 
recruit monomeric STAT to the receptor and (3) phosphorylate STAT at defined tyrosine residues (4). The 
phosphorylated STAT dimerises and translocates to the nucleus (5) where it induces the transcription of target 
genes. (6). Inhibition of STAT transcriptional activity by PIAS protein results in inactivation (7). Numbers 
indicate the flow of pathway on JAK–STAT activation and arrows indicate the direction of protein movement 
(adapted from Wormald and Hilton, 2004). 
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1.5  THE ROLE OF PIAS AND STAT PROTEINS IN CANCER AND OTHER 
HUMAN DISEASES 
Cytokine–mediated gene activation pathways are tightly controlled by positive and negative 
regulators. Abnormal cytokine signalling is associated with cancer and immune disorders. 
STAT proteins activate transcription in response to numerous
 
cytokines controlling 
proliferation, gene expression, and apoptosis.
 
Aberrant activation of STAT3 and STAT5 
and/or loss of STAT1 signalling is found in a large group of diverse tumours including 
Glioblastoma multiforme (GBM) (Brantley et al., 2008).  
STAT proteins regulate many pathways important in oncogenesis including cell–cycle 
progression, apoptosis, tumour angiogenesis, and tumour–cell evasion of the immune system. 
The recent number of new cases of prostate cancer was estimated at 9,034,542 worldwide 
accounting for 7.1 % of all cancers (Globocan, 2008). Androgen plays an important role in 
the development and growth of prostate carcinoma (Kokontis and Liao, 1999). The 
transcriptional activity of AR is regulated by positive or negative transcriptional cofactors 
that include, PIAS1, PIAS3, and PIASy, which are expressed in the human prostate, and have 
distinct effects on AR–mediated gene activation in prostate cancer cells. While PIAS1 and 
PIAS3 enhance the transcriptional activity of AR, PIASy acts as a potent inhibitor of AR in 
prostate cancer cells (Mitchell et al., 1999). The N–terminal LXXLL signature motif of 
PIASy is essential for the trans–repression activity of PIASy (Mitchell et al., 1999). 
Cystic fibrosis (CF), a disease caused by a defective gene encoding a protein called the cystic 
fibrosis trans–membrane conductance regulator (CFTR) (Welsh et al., 1995), is characterised 
by chronic lung infection resulting in inflammation and progressive lung damage. Increased 
levels of PIAS1 interrupt normal STAT1 cell signalling pathways, resulting in reduced IFN 
regulatory factor–1 (IRF–1) and nitric oxide synthase–2 (NOS2) expression in CF epithelial 
cells because NOS2 and IRF–1 expression are dependent on the activation of STAT1. This 
reduction in NOS2 expression and subsequent reduction in nitric oxide (NO) production has 
been postulated to play a role in the abnormal regulation of trans–epithelial sodium 
absorption observed in CF and its associated characteristic of susceptibility to bacterial 
infection (Meng et al., 1998; Kelly and Drumm, 1998). Phosphorylated STAT1 was 
subsequently found associated with PIAS1 in CF epithelial cells (Kelly and Elmer, 2000). 
Lung cancer is the leading cause of death in adult men in Europe, the United States, and 
Japan. Lung cancer cells are relatively resistant to conventional chemotherapeutic drugs but 
undergo extensive apoptosis after treatment with pharmacological inhibitors of lipid kinase 
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(PI3–K/Akt) or Janus kinase (JAK/STAT) signalling pathways (Sordella et al., 2004). 
Treatment with LY294002, an inhibitor of phosphatidylinositol 3–kinase, retarded the growth 
of human lung cancer cells and rendered them more sensitive to chemotherapeutic agents 
(Ogata et al., 2006). Overexpression of PIAS3 not only significantly inhibited cell growth but 
also rendered cancer cells up to 12–fold more sensitive to the above drugs. However, the 
inhibition of JAK-STAT significantly suppressed cell growth but did not increase drug 
sensitivity (Ogata et al., 2006). 
It has been reported that PIAS1 can regulate the transcriptional activity of the tumour 
suppressor p53, the p53–related protein p73, and the p53 regulator MDM2 (mouse double 
minute 2 homologue) (Melino et al., 2003; Urist and Prives, 2002). The tumour suppressor 
protein p53 and its two homologues p63 and p73 activates overlapping as well as specific sets 
of genes that have important roles in the regulation of the cell cycle and apoptosis (Urist and 
Prives, 2002; Melino et al., 2003). Under normal conditions, p53 is short lived and undergoes 
proteasome-mediated degradation. After exposure to various forms of stress and DNA 
damage, p53 is activated by post–transcriptional modifications which lead to p53 
accumulation and downstream gene activation and ultimately cell–cycle arrest or apoptosis 
(Levine, 1997; Vousden and Prives, 2005). MDM2, which mediates negative–feedback 
control of p53, can repress the transcriptional activity of p53 and target it for degradation 
(Honda et al., 1997; Prives, 1998; Yang et al., 2004). It has been shown that PIAS1 and 
PIASx–β can promote the conjugation of SUMO to MDM2 in both in vivo and in vitro assays 
(Miyauchi et al., 2002).  
1.6 THE PIAS PROTEIN FAMILY: STRUCTURE AND FUNCTION  
 
The PIAS family members: PIAS1, PIAS2, PIAS3, PIAS4, PIASx (consisting of two splice 
variants: PIASxα and PIASxβ), and PIASy (Shuai et al., 1994) were initially identified in 
trying to understand the JAK–STAT signalling pathway (Chung et al., 1997; Liu et al., 
1998). The existence of splice variants of PIAS isoforms adds to the complexity of PIAS 
protein family. They belong to the second class of SUMO E3 ligases and their homologues 
were found in non–vertebrate animal species, plants and yeast, including a protein encoded 
by the Drosophila melanogaster gene Zimp and the Saccharomyces cerevisiae proteins Siz1, 
Siz2/Nfi1, Mms21, and Zip3 (Johnson and Gupta, 2001; Takahashi et al.,2001; Zhao and 
Blobel, 2005; Cheng et al., 2006). A single Drosophila PIAS-encoding gene termed Su (var) 
2–10 was shown to be a gene required for normal chromosome function (Hari et al., 2001). 
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This gene was described as zimp, has strong homology to the mammalian PIAS-encoding 
genes, and was named dPIAS/Zimp (Mohr and Boswell, 1999). Human Zimp10 and Zimp7 
may be more distantly related mammalian homologues of PIAS proteins (Beliakoff and Sun, 
2006). Nevertheless, evolutionary conservation suggests a common function which includes 
modulation of the activity of transcription factors either by protein–protein interactions or 
DNA binding or both. These two novel PIAS–like proteins contain the SP–RING/Miz 
domain (Sharma et al., 2003; Huang et al., 2005) resulting in the names Zimp7 and Zimp10 
(Zinc finger containing, Miz–1, PIAS–like protein on chromosome 7 or 10). Other PIAS–like 
proteins such as the non–structural maintenance of chromosomes element 2 homolog (NSE2), 
zinc finger MIZ domain–containing protein 1 (ZMIZ1) or ZMIZ2, possess the PIAS RING 
(SP–RING) signature. KChAP (K+ channel associated protein) was discovered by yeast two–
hybrid screening using the rat brain cDNA library with full–length Kvβ1.2 subunit of the K+ 
channel as bait (Wible et al., 1998). The rat KChAP has high sequence identity with PIAS3 
and was termed PIAS3β to distinguish it from mouse PIAS3 (Wible et al., 1998). KChAP is a 
potassium ion channel protein that acts as a chaperone to enhance expression of Kv2.1 
protein and it belongs to the PIAS family (Chung et al., 1997). KChAP is homologous to 
PIAS3 and the two may be the products of alternative splicing of a single gene. KChAP 
contains an in–frame insertion of 35–amino acids at the N–terminal region (Kuryshev et al., 
2000) which is lacking in human PIAS3. The Kv channel binding region, KChAP–M, is 
present in both KChAP and PIAS3, suggesting that KChAP and PIAS3 may interact with the 
potassium ion channels (Kuryshev et al., 2000). 
1.6.1 PIAS Domains, Structure and Function 
Members of the PIAS family share a high degree of sequence identity. Overall, five different 
domains have been identified in the PIAS protein family, namely DNA binding scaffold 
attachment factor–A/B/ACINUS/ PIAS (SAP) domain (Okubo et al., 2004), PINIT (proline, 
isoleucine, asparagine, isoleucine, threonine) domain (Duval et al., 2003), a putative really 
interesting new gene (RING)–type zinc–finger binding domain (Hanson et al., 1991; 
Hochstrasser, 2001), a SIM (SUMO–interacting motif), and the serine/theroine–rich (S/T) 
acidic domain (Minty et al., 2000) (Figure 1.4). 
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Figure 1. 4 Schematic representation of the domains of PIAS family members and their orthologs. 
Illustration of the domain structures of the different human PIAS proteins from Homo sapiens and their 
orthologous PIAS proteins from S. cerevisiae are also shown. PIAS3 is shorter that PIAS3L by 35 amino acids 
depicted after the SAP domain of PIAS3. Also, the PIASyE6
– 
lacks the PINIT motif. Numbers on the left and 
right depict the first and last amino acid in each PIAS protein. SIM and S/T. SAP domain is in turquoise colour, 
the PINIT domain is in purple colour and SP-RING domain is in pink colour, a SIM is in green colour and the 
C-terminal domain is in yellow colour. (adapted from Rytinki et al., 2009).  
The S/T region is shorter in PIAS4 than in other PIAS proteins and the PINIT domain does 
not exist in the splice variant of PIASy (PIASyE6
–
). The splice variants PIASxα and PIASxβ 
have different lengths of the S/T region (Wu et al., 1997; Moilanen et el., 1999). Isoforms of 
PIAS3 and PIAS3L differ by a stretch of 35–amino acids between the SAP domain and the 
PINIT domain. The non–vertebrate PIAS orthologues essentially have the same motifs and 
domains as their mammalian PIAS counterparts.  
1.6.2 The SAP domain  
The sequence alignment of the four–helix SAP domain of PIAS1 and the SAP–domain of 
other PIAS family members (Figure 1.5) showed a high degree of sequence identity of 86, 
77, and 57% for PIAS3, PIASxa, and PIASy respectively. Therefore, it is likely that all of the 
N–terminal domains of the PIAS family adopt a four–helix bundle conformation (Okubo et 
al., 2004). 
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Figure 1.5 Sequence alignment of the SAP domains of the PIAS family members. Alignment of the C–
terminal domain sequences of PIAS protein family using CLUSTAL W software (Larkin et al., 2007). The 
numbers indicate the first and last residue in the particular sequence and the numbers at the top indicate the 
position of mouse PIAS3 residues. Shading represents the conservation of residues (scored according to 
Blosum62 score table). Identical residues are in red, and highly conserved residues are in blue, and of low 
residues conservation are in black. A black box indicates the SAP domain signature sequence LQVLL. 
Secondary structural elements for SAP domain are indicated below as helices and loops (L1, L2, and L3). The 
sequence accession numbers: PIAS3 Mouse (Mus musculus), AF034080; PIAS3 Homo (Homo sapiens), 
NP_006090.2; PIAS1 Mouse (Mus musculus), NP_062637.2; PIAS1 Homo (Homo sapiens), ABP49566.1; 
PIAS2 Homo (Homo sapiens), NP_004662.2; PIAS2 Mouse (Mus musculus), NP_032628.3; PIAS4 Mouse 
(Mus musculus), NP_067476.2; PIAS4 Homo (Homo sapiens), AAH10047.1.  
The N–terminal SAP domain is found in many chromatin–associated proteins and is involved 
in sequence or structure–specific DNA binding (Aravind and Koonin, 2000). The N–terminal 
SAP domain of PIAS1 was found to be a four–helix bundle with crossover loops connecting 
the two pairs of helices (Okubo et al., 2004) (Figure 1.6) and a putative DNA–binding motif 
involved in chromosomal organization (Romig et al., 1992). The SAP domain binds to 
adenine/thymine rich (A/T) chromosomal regions known as scaffolding or matrix–attachment 
region (SAR/MAR) (Romig et al., 1992) and performs a specific role in chromosomal 
organization that provide links between transcription repair, RNA processing and apoptotic 
chromatin degradation. The LXXLL signature sequence in the SAP domain has been shown 
to be important in the assembly of nuclear receptor co–activator complexes (Wu et al., 1997). 
The SAP motif is predicted to have a helix bundle with two amphipathic helices that plays a 
crucial role in helix–helix interaction. The solution structure of the N–terminal domain 
(residues 1–65) of PIAS1 was determined to be a four–helix bundle (Okubo et al., 2004) 
(Figure 1.6). 
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Figure 1.6 Three dimensional ribbon representation of the SAP domain of PIAS1. A four–helix bundle 
with a topology of an up–down–extended loop–down–up, a part of which the helix–extended loop–helix 
represents the SAP domain structure of PIAS. The indicated conserved leucine residues (Leu 18, Leu 22 and 
Leu 23) forms part of LXXLL motif which is the signature sequence of the SAP domain. The structure was 
determined by nuclear magnetic resonance spectroscopy (NMR) (PDB ID: 1v66) (adapted from Okubo et al., 
2004). 
 
The four–helix bundle adopts a topology of up–down–extended loop–down–up with two 
cross–over loops connecting the two pairs of helices as depicted in Figure 1.6. Although the 
domain exhibits strong DNA binding ability it does not resemble any of the known motifs of 
DNA–binding domains such as the helix–turn–helix or helix–loop–helix DNA binding motif 
and the leucine zipper or the zinc finger motif (Okubo et al., 2004). 
1.6.3 The PINIT domain  
The PINIT motif previously identified by Duval et al, 2003 is located in a highly conserved 
region of PIAS proteins (Figure 1.7). The PINIT domain is present in all PIAS proteins 
except PIASy
E6–
, which is a splice variant of PIASy that lacks exon 6 (Wong et al., 2004). 
The holo-PIAS3 protein structure has not been determined and the PINIT domain structure of 
the PIAS3 protein does not exist. However, the Siz1 X–ray crystallographic structure, 
determined by Yunus and Lima (2009), revealed that the PINIT domain of Siz 1 was formed 
by two antiparallel β–sheets connected by helix and loop (Figure 1.8). The PINIT motif was 
located at the hydrophobic core of the domain (Yunus and Lima, 2009) and mutation of the 
motif affected PIAS3 nuclear retention (Duval et al., 2003) and disruption of restricted 
nuclear localisation of PIAS3 (Wong et al., 2004). 
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Figure 1.7 Sequence alignment of PINIT domains of the Siz and PIAS family of proteins. Amino acid 
alignment of sequences for PINIT domains from Siz and PIAS family members, S. cerevisiae (Siz1, Siz2), 
Homo sapiens (PIAS1, PIASxβ, PIAS3, and PIASy. Secondary structure elements of the PINIT domain are 
shown above the alignment; helices are indicated as bars and β–strands as arrows. The numbers indicate the first 
and last residue in the particular sequence. Identical residues in all sequences (black background) and highly 
conserved residues (grey) and low conserved residues (light grey). (adapted from Yunus and Lima, 2009). 
 
The PINIT domain plays a role in the ligase function with some substrates that recognize 
Siz1–dependent substrates (Reindle et al., 2006). Experimental evidence revealed interactions 
between PCNA (proliferating cell nuclear antigen) and GST–PINIT (Yunus and Lima, 2009). 
The PINIT motif has been shown to be essential for the nuclear retention (Duval et al., 2003) 
and a short specific peptide sequence (V82-T104) within the PINIT domain binds to both 
STAT3 and MITF (Sonnenblick et al., 2004; Levy et al.,2006). This short peptide of 23 
amino acids is capable of inducing apoptosis in both RBL–2H3 and mouse melanoma cells 
by inhibiting the transcriptional activity of both MITF and STAT3 (Yagil et al., 2009).  
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Figure 1.8 Ribbon representation of the three–dimensional structure of the PINIT domain of Siz 1 
protein (PDB ID: 3i2D). The PINIT domain of Siz1 protein showing by two antiparallel β–sheets connected by 
loops joining strands at one end of the molecule and connected by helix and loop. The N–terminal PINIT 
domain (amino acids 172–315; in cyan colour) is formed by two antiparallel β–sheets; one includes β1, β2, β4, 
and β9, and the other includes β3, β5 and β8. The β–sheets are connected by protruding loops (L1, L2, and L3) 
that join strands β2–3, β4–5, and β8–β9 at one end of the molecule, while β3–4 and β5–8 are connected by a 
helix α1 and a loop, respectively, on the opposite surface. The C-terminus helix (α2) (red) connects the PINIT 
domain to the SP-RING domain. (adapted from Yunus and Lima, 2009). 
 
The PINIT domain has been suggested to interact with the STAT3 specifically on the DNA 
binding domain of STAT3 (Chung et al., 1997). Interaction of STAT3 with various fragment 
lengths of PIAS3 has been shown. PIAS3 (1–123) fragment did not interact with STAT3 
(Yamashina et al., 2006) despite carrying part of the PINIT domain. However, PIAS3 (224–
584) formed a complex with STAT3 and it encompasses the C–terminus of the PINIT 
domain. The determination of the PINIT domain structure forms the critical basis of 
understanding the molecular mechanism of PIAS3 protein.  
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1.6.4 The SP–RING domain  
The classical RING domain contains eight zinc–binding cysteine or histidine residues 
(Weissman, 2001). The residues can coordinate two zinc ions, creating a globular domain that 
can mediate protein–protein interactions. RING proteins function as ubiquitin E3 ligases bind 
substrates with their RING and directly interact with the E2 dependent–enzymes to govern 
the specificity of ubiquitylation. They facilitate the transfer of ubiquitin from the E2 to the 
substrate without formation of covalent intermediates (Weissman, 2001). The SP–RING 
motif lacks two zinc–coordinating cysteines found in the classical RING domain but has a 
similar fold as in the RING finger (Joazeiro et al., 2000). The RING–type zinc–finger domain 
is defined to be any small, functional, independently folded domain that requires coordination 
of one or more zinc ions to stabilise its structure (Laity et al., 2001). The zinc is complexed to 
four conserved cysteine residues and/or histidines stabilizing a finger–like structure that can 
coordinate two zinc atoms and mediate multi–protein complex formation and protein–protein 
interactions (Weissman, 2001). The RING–finger domain is mostly involved in DNA binding 
or in protein–protein interaction. The consensus sequence of a single finger is Cys–X2–4–
Cys–X3–Phe–X5–Leu–X2–His–X3–His. The spacing between potential zinc co–ordinating 
residues and the amino acid composition of the mammalian PIAS RING–like structure differ 
substantially from the C3HC4 (RING–HC)–type RING finger found commonly in ubiquitin 
E3 ligase (Weissman, 2001). 
An alignment of the SP–RING motifs from mammalian PIAS proteins and the RING finger 
region from PIAS yeast homologues and the c–cbl ubiquitin ligase showed conserved 
cysteine and  histidine residues that formed the RING finger that bind to the zinc ion (Figure 
1.9). When compared with the classical RING finger, the SP–RING motif lacks the second 
and sixth cysteine residues that are part of the first and third pair of cysteine/histidine 
residues in the RING motif. In a cross–brace arrangement the first and third pair of 
cysteine/histidine residues forms one zinc binding site, while the second and fourth pairs 
form the second binding site in the RING motif (Aravind and Koonin, 2000; Ohi et al., 
2003).  
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Figure 1.9 Sequence alignment of the SP–RING domains of the PIAS family and the orthologs. 
Sequence alignment of S. cerevisiae Siz proteins, human PIAS family, and Drosophila zimp. Identical residues 
have red background, highly conserved residues have pink background and residues of low conservation have 
white background. Cysteine/cysteine and cysteine/histidine zinc coordinating residues in „cross–brass‟ 
arrangement are shown above the alignment. The numbers indicate the first and last residue in the particular 
sequence. Sequence accession numbers: c–cbl ubiquitin ligase (gi: 50315), Miz–zinc finger (MiZ1–2773148), 
Siz1 (gi: 258588585), KChAP (3127051), PIAS3 (2689028), PIAS1 (gi: 31543478), PIAS2 (gi: 56404605), 
PIASX (gi: 56699458), PIASy (gi: 45219874). (adapted from Schmidt and Müller. 2003). 
 
The SP–RING motif of PIAS family is structurally conserved and is suggested to have a 
similar fold as in the RING finger, although it lacks two zinc co–ordinating cysteines found 
in the classical RING domain. The zinc ion is crucial for the stability of this domain type  in 
the absence of the metal ion the domain unfolds as it is too small to have a hydrophobic core. 
Many zinc finger proteins are transcription factors that function by recognizing a specific 
DNA sequence (Laity et al., 2001). It is also required for sumoylation, which plays a role in 
targeting proteins to specific subcellular locations, stabilizing target proteins and modulating 
the transcriptional activity of substrate proteins. However, several structurally different types 
of proteins can exhibit E3–type ligase activity in sumoylation reactions (Kerscher et al., 
2006). Also, proteins such as the non–structural maintenance of chromosomes element 2 
homolog (NSE2) and the zinc finger MIZ domain–containing protein 1 (ZMIZ1) or ZMIZ2, 
that possess the PIAS RING (SP–RING) signature or its extended version, are considered 
only very distantly related to the PIAS proteins (Beliakoff and Sun, 2006). 
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1.6.5 The acidic domain and SUMO interacting motif (SIM)  
The acidic domain at PIAS C–terminal region contains Serine/Theronine (S/T) residues. This 
region is the most diverse region in the PIAS family. The acidic domain was shown to be 
involved in the binding of PIAS3 to the nuclear receptor coactivator (TIF2) (Jimenez–Lara et 
al., 2002) and to bind to STAT3 (Chung et al., 1997, Borghouts et al., 2010). The C–terminal 
domain of PIAS proteins harbours a putative SUMO1 interacting motif (SIM) (Minty et al., 
2000). The SIM is defined as a sequence of wxww or wwxw (where w is often V or I) and 
usually next to a C–terminal cluster of negatively charged residues. The SIM motif interacts 
non–covalently with SUMO proteins and has less consensus sequence (Minty et al., 2000). 
The SUMO1 interaction motif and S/T rich region are found in all PIAS proteins, except for 
PIAS4 (Shuai, 2006). 
1.7 PIAS PROTEIN INTERACTION WITH TRANSCRIPTIONAL FACTORS AND 
OTHER PROTEINS 
Different regions of PIAS proteins are involved in protein–protein interactions and regulate 
the transcription activation activities of transcription factors (Figure 1.10). More than 60 
proteins, most of them transcription factors, have been suggested to interact with members of 
the PIAS family (Shuai and Liu, 2005). Regions of PIAS proteins that are involved in 
protein–protein interactions have been identified in many studies. Interestingly, various 
regions of PIAS proteins seem to be involved in different protein–protein interactions 
(Figure 1.10). For example, the N–terminal region of PIAS1 can interact with the p65 
subunit of nuclear factor kappa B (NF–κB), whereas the C–terminal region of PIAS1 can 
bind STAT1 (Liao et al., 2000). These findings were results of targeted mutational analysis to 
dissect the functional role of PIAS proteins in various signalling events (Shuai and Liu, 
2005). 
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Figure 1.10 PIAS proteins interaction with transcriptional factors and other proteins. The top panel is 
the schematic illustration of PIAS protein domains and regions that are involved in interaction with 
transcriptional factors and other protein below as black horizontal lines. The PIAS family member that interacts 
with the transcriptional factor or other protein is shown at the left side. The broken line illustrates the PINIT 
domain of PIAS3 that associates with STAT3. C/EBP–ε, CCAAT/enhancer–binding protein–ε; COUP–TFI, 
chicken ovalbumin upstream promoter transcription factor 1; GATA2, GATA–binding protein 2; IRF1, 
interferon–regulatory factor 1; MITF, microphthalmia–associated transcription factor; MR, mineralocorticoid 
receptor; NF–κB, nuclear factor–κB; NP, nucleocapsid protein, from hantavirus; p53, tumour suppressor protein 
p53; p73, tumour protein p73; SMAD, SMA (small body size) and MAD (mothers against decapentaplegic)–
related protein; DJ1, a Parkinson‟s disease protein; TIF2, transcriptional intermediary factor 2; ZNF76, zinc–
finger protein 76. (adapted from Shuai and Liu, 2005) 
1.8  PIAS3–STAT3 DOMAINS INVOLVED IN INTERACTION 
 
PIAS3 is a multifunctional protein domain comprised of distinct functional domains that are 
capable of interacting with various proteins (Figure 1.10). The interaction of PIAS3 with 
STAT3 was first shown in IL–6 treated M1 cells by immunoprecipitation and no evidence of 
PIAS3–STAT3 association in untreated cells (Chung et al., 1997). Furthermore, treatment of 
23 
 
the HepG2 cells with another STAT3 activation cytokine, ciliary neurotrophic factor (CNTF) 
and oncostatin M (OM), showed the association of PIAS3 and STAT3 but not in untreated 
cells (Chung et al., 1997). These data suggested that PIAS3 associates with STAT3 following 
STAT3 stimulation and activation. However, stimulation of STAT3 results in the formation 
of the dimer as described in section 1.4. Further analysis of the form of STAT3 that 
associates with PIAS3 was achieved by probing for phosphorylated STAT3 in the 
immunoprecipitated complex. Interestingly Chung et al. (1997) showed that the PIAS3 
completely inhibited the DNA–binding activity of STAT3–STAT3 homodimer in HepG2 IL–
6 treated cells. These findings confirmed the similar inhibitory effect of PIAS3 on the DNA–
binding activity of STAT3 which was observed in nuclear extracts prepared from IL–6–
treated M1 and MCF7 cells. These data suggest the possibility that PIAS3 interferes with the 
DNA binding domain of STAT3. 
Yamamoto et al. (2003) showed by immunoprecipitation that STAT3320–493 and STAT3494–750 
regions interact with PIAS3 and not the N–terminal domain (STAT31–137) or the CCD 
(STAT3138–319). These results supported the findings by Chung et al. (1997) that PIAS3 
interacts with DNA binding domain of STAT3 (Figure 1.11). Levy et al. (2006) showed that 
the PIAS382–132 region associates with STAT3 and this region is encompassed in the PINIT 
domain (Figure 1.11). However, it is important to mention that the different PIAS3 
fragments used were in vitro translated [
35
S] methionine labeled (Levy et al., 2006). The 
effect of folding and whether the different fragments were synthesised in vitro with similar 
efficiency was not validated. Furthermore, interpretation of the data from the mutational 
analysis performed to determine the region critical for PIAS3–STAT3 interaction was 
problematic. PIAS3–Y94P was found to be disruptive with respect to STAT3 binding (Levy 
et al., 2006). However, the loss of binding was probably as a result of structural changes and 
thus may not necessarily be due to the amino acid substitution. Protein-protein interaction 
analysis using PIAS3 domains which are characterised for their folding need to be conducted 
(e.g. using surface plasmon resonance spectroscopy [SPR]). In addition, mutations which 
maintain the structural integrity were necessary to determine critical residues in the PIAS3–
STAT3 interaction. In an attempt to find the minimum fragment that can perform the same 
function as the full length PIAS3, Yagil et al. (2009) showed that the PIAS82–104 fragment 
(Figure 1.11) was sufficient to induce apoptosis by arresting STAT3 transcriptional activity 
and this work was conducted in vivo with no further mutational analysis. 
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Dabir et al. (2009) focused on STAT3 residue Y705 with experimental results that suggested 
the PIAS3–STAT3 interaction was based on the phosphorylation of STAT3 Y705 and the 
disruption of PIAS3-STAT3 was based on dephosphorylation of STAT3 Y705 by PIAS3 in 
the nucleus.  
Recently Borghouts et al. (2010) focused on the C–terminal region of the PIAS3 by 
performing yeast two–hybrid and coimmunoprecipitation experiments using recombinant 
peptides of both STAT3 and PIAS3. Yeast two–hybrid analysis with the N–terminal  PIAS31–
319 showed no interaction with STAT3. However, yeast two–hybrid showed that PIAS3400–523 
and PIAS3400–543 fragments interacted with STAT3 (Borghouts et al., 2010). It should be 
noted that the C–terminal region of PIAS1 freely interacted with phosphorylated or 
unphosphorylated STAT1. However, the presence of the N–terminal region prevented 
PIAS1–STAT1 interaction (Liao et al., 2000). Nevertheless, Borghouts et al. (2010) showed 
that the interaction of these PIAS3 fragments were specifically with the CCD of STAT3.  
Presently, the understanding of the PIAS3–STAT3 association is not clear. Various regions of 
PIAS3 have been suggested to be involved in the PIAS3–STAT3 association. Also, multiple 
regions of STAT3 have been suggested to associate with PIAS3. The main problem with the 
understanding of the PIAS3–STAT3 interaction is the limited structural data available for the 
PIAS family members. Hence, in this study using structural bioinformatics, mapping of the 
regions and residues potentially important for the PIAS3–STAT3 interaction was based on 
the conservation of residues and their orientation in the tertiary structure. Furthermore, using 
biophysical and biochemical approaches not previously employed, the PIAS3–STAT3 
association was further investigated in this study.  
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Figure 1.11 Schematic representation of STAT3 and PIAS3 binding regions. Various PINIT domain 
regions that have been suggested to associate with STAT3 DNA binding domain. The PINIT domain (residues 
82–272) of PIAS3 associates with STAT3 DNA binding domain (residues 400–500). The short region of PINIT 
domain (residues 82–132) associates with STAT3 (Levy et al., 2006). The shortest region of the PINIT domain 
(residues 82–104) has been suggested to associate with STAT3 (Yagil et al., 2009). PIAS3 (residue 400–523) 
has been suggested to associate with the CCD of STAT3 (Borghouts et al., 2010). 
 
 
 
1.9 PROBLEM STATEMENT 
 
A number of regions of PIAS3 have been suggested to interact with STAT3 using in vivo and 
in vitro experiments. Various peptides of PIAS3 have been characterised as the determinants 
of PIAS3–STAT3–interaction. The multidomain structure of PIAS3 makes it a major 
challenge to identify a specific domain when studied in isolation that confers the same 
activity as full length PIAS3. These problems are exacerbated by difficulties around 
production of protein quantity and quality  suitable for structural analysis, and furthermore, 
by the lack of holo-PIAS3 structure or the structure of any PIAS family member that can be 
used as template. 
 
 
 
 
1.10 HYPOTHESIS 
PIAS3 individual domains alone are necessary but not sufficient for its functional interaction 
with STAT3.  
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1.11 BROAD OBJECTIVES 
 
A. Bioinformatics analysis of PIAS3 and its domains. 
 
B.  Analysis of the cellular localisation of PIAS3 and its domains. 
 
C.  Development of a suitable expression system for the heterologous expression and 
purification of PIAS3 or its domains.  
 
D. The in vitro analysis of the PIAS33–STAT3 interaction. 
 
1.12 SPECIFIC OBJECTIVES 
 
A1. Bioinformatics analysis of PIAS3, the PINIT domain and the acidic domain. 
Homology modeling of the PINIT domain and its mutants and validation of the 
models.  
 
B1. Investigation of the localisation of PIAS3, the PINIT domain, the acidic domain, 
mutant PIAS3, and their co–localisation with STAT3.  
 
C1. Plasmid construction for the heterologous expression and purification of the PINIT 
domain, characterisation of the size and folded state of the PINIT domain and its 
mutant derivatives.  
 
D1.  PINIT–STAT3 binding analysis using SPR, including the generation of PINIT domain 
mutants to assess effects of the mutations on PINIT–STAT3 association. 
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CHAPTER 2 
 
 
BIOINFORMATICS ANALYSIS OF THE PIAS3, PINIT DOMAIN AND THE 
ACIDIC DOMAIN OF PIAS3 PROTEIN. 
 
 
In human there are four different PIAS isoforms encoded by separate genes that modulate the 
activities of transcriptional factors. The high degree of sequence identity among PIAS 
proteins predicts similar functions. The conserved multiple domains have distinct functions 
and have been suggested to modulate the transcriptional activity of the STAT protein family. 
The broad objective of this study was to analyse the conservation pattern of the PIAS protein 
family and thereby identify residues conserved in individual domains capable of addressing 
PIAS3 biological function. Secondly, the prediction of secondary structure elements of the 
PINIT domain allowed for the generation of the PINIT domain homology model to evaluate 
the structural determinants in PIAS3–STAT3 interaction. Furthermore, the study aimed to 
predict and mutate critical residues that potentially determine PIAS3 function. 
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2.1 INTRODUCTION 
 
The molecular mechanism of the PIAS3 interaction with STAT3 can be understood better by 
having structural insight of the protein and its domains. Structures can be determined using 
X–ray crystallography and nuclear magnetic resonance spectroscopy (NMR), but these 
techniques are dependent on factors such as production of sufficient protein and the size of 
the protein. NMR spectroscopy resolution has a size limitation of 30 kDa. To date the PIAS3 
structure does not exist in available structural databases. Of the PIAS family members the 
SAP domain of PIAS1 has been solved by NMR (Okubo et al., 2004), and the PINIT domain 
of Siz1, a yeast ortholog of PIAS family, was recently elucidated using X–ray 
crystallography (Yunus and Lima, 2009). Advances in the computational systems have 
allowed for the development of bioinformatics approaches to calculate in silico homology 
models from available templates using known protein sequences of the protein of interest. 
This is referred to as the template based approach to determine structure based on sequence 
and fold similarity.  
Comparative or homology modeling approaches are based on the conservation of protein 
structures and sequences. Proteins with high sequence identity are likely to share similar 
structure (Sancheze and Sali, 1997). Homology modeling depends heavily on the accuracy of 
alignment, which allows detection of conserved domains. The confidence of the model 
increases with increase in similarity between the target and template sequences.  
Three–dimensional structure generally provides more information about a protein function 
than the sequence because interactions of a protein with other molecules are determined by 
amino acids that are close in space but are frequently distant in sequence. Homology 
modeling is a multistep process that is described by four iterative steps: template recognition, 
target–template sequence alignment, model generation and model validation (Figure 2.1). 
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Figure 2.1 Flowchart illustrating the steps in comparative protein structure modeling. Steps in 
construction of a homology model as implemented in MODELLER 9v3 (adapted from Sanchez and Sali, 1997). 
 
Step 1: Template recognition  
Template searches are performed using known protein sequences and structure databases; this 
is done by comparing the query sequence with the sequence of each of the known structures 
in the available database. Algorithms employed include Basic Local Alignment Search Tools 
(BLAST) or sequence profile methods using position specific iterative (PSI)–BLAST 
(Altschul and Koonin, 1998) which are based on pairwise comparative methods. Sensitive 
search with profile methods such as Hidden Markov Models (HMM) (Söding et al., 2005) 
and HHpred (Söding et al., 2005) available as web based servers 
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(http://toolkit.tuebingen.mpg.de) may be required and also it is necessary to directly evaluate 
the compatibility between the target sequence and each structure in the data base using 
“Threading” (Jones et al., 1992). From the list of templates, the most suitable template with 
high percentage sequence identity to the query is selected for modeling.  
Step 2: Target–template sequence alignment correction 
Specialised methods are used to align the template sequence with the target sequence such as 
CLUSTALW (Higgins and Sharp, 1998; Thompson et al., 1994). The use of the multiple 
sequence alignment to derive position specific scoring matrices (profiles) (Taylor, 1986; 
Dodge et al., 1998) can be used during manual intervention to correct gaps in the alignment 
and also the alignment can be improved by including structural information from the 
template, for example gaps should be avoided in secondary structure elements and in buried 
hydrophobic regions (Sancheze and Sali, 2000). Manual alignment by visual inspection of the 
template is important, as mis–alignment of a single amino acid may result in spatial errors of 
approximately 4 Å in the calculated model. 
Step 3: Model Building  
MODELLER is an automated computer program that models a protein by satisfaction of 
spatial restraints; it uses either distance geometry or optimization techniques to satisfy spatial 
restraints obtained from alignment of the target sequence with the template structure (Sali and 
Blundell, 1993). MODELLER extracts atom–atom distance and dihedral angle restraints on 
the target from the template structure(s) and combines them with general rules of protein 
structure such as bond length and angle preference (Sancheze and Sali, 2000). 
Step 4: Model evaluation 
Model errors mainly depend on the percentage sequence identity between template and the 
target. If the sequence identity is below 30 %, the alignment will be the key to the accuracy of 
the homology modeling (Chothia and Lesk, 1986; Sippl, 1993). Also, errors from the 
template affect the accuracy of the homology. Model evaluation can be performed using 
programs such as PROCHECK (Laskowski et al., 1993) and WHATCHECK (Hooft et al., 
1996) to assess the model stereochemistry, bonds, bond angles, dihedral angles, and 
nonbonded atom–atom distances. To predict whether or not a template is correct, it is 
necessary to compare the calculated modeller Z–score (Sippl, 1993) for the model and the 
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template structure(s). The Z–score of a protein is defined as the energy separation between 
the native fold and the average of an ensemble of misfolds in the units of the standard 
deviation of the ensemble (Zhang and Skolnick, 1998) and should be comparable to that of 
the template. External evaluation is the prediction of unreliable regions in the model using 
programs like MetaMQAPII (Pawlowski et al., 2008) and Verify3D (Eisenberg et al., 1997) 
(available as web based servers Appendix F1).  
The model can also be improved by iterations consisting of template selection, alignment, 
and model building, guided by model assessment. The iterations may be repeated until no 
improvement in the model is detected (Guenther et al., 1997; Sanchez and Sali, 1997). 
Loops vary among homologs while the core regions are conserved and accurately aligned. 
Loop refinement is achieved by optimizing a scoring function (Spassov et al., 2008) using 
methods exploiting different protein representations, objective functions, and optimization 
algorithms thereby improving the quality of the predicted model.  
Based on the systems described above, the objective of the current study was to use 
bioinformatics tools to analyse available PIAS protein sequences and identify conserved 
regions and motifs to map specific residues critical for PIAS3 function. The homology model 
of the PINIT domain of PIAS3 was generated using MODELLER–9v3. Conserved residues 
deemed potentially important to the structural and functional integrity of PIAS3 were 
identified. Interesting domains capable of addressing biological questions may be 
investigated based on knowledge of protein structure, sequence conservation pattern and 
prediction of the secondary structures elements. The outcome of the study presented here 
guided the in vitro and in vivo work in the subsequent chapters (Chapter 3–5) 
2.2 PROCEDURES 
2.2.1 Sequence retrieval and alignment  
Searches for non–redundant sequences in databases (nr) were performed using default 
parameters at the NCBI using PSI–BLAST (Altschul and Koonin, 1998) 
(www.ncbi.nlm.nih.gov/blast) and HHpred (Söding et al., 2005) 
(http://toolkit.tuebingen.mpg.de/hhpred). The available sequence of mouse PIAS3 (accession 
number: AF034080) was used as query. Profile based alignments of sequences from the PIAS 
family were performed using ClustalW (Higgins, et al. 1994), set to Blosum62 matrix; all 
other parameters were set to default (Thompson et al., 1994). The final multiple sequence 
alignment was manually refined to ensure that there were no unwarranted gaps introduced 
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within potential structural elements like α–helices and β–strands. Accession numbers for the 
protein sequences used in the multiple sequence alignments are: PIAS3 Mouse (Mus 
musculus), AF034080; PIAS3 Homo (Homo sapiens), NP_006090.2; PIAS1 Mouse (Mus 
musculus), NP_062637.2; PIAS1 Homo (Homo sapiens), ABP49566.1; PIAS1 Gal (Gallus 
gallus), NP_001025797.1; PIAS2 Homo (Homo sapiens), NP_004662.2; PIAS2 Mouse (Mus 
musculus), NP_032628.3; PIASx Gal (Gallus gallus), NP001025797.1; PIASx Homo (Homo 
sapiens), AAC36705.1; PIASy Homo (Homo sapiens), AAC36703.1; PIAS4 Rat (Rattus 
norvegicus), NP_001094227.1; PIAS4 Homo (Homo sapiens), AAH10047.1; Siz1 
(Saccharomyces cerevisiae), (PDB ID: 3I2D).  
 
2.2.2 Secondary structure prediction and assessment 
Secondary structure prediction of the PINIT domain of PIAS3 protein was achieved by 
application of the following software packages: PSIPRED (Jones, 1999); JNET (Cuff and 
Burton, 1999); Prof (Rost) (Rost, 2001); and Prof (Ouali) (Ouali and King, 2000). Matches 
between the query sequence and known protein structures identified by alignment of the 
predicted secondary structures was carried out using 3DPSSM (Kelly et al., 2000) and 
HHpred (Söding et al., 2005). Predicted fold recognitions produced were compared and 
evaluated; template sequences remotely related to target sequences were eliminated.  
 
2.2.3 PINIT domain model building 
The PINIT domain region, consisting of residues 85 to 272 of the PIAS3 protein (accession 
number: AF034080), was submitted to the HHpred web server to identify templates (Söding 
et al., 2005). The server identified only one template, Siz/PIAS SUMO E3 ligase Siz1 (PDB 
ID: 3I2D) (Yunus and Lima, 2009) with 17 % sequence identity. A target–template sequence 
alignment was automatically built with the automated HHpred alignment function. Since 
sequence identity was low, the target–template alignment was compared with multiple 
sequence alignments produced with ClustalW and manually corrected. The secondary 
structure was matched between the predicted secondary structure of the target protein and the 
calculated secondary structure of the template. The alignment file was submitted to 
MODELLER–9v3 and 100 models of the PINIT domain (PIAS85–272) were built using python 
scripts run in MODELLER-9V3 (Appendix F2). DOPE Z (normalized Discrete Optimised 
Protein Energy) scores were calculated for all models (Shen and Sali, 2006).  
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2.2.4 Model evaluation 
The DOPE Z–scores of the 100 generated models were calculated using an automated python 
script run in MODELLER–9v3 (Appendix F2). The model with the best DOPE Z–score was 
subjected to loop refinement using automated python scripts run in MODELLER–9v3. 
During refinement, 100 models were generated and their DOPE Z–score calculated and best  
model was used for further refinement of other loops. After loop refinement and picking the 
model with the best DOPE Z–score, the model quality assessment was further performed by 
MetaMQAPII (Pawlowski et al., 2008) which assesses the model accuracy according to 
temperature scheme. Furthermore, the PINIT model was evaluated by quality assessment 
using Verify3D (Eisenberg et al., 1997). Visual evaluations were performed by inspecting the 
models with UCSF Chimera (Goddard, et al., 2005) and PyMOL (Delano, 2004) molecular 
visualisation programs. 
 
 2.2.5 Homology modeling of the mutant PINIT domain models 
Mutant models PINIT–L97A, PINIT–R99N and PINIT–R99Q were calculated and validated 
as described above from the final validated PINIT domain model as template structure. 
2.3 RESULTS 
2.3.1 PIAS protein family sequence alignment and analysis  
Analysis of the sequence alignment of the PIAS protein family revealed conserved regions 
and domains of PIAS3. Analysis of the sequence alignment (Figure 2.2) identified four 
conserved regions corresponding to the four known conserved domains of PIAS family: N–
terminal SAP domain (position 1 to 70) with the “LQVLL” signature sequence; the PINIT 
domain with its signature “PINIT” motif (position 149 to 336, Figure 2.2); the RING–type 
zinc–finger binding domain showing residues that forms a zinc–finger binding (position 337 
to 420, Figure 2.2); and the C–terminal acidic domain (position 421 to 556, Figure 2.2) rich 
with acidic residues and the signature SIM binding motif or SUMO–1 binding motif. The 
PIAS protein family sequence alignment validated the previous findings of the domains 
described in the PIAS protein family (Hanson et al., 1991; Romig et al., 1992; Minty et al 
2000; Hochstrasser, 2001; Duval et al., 2003). 
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Figure 2.2 Sequence alignment and analysis of PIAS family members from different organism 
(continued on next page). 
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Figure 2.2 Sequence alignment and analysis of PIAS family members from different organisms 
(continued from previous page). Alignment of the PIAS protein family aligned with „CLUSTALW‟ software 
(Larkin et al., 2007). The numbers at the beginning and at the end of each sequence indicate the position of the 
first and last of the aligned residues in the respective protein sequence. Shading represents the conservation of 
residues (scored according to Blosum62 score table). Identical residues are in red, highly conserved residues are 
in blue and with low conservation are residues in black. The accession numbers for the protein sequences used 
in the multiple sequence alignments are shown in procedures section 2.2.1. The broken lines at the bottom and 
top of the alignment indicate the beginning and end of the domains. The first domain is the SAP domain marked 
by its signature sequence “LQVLL” in yellow background. The second domain is the PINIT domain and is 
marked with its highly conserved signature sequence “PINIT” in grey backgrounds and underlined with a bold 
black line. The third domain is the SP–RING domain and is marked with its zinc ion binding residues indicated 
in boxes. The last domain is the diverse C–terminal acidic domain, which is marked with its signature SUMO–1 
binding motif and acidic residues “VIDLTIESSSDEED” indicated with a green background. 
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2.3.2 PINIT domain sequence alignment and analysis  
Comparative sequence analysis of the PINIT domain of the PIAS3 family with the PINIT 
domain of the Siz1 yeast revealed differential distribution of the Pro, Leu, Thr residues in the 
„PINIT‟ motif (Figure 2.3). Although the alignment of the PINIT domain of the PIAS3 with 
the PINIT domain of Siz1 showed low sequence similarity, the two proteins have common 
functions (Yunus and Lima, 2009). However, sequences may be distant with low similarity 
but the tertiary fold of the protein is often highly conserved, hence similar biological activity.  
 
 
Figure 2.3 Sequence alignment and analysis of the PINIT domains of the PIAS family and yeast Siz1 
protein.The alignment of PINIT domain sequences of the PIAS family proteins and the PINIT domain sequence 
of Siz1 using CLUSTALW software (Larkin et al., 2007). The numbers indicate the first and last residue in the 
particular sequence and the numbers at the top indicate the position of mouse PIAS3 residues. Shading 
represents the conservation of residues (scored according to Blosum62 score table). Identical residues are in red, 
highly conserved residues are in blue and residues of low conservation are in black. The conserved “PINIT” 
residues are indicated in the box and the two arrows indicate PINIT residues subjected to mutational analysis in 
this study (L97 and R99). The accession numbers for the protein sequences and the organism used in the 
multiple sequence alignments are shown in procedures section 2.2.1. (adapted from Mautsa et al., 2010) 
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2.3.3 Acidic domain sequence alignment and analysis 
 
The alignment of the C–terminal domain (PIAS3400–523) of PIAS proteins shows that it is 
more diverse, however, the distribution of several serines (Ser) at the N–terminal border of 
the domain is highly conserved (Figure 2.4). Previous studies have identified similar 
consensus sequences which include clusters of Val, Ile, Leu and the acidic residues, Asp and 
Glu (Hannich et al., 2005; Minty et al., 2000). Although the alignment showed a diverse C–
terminal domain of PIAS3, of significance is the highly conserved motif 
“VIDLTIESSSDEED” (indicated on Figure 2.4). Previous studies predicted the motif as a 
SUMO–1 binding motif (Song et al., 2005) that recognises the SUMO moiety of modified 
proteins in sumoylation–dependent cellular functions.  
 
 
Figure 2.4 Sequence alignment and analysis of the acidic domains PIAS family. Alignment of the C–
terminal domain sequences of PIAS protein family using CLUSTALW software (Larkin et al., 2007). The 
numbers indicate the first and last residue in the particular sequence and the numbers at the top indicate the 
position of mouse PIAS3 residues. Shading represents the conservation of residues (scored according to 
Blosum62 score table). Identical residues are in red and highly conserved residues are in blue and residues of 
low conservation are in black. The predicted SUMO binding motif (black box) and the acidic amino acids rich 
region (green box) are indicated in the boxes. The highly conserved motif “VIDLTIESSSDEED)” of the C–
terminal domain of PIAS is underlined with a bold black line. The accession numbers for the protein sequences 
and the organism used in the multiple sequence alignments are shown in procedures section 2.2.1. 
 
Other non–covalent SUMO binding sites of several proteins also contain similar sequences 
such as the Epstein–Barr virus nuclear antigen 3C (EBNA3C) with the sequence 
„DDVIEVIDVETTE” (Rosendorff et al., 2004). These sequences are similar to that of the 
SUMO–1 binding site of PIASx „VDVIDLT‟ (Figure 2.4 boxed) determined by Song et al. 
(2004, 2005). Substitution of the “VILT” individually with alanine reduced the binding 
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affinity of the mutated peptide to SUMO–1, particularly the threonine which resulted in 
reduction of affinity by ~10 fold (Song et al., 2005). The conservation of these residues at the 
C–terminal domain of PIAS3 protein may suggest a common function. Interestingly as 
mentioned previously, PIAS3400–523 has been suggested to interact with the coiled coil domain 
of the STAT3 protein (Borghouts et al., 2010). 
 
2.3.4 PINIT domain secondary structure prediction analysis 
 
The alignment in Figure 2.2 and 2.3 showed high conservation of the PINIT domain in the 
PIAS protein family. Although highly conserved residues exist elsewhere within the domain, 
focus on the N–terminal region of the PINIT domain is ideal since previous mutations 
elsewhere within the domain did not abrogate its biochemical functions. The “PINIT” motif 
is highly conserved (Figure 2.2 and 2.3) and secondary structure predictions of the PINIT 
domain of PIAS3 by four independent prediction software packages (Figure 2.5) indicate a 
high consensus. The N–terminal region of the PINIT domain (23 amino acids) was identified 
as the minimal epitope that can trigger apoptosis (Yagil et al., 2009).  
 
 
Figure 2.5 Prediction of the secondary structure of the PINIT domain. Secondary structure prediction of 
the PINIT domain using three independent web based algorithms (Appendix F1): PSIPRED (Jones, 1999); 
JNET (Cuff and Burton, 1999); ProfR (Rost, 2001); and ProfO (Ouali and King, 2000). H (red) indicates α–
helix; E (blue) indicates β–strand; CONF is the prediction confidence level indicated by numbers from 0 to 9 as 
the lowest and highest confidence level respectively; SS, secondary structure; and gaps indicates loops. 
 
Previous mutational studies of PIAS3 Y94P mutant protein have been found to abrogate the 
association of PIAS3 with either MITF or STAT3 (Sonnenblick et al., 2004; Levy et al., 
2006). The de novo predicted model by Levy et al, 2006 showed that the position of Y94 on 
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the helix. Furthermore, Y94P mutation resulted in disruption of the helix due to the nature of 
the proline residue. Proline does not fit into the regular part of either helix because it does not 
have a backbone-NH available to take part in an H-bonding (Williams and Deber, 1991). In 
the helix center, the ring pushes away the proceding (N-terminal) turn of the helix producing 
a bend and breaking the next H-bond. The resulting loss of protein function observed by Levy 
et al, (2006) might possibly be due to disruption of the helix. Secondary structure prediction 
analysis of PINIT mutant proteins PINIT–L97A, PINIT–R99N and PINIT–R99Q showed 
that the secondary structure predictions compare well to the unmodified PINIT domain for 
PINIT–R99N and PINIT–R99Q, with a small change in PINIT–L97A. These data suggest 
that the mutations are likely not to affect the local secondary structure features of the protein 
(Figure 2.6). 
 
 
Figure 2.6 Assessment of the effect of the mutation on the local structure of the PINIT domain. In silico 
secondary structure prediction of each residue in PINIT domain before and after mutation with confidence 
values ranging from 0 to 9. wt, represent the unmodified PINIT domain; L97A, represent PINIT–L97A mutant 
protein; R99N represent PINIT–R99N mutant; R99Q represent PINIT–R99Q mutant. The confidence levels 
from 0 to 9 is shown in the Y–axis and the secondary structure features of the unmodified PINIT domain and the 
residues in the region are shown in the X–axis. L97A mutation resulted in the lower confidence level of Alanine 
being in the β–sheet and the R99N and R99Q mutations predicted with the highest confidence level that the 
residues remain in the loop suggesting no local structural change.  
  
2.3.5 The PINIT domain modeling with MODELLER 
The PINIT domains of Siz1 and PIAS3 have 17 % sequence identity. Quality and confidence 
of any generated model is dependent on sequence identity. However, the overall assessment 
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of the secondary structure prediction of the PINIT domain of Siz1 compared to the secondary 
structure prediction of the PINIT domain of PIAS3 (Figure 2.7) showed a high consensus 
and a high degree of fold similarity (Figure 2.7). 
 
 
Figure 2.7 Sequence–structure alignment and secondary structure prediction of the PINIT domain of 
PIAS3 and Siz1 protein. Alignment was generated using CLUSTALW and the secondary structure predicted 
by PSI–PRED (Jones et al., 1999) was performed in the web based programme HHpred (Söding et al., 2005). H, 
helices prediction; E, β–strands prediction; C, coil prediction; ss–pred, secondary structure prediction; (H,E,C 
capital letter indicates prediction with high confidence and h,e,c indicates prediction with lower confidence) 
Siz1, PDB ID: 3I2D.  
 
The predicted PINIT domain model (Figure 2.8A) revealed two antiparallel β–sheets; one 
includes β1, β2, β4, and β7, and the other includes β3, β5, and β6. The β–sheets are 
connected by protruding loops (L1, L2, and L3) that join strands β2–3, β4–5, and β6–7 at one 
end of the molecule, while β3–4 and β5–7 are connected by a helix, α1, and a loop, 
respectively, on the opposite surface (Figure 2.8A). Superimposition of the predicted model 
with the X–ray structure shows a close agreement of all the secondary structure features with 
a minor mis–alignment on the flexible parts of the model (Figure 2.8B) (loops and C–
terminal) even though the predicted model has undergone rigorous loop refinement. 
 
 
.  
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Figure 2.8 Ribbon representation of the PINIT domain model of PIAS3 and its superimposition on the 
PINIT domain of Siz1. A) The PINIT domain model created using MODELLER–9v3 and evaluated as 
described below. The model revealed three antiparallel β–sheets connected by protruding loops and the helix–
loop–helix at the C–terminus. The model was generated using the PINIT domain X–ray structure of the Siz1 
(PDB ID: 3I2D) (Yunus and Lima, 2009). B) Siz1–PIAS3 PINIT domain structural alignment. The 
superimposed generated model of PINIT domain of PIAS3 (cornflower blue) with the PINIT domain structure 
of Siz1 (hot pink). The superimposition was performed in UCSF Chimera 1.5 (Goddard, et al., 2005) and the 
structure shows alignment in the helix structural features. C) PINIT domain N–terminal β–strand–loop–β–strand 
enveloped by a transparent molecular surface, residues mutated are L97 and R99, also residue Y94 mutated by 
Levy et al. (2006). 
 
2.3.6 Model quality assessment and evaluation 
The 100 generated PINIT models were visually inspected in PyMol and their quality 
assessed. Furthermore, all models were evaluated with a normalised DOPE Z–score (Discrete 
Optimized Protein Energy) from modeller package that used standard Modeller energy 
function and the best model with DOPE Z–score of –0.363 was chosen, however a good 
quality model has a DOPE Z–score of -0.5 (Shen and Sali, 2006). To further improve the 
quality of the model the loops were refined using python script for loop refinement 
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(Appendix F2) as described above (section 2.2.5). Loops Glu–134 to Thr–144, Glu–155 to 
Phe–164 and Leu–179 to Ile–199 were refined and the model was further improved to give a 
final DOPE Z–score of -0.369. The assessment of the PINIT model quality by visual 
identification of potential errors using colouring was performed using MetaMQAPII 
(Pawlowski et al., 2008) which predicts the local deviation of residues in the model for their 
counterpart in the native structures. The temperature (B–factor) fields in PINIT domain 
model file were replaced with the MetaMQAP score corresponding to linear scaling of values 
of 0.00 (predicted no deviation) and 99.99 (predicted deviation of ≥10Å) ((Pawlowski et al., 
2008). The results were visualised with PyMol version 0.98 (Delano, 2004) that allowed 
colouring of the structure according to the B–factor values. The per–residue accuracy was 
visualised as a colour in a spectrum between blue (predicted high accuracy) and red 
(predicted low accuracy) (Figure 2.9). The assessment shows that the PINIT model has high 
accuracy prediction in the core structure β–sheet compared to the template structure (Siz1) 
indicated by blue regions on β–sheet structures of the PINIT model. However, the N–terminal 
β–sheet and the C–terminal helix–loop–helix of the PINIT model deviated from the native 
structure indicated by the shift of colour spectrum from blue towards yellow and red (Figure 
2.9B). 
 
Figure 2.9 Visual identification of potential errors in the PINIT domain structure of Siz1 and the 
generated PINIT domain model using 'colouring' by MetaMQAPII. A) Quality assessment of the PINIT 
domain structure of Siz1 protein using web based programme MetaMQAPII (Pawlowski et al., 2008). The 
spectrum of colours from blue to red indicates the spectrum of residues predicted to be correct to incorrect. B) 
Quality assessment of the PINIT domain model of PIAS3 protein generated using the PINIT domain structure of 
Siz1 (PDB ID: 3I2D). The predicted deviation from the native structure is indicated by a shift of the colour 
spectrum from blue towards yellow and red. The images were rendered in PyMol version 0.98 (Delano, 2004). 
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Evaluation of the model by Verify3D (Eisenberg et al., 1997) revealed results that were 
consistent with the evaluated results from MetaMQAPII (Figure 2.10). The N–terminal β–
sheet and the C–terminal helix–loop–helix region were shown to deviate from the native 
structures (Figure 2.9B, Figure 2.10). Furthermore, Verify3D (Eisenberg et al., 1997) 
revealed residues in the N–terminal β–sheet and C–terminal helix–loop–helix local secondary 
structure were below a threshold score (0.1 indicated by a red line) and indicating a slight 
deviation from the native structure. In particular Ser 132 (indicated by a blue circle Figure 
2.10) was below 0 score and indicated a large deviation from the expected environment of the 
native structures (Figure 2.10). These regions correspond to the N–terminal β–sheet (β1) and 
the C–terminal α–helix (α2 and α3) of the predicted PINIT domain model (Figure 2.9B) 
 
 
Figure 2.10 Profile score for each residue in the PINIT model by Veryfy3D. Evaluation of the 
environment of each residue in the predicted PINIT domain model with respect to the expected environment as 
found in high resolution X–ray structures (Luthy et al., 1992). The N–terminal and the C–terminal residues 
show a deviation from the expected environment of a native protein and the residue Ser132 indicated by a blue 
circle has a negative score. 
 
2.3.7 Analysis of the predicted structure of the PINIT domain and mutated PINIT 
domain derivatives 
To identify potential structural determinants of the PINIT domain that enable it to bind to 
STAT3, the PINIT domain model was generated from the crystallographic structure of Siz1 
(PDB ID: 3I2D) as template (Yunus and Lima, 2009). The predicted structure of the PINIT 
domain revealed a conserved “PINIT” motif buried in the hydrophobic core, the R99 residue 
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is surface exposed and the L97 residue is also buried in the hydrophobic environment (Figure 
2.11). While the PINIT domain had low sequence identity to Siz1, a comparison of the 
secondary structure predictions for the two proteins showed a good match and the DOPE Z– 
score of -0.369, after loop refinement indicated that the model was relatively accurate. 
Homology models of the mutated PINIT domains were generated using the unmodified 
PINIT model as a template and evaluated in the same manner. The first helix of the PINIT 
domain is the focus of mutational studies. Previous mutations focused on the first helix gave 
little attention to the structural bases on the loss of ability to bind STAT3 (Levy et al., 2006; 
Yagil et al., 2009). The PINIT–L97A model (Figure 2.12A) showed that the replacement of 
leucine with alanine potentially resulted in a loss of hydrophobic or van der Waals contacts 
within a 3.5 Å sphere. The loss of non–polar contacts possibly results in local perturbations 
of the PINIT conformation. The PINIT–R99Q and PINIT–R99N models illustrated how the 
replacement of Arg with Gln (Figure 2.12B) or Asn (Figure 2.12C) resulted in both a 
reduction in side–chain length and a loss of charge.  
 
 
Figure 2.11 Ribbon representation of the PINIT domain of PIAS3 enveloped by a transparent 
molecular surface. The PINIT model shows the position of the mutated residues (L97 and R99); the R99 
residue protruding outside, and the L97 buried in the hydrophobic core. The PINIT motif is shown as space fill 
(yellow), and is buried in a deep cleft in the hydrophobic core. The antiparallel β–sheets are connected by 
protruding loops and the helix–loop–helix at the C–terminus. The model was generated from the crystal 
structure of the PINIT domain of Siz1 as template (PDB ID: 3I2D) (Yunus and Lima, 2009) using MODELLER 
9v3 and rendered in UCSF Chimera 1.5 (Goddard, et al., 2005). (adapted from Mautsa et al., 2010). 
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The L97A PINIT mutant model (Figure 2.13) revealed an increase in contact distance with 
neighbouring atoms when leucine is replaced with alanine residue. In solution this may result 
in possible loss of van der Waals and hydrophobic interactions and local collapse of the 
secondary structure features due to tight packing, thereby affecting the function of 
neighbouring atoms. 
 
 
 
Figure 2.12 Superimposition of the unmodified and mutant PINIT domain models. (A) PINIT–L97A 
mutant model (turquoise) superimposed with unmodified PINIT domain (blue); (B) PINIT–R99Q mutant model 
(turquoise) superimposed with the unmodified PINIT domain (blue); (C) PINIT–R99N mutant model 
(turquoise) superimposed with the unmodified PINIT domain (blue). (adapted from Mautsa et al., 2010) 
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Figure 2.13 Assessment of the contact distance of the L97 of the unmodified PINIT domain model and 
A97 of the mutant PINIT domain model with the neighbouring atoms. The distance in Angstrom between 
the L97 and the nearest neighbouring atoms increased when this residue was replaced with Ala. 
 
2.4 DISCUSSION AND CONCLUSION 
 
Computational analysis of the PIAS protein family revealed four conserved structural 
domains and motifs previously identified. The PINIT and acidic domains or the PIAS3 
protein were previously shown to interact with the STAT3. Sequence analysis of the separate 
domains showed that the PINIT domains are highly conserved. The Acidic domain showed 
sequence diversity within the PIAS family. Although the SUMO–1 binding motif is highly 
conserved within the acidic domain, no previous studies have shown involvement in PIAS3–
STAT3 interaction. The study presented here focused on the PINIT domain structural 
determinants in PIAS3–STAT3 interaction. 
While there is a very low global sequence similarity between Siz1 and other PIAS proteins 
(Figure 2.3) (17 %), sequence similarity within the PIAS family is on average 80 %. 
However, there is structural conservation across the homologs as shown by the secondary 
structure prediction of the PIAS3 PINIT domain and the Siz1 structure from HHpred (Figure 
2.7). This shows that although the sequence similarity is so diverse within the PIAS 
orthologs, structure is conserved. Comparison of predicted secondary structure features of the 
PINIT domain of PIAS3 and the predicted secondary structure features of the PINIT domain 
of Siz1 show a high degree of similarity and consensus on prediction (Figure 2.7). The 
PINIT domain of Siz1 structure was then used to generate the model of the PINIT domain of 
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PIAS3. The generated PINIT model (Figure 2.11) showed the “PINIT” motif on a loop 
buried in the hydrophobic core. However, its location on the loop indicates the possibility of 
a certain degree of flexibility to achieve its functional purpose. Furthermore, the model shows 
interesting surface exposed residues that are within the region that was previously the study 
focus of PIAS3–STAT3 interactions (Levy et al., 2006; Yagil et al., 2009). Previous studies 
on the disruption of this motif resulted in delocalisation of the PIAS3 proteins. Furthermore, 
Levy et al. (2006) determined that 50 amino acids at the N–terminus of the PINIT domain are 
sufficient to bind to STAT3 while Yagil et al. (2009) showed that 23 amino acids at the N–
terminus of the PINIT domain achieve the same function. The predicted PINIT homology 
model showed that the N–terminal 23 amino acid epitope is located on a loop–sheet–loop 
structure (Figure 2.8C). The PINIT domain showed that the N–terminal antiparallel β–sheet 
formed by β1, β2 and β3 (Figure 2.8) formed a stable structure. The final predicted PINIT 
domain model assessed by MetaMQAPII (Pawlowski et al., 2008 (Figure 2.8 and Figure2.9 
and Figure 2.10) was shown to be a good quality model that can be adopted with high 
confidence for use as a template to generate the mutant models. 
A previous mutation Y94P resulted in loss of PIAS3 function, probably due to disruption of 
secondary structure (Levy et al., 2006). The generated PINIT model showed R99 amino acid 
surface exposed (Figure 2.11C β–sheet–loop–β–sheet) and potentially able to take part in 
hydrogen bonding and ionic interactions whereas amino acid L97 on the same loop is buried 
inside. Therefore, these conserved residues were targeted for mutational analysis in this 
study. Furthermore, the sequence analysis results (Figure 2.2 and Figure 2.3), together with 
the previous in vivo and in vitro mutational analysis of PIAS3 (Levy et al., 2006; Yagil et al., 
2009) highlighted the need to investigate the involvement of these residues in the PIAS3–
STAT3 interaction. Replacement of the surface exposed R99 with Asn and Gln residues 
(which are less bulky and lack charge) and the L97 residue, with Ala (a relatively small 
residue) (Figure 2.13) could possibly affect PIAS3–STAT3 interaction. The assessment of 
the structural effect of these mutated residues (Figure 2.6 and Figure 2.12) indicated no 
potential gross disruption of the local structure of the PINIT domain. However, the PINIT 
domain model revealed that the replacement of the L97 residue buried in the hydrophobic 
core with Ala increased the contact distance between the residues within the hydrophobic 
core (Figure 2.13) and this may result in tight packing under physiological conditions 
affecting the orientation of the neighbouring residues and possibly the biochemical function 
of the PIAS3 protein. Previous PIAS3–STAT3 interactions studies focused mainly on the N–
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terminus of the PINIT domain. However, PIAS3 is a multidomain protein and other domains 
may be involved in PIAS3–STAT3 interaction. In particular, findings by Borghouts et al. 
(2010) suggested that the C–terminal domain of PIAS3 is involved in PIAS3–STAT3 
association. These findings were based on yeast two–hybrid experiments also, mutational 
analysis in the context of PIAS3–STAT3 direct interaction were not performed. However, 
performed mutational analysis were on Val, Ile, Leu, Thr residues in the context of PIAS3–
SUMO–1 association and resulted in reduced binding affinity of the SUMO–1 (Song et al., 
2005). These findings highlight the need to investigate the acidic domain of PIAS3 relative to 
PINIT domain and PIAS3 full length. 
This chapter employed bioinformatics tools to accurately predict the structural elements of 
PIAS3. A high quality PINIT domain model was generated and adopted with confidence to 
predict key residues governing the PINIT domain function and to assess the structural effect 
of mutation of identified residues. Furthermore, the information revealed by the sequence 
alignment and secondary structure predictions will guide the determination of the PINIT 
domain boundaries for in vivo and in vitro expression of a folded and functional protein. 
Insights into in vitro and in vivo activity of in silico predicted mutants presented here will be 
discussed further in Chapter 3 and 5.  
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CHAPTER 3 
 
 
ANALYSIS OF THE CELLULAR LOCALISATION OF PIAS3 AND ITS DOMAINS  
 
Regulation of STAT3 localisation by PIAS3 requires complete elucidation. It is critical to 
understand the molecular determinants governing protein–protein (PIAS3–STAT3) 
interaction and the binding interface between PIAS3 and STAT3 in order to understand 
PIAS3 potential in the regulatory control mechanism. Here, in vivo analysis of PIAS3–STAT3 
interaction was investigated by comparative localisation analysis of full length PIAS3, the 
PINIT and acidic domains with endogenous STAT3 in HeLa human cervical cancer cells in 
the presence and absence of IL–6 stimulation. 
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3.1 INTRODUCTION 
 PIAS3 subcellular localisation is contentious. PIAS3 was originally found to be localised 
mainly in the nucleus, seemingly governed by the presence of the PINIT motif (Duval et al., 
2003). More recently Dabir et al. (2009) provided evidence for a mainly cytoplasm 
distribution of PIAS3. In their description nuclear translocation was reliant on stimulation of 
the gp130/JAK/STAT3 pathway and STAT3 phosphorylation at tyrosine 705. Furthermore, 
Dabir et al. (2009) showed that phosphorylated STAT3 levels were significantly reduced in 
the nucleus and this reduction was found to be PIAS3 dose–dependent. The nuclear 
localisation signal has not been fully described. The localisation and co–localisation of 
PIAS3 and activated STAT3 suggested PIAS3 role in regulation or mediation of 
phosphorylated STAT3 transcriptional activity. Knowledge of the interaction interface of 
PIAS3–STAT3 would further our understanding of PIAS3 activity in this tightly regulated 
system. The PINIT and the acidic domains of PIAS3 were suggested to interact with STAT3, 
the former interacting with the DNA binding domain of STAT3 and the latter interacting with 
the coiled coil domain of STAT3 (Chung et al.,1997; Duval et al., 2003; Yamamoto et al, 
2003; Borghouts et al., 2010).  
 Using the HeLa cervical cancer cell model, the study presented here attempted to show the 
comparative localisation of full length PIAS3, PINIT and acidic domain of PIAS3 with 
endogenous STAT3. 
3.2 METHODS 
3.2.1 Construction of expression plasmid encoding for Flag–PIAS3, Flag–PINIT, 
Flag–acidic and mutants Flag–PIAS3 
The p513–flag–PIAS3 mammalian expression construct with expression controlled by simian 
virus 40 (SV40) promoter (Duval et al., 2003) was a kind donation from Dr Hélène Boeuf 
(Université de Bordeaux, France). The presence of the PIAS3 coding region in p513–flag–
PIAS3 plasmid was confirmed by diagnostic restriction endonuclease analysis and automated 
DNA sequencing (Rhodes University DNA sequencing unit). The plasmid was used as the 
template for amplification of the PINIT and acidic domain coding regions (as described in 
Chapter 2) using the following primer sets: PINIT domain forward primer (5'–CAT ATG 
AAG CCC CTG CCC TTC –3') with NdeI site (underlined) and the PINIT domain reverse 
primer (5'- AAG CTTATTA CAC TTC ACT GTC GGG GTC - 3') Hind III site (underlined) 
and acidic domain forward primer (5'- CAT ATG GAA GAT GGA TCC TGG TGT C –3') 
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with NdeI site (underlined) and acidic domain reverse primer (5'– 
AAGCTTTAAGCCCCCAGTGG –3') with HindIII site (underlined). The polymerase chain 
reaction (PCR) amplification of the PINIT and acidic domains coding regions were 
performed as follows: one cycle of denaturation (95°C for 30 seconds), 30 cycles of 
denaturation, annealing and extension (95°C for 30 seconds, 55°C for 30 seconds, 72°C for 
30 seconds), one cycle of final extension (72°C for 7 minutes) followed by a 4°C hold. The 
PCR–amplified fragments were purified from 0.8 % TBE agarose gel electrophoresis and 
ligated into the pGEM–T–Easy vector to generate pGEM–T–PINIT and pGEM–T–Acidic 
and transformed into E. coli JM109. The PINIT and acidic domain–encoding NdeI–HindIII 
fragment was restricted from pGEM–T and purified from 0.8 % TBE agarose gel 
electrophoresis and ligated downstream of Flag–tag coding sequence of NdeI–HindIII 
restricted p513–flag expression vector to generate p513–flag–PINIT and p513–flag–acidic. 
The restricted p513–flag vector was also purified from 0.8 % TBE agarose gel 
electrophoresis. The constructs were confirmed by restriction analysis and automated DNA 
sequencing (Rhodes University DNA sequencing unit).  
3.2.2 Mutagenesis of PIAS3 
P513–flag–PIAS3 plasmid was used as a template for site–directed mutagenesis using the 
double stranded whole plasmid linear non–PCR amplification procedure (according to the 
QuikChange mutagenesis kit; Stratagene). Complementary mutagenesis primers were 
designed for the introduction of single point mutations at L97A, R99N and R99Q (as 
previously described in Chapter 2) into the PINIT domain coding sequence (Appendix G2). 
Each mutagenesis reaction was comprised of 100 ng of p513–flag–PIAS3 parental plasmid 
template, 2.5 µl of dimethyl sulfoxide (DMSO), 10 µl of 25 mM MgCl2, 1 µl of 10 mM 
dNTP mix , 125 ng of the forward primer, 125 ng of the reverse primer, 5 µl of 10x Pfu DNA 
polymerase buffer (200mM Tris–HCl [pH 8.8], 100 mM KCl, 100 mM (NH4)2SO4, 20 mM 
MgSO4), 1 U of Pfu DNA Polymerase and sterile double distilled water to a final volume of 
50 µl. Thermal cycling was allowed to proceed as follows: one cycle of denaturation (95°C 
for 30 seconds), 18 cycles of denaturation, annealing and extension (95°C for 30 seconds, 
52°C for 60 seconds, 68°C for 5 minutes), one cycle of final extension (68°C for 7 minutes) 
and a 4°C hold at the end. Digestion of the parental p513–flg–PIAS3 plasmid in the 
amplification product was achieved by the addition of 5U of DpnI restriction endonuclease to 
the reaction mixture and incubation at 37°C overnight. Pre– and post–DpnI samples were 
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analysed by 0.8% TBE agarose gel electrophoresis (Appendix D4). An aliquot of 10 µl of 
post–DpnI samples was transformed into E. coli JM109 supercompetent cells (Promega) for 
screening purposes. Plasmid DNA was isolated from the resulting colonies and screened for 
the desired mutation by automated DNA sequencing (Appendix D7) using the designed 
forward and reverse sequencing primer set (Appendix H3). The p513–flag–PIAS3 plasmid 
was used to generate the p513–flag empty vector by engineering an NdeI site and a STOP 
codon upstream of HindIII site by the following primers: forward primers (5'– 
CCATTTCCTTGGACCATATGTAAGCTTCCTAGGTC –3') with NdeI site (bold and 
underlined) and the STOP codon (italics) and the reverse primer (5'– 
GACCTAGGAAGCTTACATATGGTCCAAGGAAATGG –3') with NdeI site (bold and 
underlined). The PIAS3 coding region was removed by restriction with NdeI enzyme and the 
p513–flag vector was purified from 0.8 % TBE agarose gel electrophoresis and re–ligated.  
3.2.3 Cell culture and maintenance 
Cell lines used in this study were MCF7 human breast cancer cell line, NIH3T3 immortalised 
mouse fibroblast cell line and HeLa cervical cancer cell line. MCF7 cell line is a breast 
epithelial adenocarcinoma cell line derived from a metastatic pleural effusion in a 69 year old 
Caucasian adult female (Soule et al., 1973). NIH3T3 cell line was originally established from 
the primary mouse embryonic fibroblast cells (Todaro and Green, 1963). HeLa cells are 
human epithelial cells from a fatal cervical carcinoma. The cell line was derived from 
cervical cancer cells taken from Henrietta Lacks 1951. All cell lines were maintained in 
Dulbecco‟s Modified Eagle Medium (DMEM) (Gibco) supplemented with 5 % heat 
inactivated foetal calf serum (FCS) 100 U.ml
–1
, penicillin–streptomycin and 2 mM L–
Glutamine, and were incubated in a humidified atmosphere at 37C with 10.0 % (v/v) CO2 in 
air. Cell were passaged at a ratio 1:3 every 3 to 4 days through trypsinisation by aspirating the 
medium prior to addition of 300 µl 1x Trypsin/EDTA (ethylenediaminetetraacetic acid) 
followed by wash with 1X PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM 
K2H2PO4, pH 7.4) and incubating the cells at 37
o
C at 10% CO2 until cells lifted. Cells were 
seeded in fresh culture dishes containing fresh culture medium. The DMEM with 
supplements described above medium was changed every second day. Cell viability was 
assessed by trypan blue (Sigma) dye exclusion using a hemocytometer and observation by 
inverted light microscopy. 
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3.2.4 Transient transfection  
Endotoxin–free plasmids encoding for PIAS3, PINIT & acidic domains and mutant PIAS3 
proteins were isolated using GenElute
TM
 endotoxin–free plasmid midiprep kit (Sigma–
Aldrich) (Appendix D2) before transfection of HeLa cells. HeLa cells were plated onto 
glass–bottomed culture well plate. The next day, the media was aspirated and cells washed 
once with Opti–MEM media (invitrogen). Transfection mixes contained 250 µl/well of 
serum–free drug–free Opti–MEM and 4 µg/well of each plasmid, and 10 µl/well 
lipofectamine–2000 were mixed and allowed to form DNA–lipofectamine complexes for 20 
minutes at room temperature. Transfection mixtures were added to washed cells in dishes and 
incubated for 5 h at 37 °C, 10 % CO2. After incubation, 1 ml of DMEM supplemented with 2 
% FCS antibiotics–free was added to each well and after 12 hours the medium was replaced 
with a complete media with antibiotics. 
3.2.5 Preparation of cell lysates  
Protein lysates were prepared 48 h post–transfection by washing cells twice in ice–cold 
phosphate–buffered saline. Cells were trypsinized by 250 µl 1x Trypsin/EDTA in calcium 
and magnesium–free phosphate buffered saline (PBS), and incubated for 3–5 min at room 
temperature. The trypsinized cells were resuspended in equal volume of DMEM containing 
10% (v/v) FCS to stop the trypsin reaction. The cells were washed in PBS buffer prior to 
resuspension in RIPA lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X–100, 
0.1% SDS, 0.8% deoxycholic acid, 10% glycerol, 1 mM EDTA, 1 mM PMSF, 5 µg/ml 
leupeptin–pepstatin–aprotinin, 0.15 mM NaVO3, and 1 mM DTT) and incubated on ice for 15 
minutes. Lysates were clarified at 10,000 × g for 5 minutes at 4 °C and the soluble protein 
lysate concentration quantified by NanoDrop 2000 (Thermo scientific).  
3.2.6 Detection of the expressed protein by immunofluorecence staining 
Transfected cells grown on a glass cover slip in a 24 well plate were starved for 12 hours in 
serum free media prior to 10 minutes and 30 minutes stimulation with 20 ng/ml IL–6 (Sigma 
Aldrich) before washing with PBS. Cells were fixed by incubation with PBS containing 4% 
paraformaldehyde and 4 % sucrose for 15 minutes at room temperature. The cells were then 
washed twice with PBS for 5 minutes and permeabilized by incubation with 0.25 % Triton
TM 
X–100 in PBS for 5 minutes followed by two washes with PBS for 5 minutes. The cells were 
blocked using 5% BSA in PBS for 30 minutes at 37
o
C followed by incubation with mouse 
anti–FLAG M2 monoclonal antibody (Sigma Aldrich) and rabbit polyclonal anti-STAT3 IgG 
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antibodies (Santa Cruz biotechnology) in 3 % BSA in PBS at a dilution of 1:500 for 2 hours 
at 37
o
C. The cells were washed twice with PBS for 5 minutes followed by incubation in 
FITC–labeled secondary antibodies, Alexa FluorR 488 donkey anti–mouse IgG (Invitrogen, 
USA) and Alexa Fluor
R
 546 chicken anti–rabbit IgG (Invitrogen, USA) at a 1: 1000 dilution 
in 3 % BSA in PBS for 45 minutes at 37
o
C. The cells were washed twice with PBS followed 
by nuclear counterstaining with Hoescht at 1:1000 dilution. The moisture was allowed to 
evaporate in a dark cupboard before the glass coverslip was mounted with cells side down on 
glass slides using a small drop of DEKO mounting medium (Invitrogen). 
Immunofluorescence images were captured using a confocal laser–scanning Zeiss LSM 510 
microscope with 40X oil objective. Images were recorded and processed digitally with Zeiss 
LSM Image Browser software (Carl Zeiss Gmb H Jena). The excitation wavelength for Alexa 
Fluor
R
 488 was 488 nm, and the emission was captured at 500–550 nm. The excitation 
wavelength for Alexa Fluor
R
 546 was 546 nm and the emission was captured at 560–600 nm. 
3.2.7 Detection of proteins by western blot analysis  
Protein lysates were prepared as described above (section 3.3.5) and protein concentrations 
were quantified by NanoDrop 2000 (Thermo Scientific). Approximately 15 µg of protein 
from each sample was separated on 11 % SDS–PAGE, electro blotted onto a HybondTM–C 
extra nitrocellulose membrane (Amersham USA). The membrane was blocked for 1 h at 
room temperature using 5.0 % (w/v) non–fat powder milk in Tris–buffered saline–Tween 
(TBST); (50 mM Tris, 150 mM NaCl, 0.1% (v/v) Tween 20, pH 7.6); the membrane was 
incubated overnight at 4
o
C on a rocking platform in 5.0 % (w/v) non fat powder milk in 
TBST, pH 7.6 containing specific primary antibodies; washed once with TBST followed by 
incubation for 1 h at room temperature on a rocking platform in 5.0 % (w/v) non fat powder 
milk in TBST, pH 7.6 containing specific secondary antibodies. The membrane was washed 
for 15 minutes three times with TBST before chemiluminescence–based protein detection. 
Chemiluminescence–based protein detection was achieved using the ECLTM western blotting 
kit (GE Healthcare) as per the manufacturer‟s instructions, and captured with a Chemidoc 
chemiluminescence imaging system (BioRad, UK). Specific antibodies and the dilutions were 
as follows: 1:1000 for mouse anti–FLAG M2 monoclonal antibodies, 1:500 for mouse 
monoclonal anti-STAT3 IgG antibodies, 1: 1000 for mouse monoclonal anti-PIAS3 IgG 
antibodies (Santa cruz biotechnology) and Horseradish peroxidise conjugated (HRP) goat 
anti–mouse IgG (GE Healthcare) at 1:5000 dilution.  
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3.2.8  Quantitative co–localisation analysis 
Immunofluoresence images captured by immunofluorescence microscopy were used to 
quantitatively analyse potential co–localisation of PIAS3 and STAT3. Images were processed 
using ImageJ 1.43 (McMaster Biophotonics Facility (MBF), McMaster University, Canada). 
The images were separated into component red and green channels. Background signal 
correction was performed by selecting areas of interest outside the cell. The red and green 
images were selected and used for intensity correlation analysis, and the colour scatter plots 
and the Pearson‟s correlation coefficient (MBF manual 
http://www.macbiophotonics.ca/imagej/) were automatically calculated. 
 
3.3 RESULTS 
3.3.1 Construction and verification of plasmids encoding for PIAS3, PINIT and the 
acidic domains of PIAS3.  
The following expression plasmids: p513–Flag–PINIT, p513–Flag–acidic, p513–Flag–PIAS3 
and p513–Flag were successfully constructed and confirmed by restriction endonuclease 
analysis (Appendix B1) and automated DNA sequencing. PIAS3 point mutation 
corresponding to L97A, R99N and R99Q were made on p513–Flag–PIAS3–L997, p513–
Flag–R99N, and p513–Flag–PIAS3–R99Q plasmids respectively and verified by automated 
DNA sequencing. 
 3.3.2 Protein expression in Cell lines 
HeLa cells express endogenous STAT3 and low but detectable levels of PIAS3, therefore 
endogenous STAT3 was stained for co–localisation studies. Western blot analysis was 
performed to confirm the expression of endogenous STAT3 and PIAS3 in HeLa, MCF7 and 
NIH3T3 cell lines. All cell lines expressed endogenous PIAS3 at low levels compared to 
STAT3 (Figure 3.1).  
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Figure 3.1 Expression of endogenous STAT3 and PIAS3 in various mammalian cell lines. Detection of 
STAT3 and PIAS3 in HeLa, MCF7 and NIH3T3 cells by western blot analysis. Equal amounts of 15 µg of 
soluble proteins were loaded in each well of 12 % SDS–PAGE and electroblotted to the membrane. Endogenous 
PIAS3 and STAT3 protein at 68 kDa and 85 kDa respectively were detected. The presence of STAT3 and 
PIAS3 were determined by western blot analysis using 3 mouse monoclonal anti-STAT3 IgG antibodies (Santa 
cruz biotechnology), mouse monoclonal anti-PIAS3 IgG and HRP–conjugated goat anti–mouse IgG (GE 
Healthcare) at 1:5000 dilution and a chemiluminescence based detection system. The signal was detected using 
a Chemidoc XR imaging system (BioRad, UK).  
 3.3.2.1 In vivo expression of Flag–tagged proteins  
Endotoxin–free plasmids encoding for the PIAS3, PINIT and acidic proteins were 
successfully isolated and characterised. Human HeLa cervical cancer cells were successfully 
cultured and transfected. All analyses were done by transiently transfection of plasmids 
encoding for PIAS3, PINIT and acidic domains and the transfection efficiency of 
approximately 5 % was observed in all transfections. The plasmids that were transfected into 
the cells encoded the flag–tag, facilitating detection. The expression of Flag–PIAS3, Flag–
PINIT and Flag–acidic proteins in the transfected HeLa cells were confirmed by western blot 
analysis of the soluble protein lysates of transfected HeLa cell lysates prepared 48 hours post 
transfection. Molecular mass species of 68 kDa, 23 kDa and 19 kDa corresponding to Flag–
PIAS3, Flag–PINIT and Flag–acidic, respectively, were detected (data not shown). 
3.3.3 Localisation of the PIAS3, PINIT domain and acidic domain in IL–6 stimulated 
and unstimulated HeLa cells 
HeLa cells were successfully transfected with flag–tagged plasmid encoding for PIAS3, 
PINIT and acidic domains. The transfection efficiencies were estimated by 
immunofluorescence microscopy and approximately averaged at 5%. PIAS3 localisation was 
examined in the presence and absence of IL–6 stimulation. Flag–PIAS3 was found 
completely localised in the nucleus of all transfected HeLa cells (Figure 3.2). PIAS3 exhibits 
a similar pattern after stimulation with IL–6 for 10 and 30 minutes. PIAS3 displayed a 
speckled staining pattern of nuclear distribution but no definitive conclusions could be drawn 
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from this (Figure 3.2). Localisation of the PIAS3 protein in the nucleus was consistent with 
previous findings from various cell lines Table 1.1 (Kotaja et al., 2002; Sonnenblick et al., 
2004; Duval et al., 2003). However, in this study no response in PIAS3 was observed on 
treatment of transfected HeLa cells with IL–6, unlike IL-6 treatment on human pulmonary 
epithelial cell lines (A549 and H520) with EGF (Dabir et al., 2009).  
 
 
Figure 3.2 The subcellular localisation of PIAS3 in HeLa cells. HeLa cells were seeded in a glass bottomed 
culture dish for 24 hours and transfected with a p513–flag–PIAS3 plasmid encoding flag–PIAS3 protein. After 
48 hours the cells were starved for 12 hours in serum free medium before being left unstimulated or stimulated 
with 20 ng/ml IL–6 for 10 minutes and 30 minutes. The cells were fixed and permiabilised as described in 
section 3.2.3. Immunofluorescent labeling was performed with mouse anti–FLAG M2 monoclonal antibodies 
followed by one hour incubation with Alexa Fluor
R
 488 donkey anti–mouse IgG (green). Cell nuclei (blue) were 
directly labelled with Hoescht 33258. The immunofluoresence images were captured using a confocal 
fluorescence microscopy on a laser–scanning Zeiss LSM 510 confocal microscope. Merged images were 
automatically created by merging the flag–PIAS3 image with nuclei hoescht staining image using Zeiss LSM 
Image Browser software (Carl Zeiss Gmb H Jena). 
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To examine if the nuclear retention “PINIT” motif may also act as a nuclear localisation 
signal, HeLa cells were transfected with a plasmid encoding the PINIT domain alone and 
treated under the same conditions as that of full length PIAS3. The PINIT domain was found 
to be predominantly localised at the periphery of the nucleus in most cells however, the 
PINIT protein was also observed in the cytoplasm in lower amount in all cells (Figure 3.3). 
 
Figure 3.3 The subcellular localisation of PINIT domain of PIAS3 in HeLa cells. HeLa cells were seeded 
in a glass bottomed culture dish for 24 hours and transfected with a p513–flag–PINIT plasmid encoding flag–
PINIT protein. After 48 hours the cells were starved for 12 hours in serum free medium before being left 
unstimulated or stimulated with 20 ng/ml IL–6 for 10 minutes and 30 minutes. The cells were fixed and 
permiabilised as described in section 3.2.3. Immunofluorescent labeling was performed with mouse anti–FLAG 
M2 monoclonal antibodies followed by one hour incubation with Alexa Fluor
R
 488 donkey anti–mouse IgG 
(green). Cell nuclei (blue) were directly labelled with Hoescht 33258. The immunofluoresence images were 
captured using a confocal fluorescence microscopy on a laser–scanning Zeiss LSM 510 confocal microscope. 
Merged images were automatically created by merging the flag–PINIT image with nuclei Hoescht staining 
image using Zeiss LSM Image Browser software (Carl Zeiss Gmb H Jena). 
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Upon stimulation with the IL–6, the PINIT domain showed a similar pattern. Unlike the full 
length PIAS3 protein, the PINIT domain, despite carrying the nuclear retention motif, does 
not appear to localise exclusively to the nucleus in all transfected cells as observed for full 
length PIAS3.Upon stimulation with IL–6 STAT3 was phosphorylated, and translocated into 
the nucleus potentially either associating with nuclear PIAS3 or forming complexes with 
cytoplasmic PIAS3 prior to nuclear translocation (Dabir et al., 2009). The distribution of the 
PINIT domain alone in HeLa cells appeared to exhibit nuclear and cytoplasmic distribution. 
To examine its localisation in comparison to the PINIT domain, the flag–acidic domain was 
expressed in HeLa cells.  
 
 
Figure 3.4 The subcellular localisation of the acidic domain of PIAS3 in HeLa cells. HeLa cells were 
seeded in a glass bottomed culture dish for 24 hours and transfected with a p513–flag–acidic plasmid encoding 
flag–acidic protein. After 48 hours the cells were starved for 12 hours in serum free medium before being left 
unstimulated or stimulated with 20 ng/ml IL–6 for 10 minutes and 30 minutes. The cells were fixed and 
permiabilised as described in section 3.2.3. Immunofluorescent labeling was performed with mouse anti–FLAG 
M2 monoclonal antibodies followed by one hour incubation with Alexa Fluor
R
 488 donkey anti–mouse IgG 
(green). Cell nuclei (blue) were directly labelled with Hoescht 33258. The immunofluoresence images were 
captured using a confocal fluorescence microscopy on a laser–scanning Zeiss LSM 510 confocal microscope. 
Merged images were automatically created by merging the flag–acidic image with nuclei Hoescht staining 
image using Zeiss LSM Image Browser software (Carl Zeiss Gmb H Jena). 
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The cellular localisation of the acidic domain showed diffuse cytoplasm distribution with 
apparent accumulation in the nuclear periphery in all the cells (Figure 3.4). The acidic and 
the PINIT domains exhibited similar localisation in terms of the perinuclear accumulation. 
However, the acidic domain showed more cytoplasmic localisation than PINIT domain while 
the PINIT domains showed more nuclear localisation than acidic domain. The acidic and 
PINIT domains had localisations that were different from the PIAS3 which showed a 
complete nuclear localisation. 
 
3.3.4 Localisation of the mutant PIAS3 in IL–6 stimulated and unstimulated HeLa 
Cells 
 
Conserved residues L97 and R99, potentially important for PINIT domain function in 
PIAS3–STAT3 association and predicted structural effects upon mutation (L97A, R99N and 
R99Q), were shown in chapter 2. To determine whether the mutations affected the 
localisation by structural disruption of the PINIT domain and holo PIAS3, the flag–PIAS3 
mutants were expressed in HeLa cells. The expressed flag–PIAS3–L97A was found to 
predominately localise diffusely in the nucleus with punctate pattern in most of the 
transfected cells. However, unlike wildtype PIAS3, PIAS3–L97A exhibited traces in the 
cytoplasm in most cells (Figure 3.5). PIAS3–L97A showed a similar pattern after stimulation 
with IL–6 for 10 and 30 minutes. The L97A mutation reduced complete nuclear localisation 
as observed in wildtype PIAS3 (Figure 3.2). 
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Figure 3.5 The subcellular localisation of PIAS3–L97A in HeLa cells. HeLa cells were seeded in a glass 
bottomed culture dish for 24 hours and transfected with a p513–flag–PIAS3–L97A plasmid encoding flag–
PIAS3–L97A protein. After 48 hours the cells were starved for 12 hours in serum free medium before being left 
unstimulated or stimulated with 20 ng/ml IL–6 for 10 minutes and 30 minutes. The cells were fixed and 
permiabilised as described in section 3.2.3. Immunofluorescent labeling was performed with mouse anti–FLAG 
M2 monoclonal antibodies followed by one hour incubation with Alexa Fluor
R
 488 donkey anti–mouse IgG 
(green). Cell nuclei (blue) were directly labelled with Hoescht 33258. The immunofluoresence images were 
captured using a confocal fluorescence microscopy on a laser–scanning Zeiss LSM 510 confocal microscope. 
Merged images were automatically created by merging the flag–PIAS3–L97A image with nuclei hoescht 
staining image using Zeiss LSM Image Browser software (Carl Zeiss GmbH Jena). 
 
To examine the effect of mutation of residue R99 of PIAS3, flag–PIAS3–R99N protein was 
expressed in HeLa cells under the same conditions as previously described. The flag–PIAS3–
R99N showed a complete nuclear localisation like the wildtype PIAS3 (Figure 3.6). Unlike 
wildtype PIAS3 and PIAS3–L97A, PIAS3–R99N showed a diffuse nuclear localisation and 
no punctate pattern was observed in most cells. This observation suggests a possibility of 
destabilisation of PIAS3 function due to the mutation. The residue R99 was further analysed 
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by replacement with Q and flag–PIAS3–R99Q analysed in the same manner. 
 
Figure 3.6 The subcellular localisation of PIAS3–R99N in HeLa cells. HeLa cells were seeded in a glass 
bottomed culture dish for 24 hours and transfected with a p513–flag–PIAS3–R99N encoding flag–PIAS3–R99N 
protein. After 48 hours the cells were starved for 12 hours in serum free medium before being left unstimulated 
or stimulated with 20 ng/ml IL–6 for 10 minutes and 30 minutes. The cells were fixed and permiabilised as 
described in section 3.2.3. Immunofluorescent labeling was performed with mouse anti–FLAG M2 monoclonal 
antibodies followed by one hour incubation with Alexa Fluor
R
 488 donkey anti–mouse IgG (green). Cell nuclei 
(blue) were directly labelled with Hoescht 33258. The immunofluoresence images were captured using a 
confocal fluorescence microscopy on a laser–scanning Zeiss LSM 510 confocal microscope. Merged images 
were automatically created by merging the flag–PIAS3–R99N image with nuclei Hoescht staining image using 
Zeiss LSM Image Browser software (Carl Zeiss GmbH Jena). 
 
Flag–PIAS3–R99Q expressed in HeLa cells showed a diffuse nuclear distribution pattern 
which persisted under IL–6 stimulation (Figure 3.7). Traces of PIAS3–R99Q in the 
cytoplasm were observed on IL–6 stimulation in all of the transfected cells. Complete 
localisation of PIAS3–R99Q observed in resting cells was similar to the wildtype PIAS3. The 
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existence of cytoplasmic PIAS3–R99Q and the diffuse localisation after IL–6 stimulation in 
all cells may suggest destabilisation of PIAS3 function due to the mutation.  
 
Figure 3.7 The subcellular localisation of PIAS3–R99Q in HeLa cells. HeLa cells were seeded in a glass 
bottomed culture dish for 24 hours and transfected with a p513–flag–PIAS3–R99Q encoding flag–PIAS3–R99Q 
protein. After 48 hours the cells were starved for 12 hours in serum free medium before being left unstimulated 
or stimulated with 20 ng/ml IL–6 for 10 minutes and 30 minutes. The cells were fixed and permiabilised as 
described in section 3.2.3. Immunofluorescent labeling was performed with mouse anti–FLAG M2 monoclonal 
antibodies followed by one hour incubation with Alexa Fluor
R
 488 donkey anti–mouse IgG (green). Cell nuclei 
(blue) were directly labelled with Hoescht 33258. The immunofluoresence images were captured using a 
confocal fluorescence microscopy on a laser–scanning Zeiss LSM 510 confocal microscope. Merged images 
were automatically created by merging the flag–PIAS3–R99Q image with nuclei Hoescht staining image using 
Zeiss LSM Image Browser software (Carl Zeiss GmbH Jena). 
 
The differences observed in localisation of mutants PIAS3 compared to the wildtype PIAS3 
suggests that a mutation of L97 and R99 causes a subtle shift in PIAS3 localisation. PIAS3–
L97A and PIAS399Q showed a slightly more cytoplasmic localisation compared to wildtype 
PIAS3. 
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3.3.5 Co–localisation of PIAS3, PINIT domain and acidic domain with STAT3 
 
STAT3 was predominantly localised in the nucleus in all cells and was less distributed in the 
cytoplasm in all cells. Also punctate structures of STAT3 localisation in the cytoplasm were 
observed (Figure 3.8B). PIAS3 displayed speckled pattern and diffuse distribution in the 
nucleus but completely localised in the nucleus unlike STAT3. The distribution of PINIT 
domain was observed predominantly in the perinucleus and nucleus in most cells, but also 
less distributed in cytoplasm in all cells. The acidic domain was distributed predominantly in 
the perinucleus, with some traces in the cytoplasm in all cells. There was more cytoplasmic 
localisation of acidic domain compared to PINIT domain in most cells. 
Co–localisation of PIAS3, PINIT and acidic with STAT3 was investigated in transfected 
HeLa cells 30 minutes post IL–6 stimulation using immunofluroscence staining as described 
in section 3.2.3. STAT3 and PIAS3 showed a different distribution; however, the PIAS3–
STAT3 merged picture (Figure 3.8A) showed potential co–localisation of PIAS3 and STAT3 
in the nucleus. Co–localisation of PINIT and STAT3, merged red (STAT3) and green (PINIT) 
image observed on yellow regions of the image (Figure 3.8B) showed a high degree of co–
localisation in the nucleus. The acidic domain was observed co–localised with STAT3 in 
cytoplasm and perinucleus region indicated by yellow region of the merged picture (Figure 
3.8C).  
Also observed was the change of cell morphology with time after transfection (data not 
shown). Comparing cells in Figure 3.8 (A–C) , it was observed that 48 hours post 
transfection cells expressing PIAS3, PINIT and acidic domain displayed different 
morphology which probably suggested that expressed proteins selectively affects the growth 
and survival of cells. In particular the PINIT domain and the acidic domain transfected cells 
displayed similar morphology but as a whole different from the PIAS3 transfected cells.  
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Figure 3.8 Co–localisation analysis of PIAS3, PINIT and acidic domain with STAT3 in HeLa cells. A) 
HeLa cells grown on glass cover slips were transfected for 48 hours with a p513–flag–PIAS3 plasmid. B) Hela 
cells grown on glass cover slips were transiently transfceted for 48 hours with p513–flag–PINIT plasmid. C) 
HeLa cells grown on cover slips were transiently transfected for 48 hours with p513–flag–acidic. Cells were 
starved for 12 hours and stimulated for 30 minutes with IL–6 before fixing as described in section 3.2.3. 
Immunofluorescent labeling was performed with mouse anti–FLAG M2 monoclonal antibodies followed by one 
hour incubation with Alexa Fluor
R
 488 donkey anti–mouse IgG (green). Cell nuclei (blue) were directly labelled 
with Hoescht 33258. The endogenous STAT3 was stained with rabbit polyclonal anti-STAT3 IgG antibodies and 
followed by one hour incubation Alexa Fluor 546 chicken anti–rabbit IgG. The immunofluoresence images were 
captured using a confocal fluorescence microscopy on a laser–scanning Zeiss LSM 510 confocal microscope. 
Merged images were automatically created by merging the green image with nuclei Hoescht staining image and 
STAT3 (red) image using Zeiss LSM Image Browser software (Carl Zeiss GmbH Jena). 
 
 
The degree of co–localisation of PIAS3 and its domains with STAT3 in HeLa cells was 
quantitatively assessed using Pearson‟s correlation coefficient (PCC). This is the relationship 
between the red and green pixels in an image and was displayed as an intensity–scatter plot 
where the red image component is represented along the x–axis and green image component 
along the y–axis (Appendix B3). The co–localization results were shown in a pixel 
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distribution along a linear correlation line and the deviation from the linear distribution is 
quantified by the Pearson‟s correlation coefficient (PCC). The PCC defines the quality of the 
linear relationship between two signals as the red and green channel intensity distributions 
are linked. For confocal images PCC value close to 1 indicate reliable co–localisation. 
Quantitative analysis of co–localisation showed a lower degree of co–localisation of acidic 
domain (PCC of 0.574) with STAT3 in comparison with PINIT (PCC of 0.732) and PIAS3 
(PCC of 0.638).  
3.4  DISCUSSION AND CONCLUSION 
 
The localisation studies showed that the PIAS3 protein completely localised in the nucleus in 
all cells under both unstimulated and IL–6 stimulated conditions. PIAS3 exhibited nuclear 
punctate pattern in all cells. The PINIT domains alone showed a predominant localisation in 
the perinucleus and nucleus in most cells. However, cytoplasmic PINIT protein was also 
observed in all cells. The acidic domain alone was observed predominantly in the perinucleus 
in all cells; nevertheless more cytoplasmic acidic domain was observed compared to the 
PINIT domain. The PINIT and acidic domains exhibit cytoplamic distribution compared to 
wildtype PIAS3 which had complete nuclear localisation. The findings on PIAS3 localisation 
in this study were consistent with previous researchers (Kotaja et al., 2002; Sonnenblick et 
al., 2004; Duval et al., 2003; Man et al., 2006; Yamashina et al., 2006; Peng et al., 2010). 
However, previous studies by Dabir et al. (2009) showed cytoplasm localisation of 
endogenous PIAS3 which translocation into the nucleus upon EGF stimulation. Also, 
cytoplasmic localisation of endogenous PIAS3 was observed and its nucleus translocation 
upon proestrogene stimulation (Man et al., 2006).  
Differences in findings by previous researchers on PIAS3 localisation may be due to 
influences by different cell line. HeLa cells constitutively express IL–6 (Eustace et al., 1993) 
and IL–6 acts in an autocrine manner (Eustace et al., 1993). Also, it was observed that 
exogenous IL–6 did not activate STAT3 in cervical carcinoma cells (Hess et al., 2000). The 
non effect on IL–6 stimulation on HeLa cells observed on PIAS3, PINIT and acidic domains 
might be either due to stimulated pathway by autocrine system or a specific defect in the 
signalling pathway. It was also observed that glycoprotein 80 (gp80) was not detected on the 
surface of carcinoma cell lines that include HeLa cell line (Hess et al., 2000), but shedded 
sgp80 was detected, hence should be able to bind IL–6 and complete IL–6R–signaling 
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complex. This explains the weak response of HeLa cells to exogenous IL–6 (Hess et al., 
2000).  
The nuclear retention of the PIAS3 was suggested to be a result of the “PINIT” motif (Duval 
et al., 2003). The in vivo expression of the PINIT domain showed that the PINIT is diffusely 
localised in the perinucleus and cytoplasm unlike the wildtype PIAS3 despite both carrying 
the “PINIT” motif. These data suggest that the “PINIT” motif may not be critical for nuclear 
retention as suggested by previous studies conducted by deleting the “PINIT” motif (Duval et 
al., 2003). However, the delocalisation observed by Duval et al. (2003) may have been a 
result of disruption of the PIAS3 structure due to the deletion mutation of the “PINIT” motif. 
The acidic domain showed a diffuse localisation in the cytoplasm unlike the wildtype PIAS3 
which was completely localised in the nucleus. 
All the PIAS3 mutants exhibited a slight difference on the localisation pattern compared to 
the wildtype PIAS3. Unlike the wildtype PIAS3, the existence of the cytoplasmic PIAS3–
L97A and PIAS3–R99Q, and the diffuse nuclear localisation of PIAS3–R99N suggested a 
mutational effect on PIAS3 localisation. Residue R99 was predicted in silico to be surface 
exposed and has been predicted to be strongly involved in the PIAS–STAT3 interaction. 
Therefore abrogation of the punctate structures on PIAS3–R99N and PIAS3–R99Q suggest a 
functional purpose of the residue. Furthermore, diffusely localised PIAS3–L97A in the 
cytoplasm suggests an effect of the mutation. In chapter 2, this residue was shown buried in 
the hydrophobic core, although it was not predicted to be directly involved in the PIAS3–
STAT3 interaction. Replacement of this residue with a less bulk residues may have affected 
the neighbouring residues as described in chapter 2. Similar punctate granule pattern in 
PIAS3 localisation were observed in PIAS3–L97A, unlike wildtype PIAS3, PIAS3–L97A 
was diffusely localised in the cytoplasm.  
Despite the minor discrepancies described above, no major delocalisation effects were 
observed for all the PIAS3 mutants. However, observed traces of diffuse cytoplasmic staining 
of the PIAS3–L97A and PIAS3–R99Q could possible be due to abrogation of mutant PIAS3–
STAT3 interaction. Therefore, it is necessary for detailed in vitro analysis of the PIAS3–
STAT3 interaction with major focus on the region carrying the mutated residues in particular 
the PINIT domain. Also, further analysis (e.g. immunoprecipitation) of the mutant ability to 
interact with STAT3 in vivo is required. 
Co–localisation of the PIAS3, PINIT and acidic domains with STAT3 was qualitatively and 
quantitatively analysed. The qualitative assessment was performed by overlaying the flag–
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tagged image (green) and the STAT3 (red) image and the yellow regions shows a complete 
co–localisation of the red and green pixels. The quantitative assessment was performed by 
plotting the flag–tagged (green, y–axis) and the STAT3 (red, x–axis) image pixels and 
calculation of the Pearson‟s correlation coefficient to determine the extent of co–localisation 
(Appendix B3). The localisation of endogenous STAT3 was observed by staining using 
STAT3 rabbit polyclonal IgG antibodies that target both the phosphorylated and 
unphosphorylated forms of STAT3. The observed predominantly nuclear localised STAT3 
was most probable the phosphorylated STAT3. Therefore, staining with anti–phospho–STAT3 
rabbit monoclonal antibodies could validate these findings.  
Qualitative and quantitative analysis of co–localistion revealed a high degree of PINIT 
domains co–localisation with STAT3 and these data suggest a possibility of interaction with 
STAT3. This domain was of interest in this study because it was previously suggested to 
interact with STAT3 (Chung et al., 1997; Borghouts et al., 2010). Furthermore, the 
predominance of STAT3 nuclear localisation and the perinuclear and nuclear localisation of 
the PINIT domain in all transfected cells suggested the necessity to further investigate the 
nature of PINIT–STAT3 interaction. The difference in morphological changes in cells 
expressing PIAS3, PINIT and acidic domain suggested a selective effect of the protein in 
cells. Similar morphologic changes were observed in late apoptotic murine high–grade 
glioblastma cells (Tu–9648, Tu–2449) transfected by recombinant purified PIAS3 (400–523) 
peptide (Borghouts et al., 2010). The apoptotic effect of PIAS3 (82–132) and PIAS3 (82–
104) peptides was observed in RBL–2H3 cell lines (Levy et al., 2006; Yagil et al., 2009), and 
these peptide regions are encompassed in the PINIT domain. All these findings suggest 
further investigation of PINIT–STAT3 interaction using in vitro assays.  
The study concludes that the PIAS3 completely localised in the nucleus and mutation of 
residues R99 and L97 did not affect the nuclear retention signal. The PINIT domain, despite 
carrying the “PINIT” motif, was not completely localised in the nucleus, but had more co–
localisation with the STAT3 compared to full length PIAS3 and acidic domain. In vitro 
characterisation of the PINIT domain and the mutants will reveal further information. The 
investigation of the PINIT domain and its mutants using recombinant proteins by employing 
biophysical techniques will reveal more information about the PINIT domain and its binding 
affinity. Also, mutant PINIT–STAT3 direct interaction studies will reveal the extent of the 
effect of residues R99 and L97 predicted in silico.  
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CHAPTER 4 
 
CLONING, EXPRESSION AND PURIFICATION OF (HIS)7–PINIT PROTEIN 
 
PIAS proteins located in distinct chromosomes in the human genome are negative regulators 
of cytokine–mediated gene activation pathways. The PINIT domain of the PIAS3 has been 
suggested to be the determinant domain for PIAS3–STAT3 interaction. Here, molecular 
techniques were employed to design expression constructs encoding the PINIT domain of 
PIAS3 for heterologous expression and purification of recombinant PINIT protein. Using size 
exclusion chromatography, Fourier Transformed Infrared Spectroscopy and simple 
immunological assays, recombinant proteins were characterised both in terms of structural 
integrity and functional biological activity.  
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4.1 INTRODUCTION  
Although PIAS3 protein is a multidomain protein, only the PINIT and acidic domains were 
suggested to interact with STAT3 (Chung et al., 1997; Levy et al., 2006; Yagil et al., 2009; 
Borghouts et al., 2010). In silico and in vivo analysis of the PIAS3, PINIT and acidic domains 
showed that findings about the PINIT domain highlighted the need for its further 
investigation using an in vitro approach. 
The objective of recombinant PINIT protein expression is to produce a protein with 
detectable biological activity. In most cases the desired activity is supported by a discrete 
domain and it is often not necessary to express the full–length protein to address particular 
biological questions. For successful expression of a fragment of the holo–protein, the choice 
of domain boundary is critical. Small structural differences often have great influence in the 
expression and solubility. Therefore, prior knowledge of protein structure, sequence 
conservation pattern and prediction of the secondary structures or unfolded/ disordered 
regions must be considered (Ginalski et al., 2003; Ward et al., 2004). The use of secondary 
structure prediction software can avoid disruption of the predicted secondary structural 
elements and borders should be engineered to encompass these secondary structure features 
(Yang et al., 2005). In addition, it has been advised to avoid inclusion of low complexity 
regions or hydrophobic residues at the termini (Yang et al., 2005). 
Practical key points to consider are: expression strain; expression vector plasmid; size of the 
fragment to express; the affinity tag; and the purification strategy to use. Among the many 
systems available for heterologous protein expression, the gram-negative bacterium 
Escherichia coli remains one of the most attractive because of its ability to grow rapidly to 
high densities on inexpensive substrates. Methodical solubility studies with variable 
induction and growth strategies need to be employed to yield soluble and correctly folded 
protein. The use of affinity tags often improves the expression and purification of high 
quality proteins. Some tags potentially interfere with protein folding and function. Certain 
affinity tags have a beneficial effect on protein solubility especially in bacterial protein 
expression (Kapust et al., 1999; Chong, 2001). Small tags, such as His–tag (Hochuli et al., 
1988), bear a smaller risk of steric interference than larger tags such as glutathione–S–
transferase (GST) (Chong, 2001) or maltose binding protein (MBP) (Terpe, 2003). In 
comparison to His–tag, GST have combinations of disadvantages that includes its homo–
dimeric nature which affect the protein solubility and folding (Kaplan et al.1997). 
Furthermore, the solvent exposed cysteine residues of GST can lead to oxidative aggregation 
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and expenditure of more metabolic energy during expression compared to His–tag (Kaplan et 
al., 1997). However, successful expression of a protein is by performing empirical trials 
through altering expression conditions such as temperature, inducer concentration and 
observing the solubility and stabilities of the recombinant proteins that are obtained (Riggs et 
al., 1994). 
The Fourier transform infrared spectroscopy (FTIR) technique is applied to structurally 
characterise the protein in aqueous and non-aqueous environments. FTIR provides 
information about the secondary structure content of protein and indicates the conformation 
of the protein (Lamba et al., 1993; Haris and Severcan, 1999). Also, circular dichroism 
spectroscopy is used to gain information about the secondary structure of proteins and 
polypeptides in solution (Alder et al., 1973). The advantages of both techniques are that they 
use very little sample (200 µl of 0.5 mg/ml solution in standard cells) and are non–
destructive. The disadvantages of both techniques are the interference with solvent absorption 
in the UV region. However, this can be digitally subtracted in FTIR technique. Furthermore, 
the disadvantage of CD is that it is operated below 200 nm wavelength where only very dilute 
and non–absorbing buffers allow measurements.  
Here, the successful cloning, heterologous expression and purification of functional, folded 
recombinant PINIT domain is described. In addition, the PINIT domain protein was 
characterised by size exclusion chromatography and FTIR and its preliminary functional 
analysis were performed by dot blot association assay. 
 
4.2 METHODS 
4.2.1  Materials 
Specialised materials and reagents utilised are listed in the Appendix E. Reagents were 
obtained from Sigma Chemicals (USA), Roche Molecular Biochemical (USA) and Merck 
Chemicals (Germany). Optimized oligonucleotides were synthesized by IDT Oligo (USA) 
and distributed by Whitehead Scientific (South Africa). Nickel–chelating Sepharose Fast 
Flow matrix was obtained from Pharmacia Biotech (Sweden). The p513–Flag–PIAS3–WT 
plasmid was a kind donation by Dr Hélène Boeuf (Université de Bordeaux, France) (Duval et 
al., 2003), and the pET32b–STAT3b–tc plasmid was a kind donation by Dr Christoph Müller 
(EMBL, Germany) (Becker et al., 1998). The pQE2 and pQE60 plasmids were purchased 
from Qiagen (USA) and the pGEM–T–EASY vector and pGEX–4T–1 were purchased from 
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Promega (USA). Bacterial expression strains E.coli XL1 Blue, E. coli BL 21(DE3) and 
JM109 were purchased from Novagen (USA). Rosseta and E. coli M15[pREP4] were 
purchased from Qiagen (USA). The Hybond
TM–C Extra nitrocellulose membranes, and the 
size exclusion column, Superdex 200 HR 10/30 were purchased from Amersham–Phamarcia 
Biotech, (USA). The mouse monoclonal anti–His primary antibody, horseradish peroxidase 
(HRP)–conjugated goat anti–mouse IgG antibody, mouse Anti–Glutathione–S–transferase 
(GST) monoclonal antibody and the Enhanced Chemiluminescence (ECL) kit were purchased 
from GE Healthcare (UK). Amicon
R
 Ultra Ultracel
R
 (10K) Centrifugal Filters were purchased 
from Millipore (Ireland). HisTrap columns were purchased from GE Healthcare (UK). 
4.2.2 Construction of double tagged pGEX4T–PINIT plasmid encoding GST–
PINIT–(His)6 protein  
The PINIT domain coding region was amplified from purified p513–flag–PIAS3 construct 
using the following primers: forward primer 
(5'CATATGAAGCCCCTGCCCTTCTATGAAGTCTATGGG –3') (annealing temperature 
64.4
o
C) with NdeI (underlined) and reverse primer 
(5'GTCGACTTAGTGATGGTGATGGTGATGCACTTCACTG –3') (annealing temperature 
64.6
o
C) with a SalI site (underlined) and His6–tag (bold and italics). Polymerase chain 
reaction (PCR) was used to amplify the PINIT domain coding region (initial denaturation, 
94
o
C for 2 minutes; cycles of denaturation, annealing and elongation, 30 cycles of 94
o
C for 
30 seconds, 55
o
C for 30 seconds and 72
o
C for 30 seconds respectively; and final elongation, 
1 cycle at 72
o
C for 7 minutes). The PCR–amplified fragment was ligated into the pGEM–T–
Easy vector to generate pGEM–T–PINIT. The PINIT–encoding NdeI–SalI fragment was 
restricted from pGEM–T–PINIT and ligated downstream of the GST–tag coding region of 
NdeI–SalI restricted pGEX4T–1 expression vector to generate pGEX4T–1–PINIT with two 
tags (GST and His–tag). Restriction endonuclease analysis was performed using NdeI and 
SalI restriction enzymes and the fidelity of the constructs were confirmed by automated direct 
sequencing (Rhodes University DNA sequencing unit, South Africa). 
4.2.3 Construction of single tagged pGEX4T–PINIT plasmid encoding GST–PINIT 
protein  
A GST–tagged PINIT single tagged construct was generated from the double tagged 
pGEX4T–1–PINIT (GST–PINIT–(His)6) by insertion of a stop codon upstream of the His–
tag coding region. The insertion mutagenesis was performed by PCR using the double 
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stranded whole plasmid linear non–PCR amplification procedure (QuikChange mutagenesis 
kit; Stratagene). With the following primers: (5'–
CCCCGACAGTGAAGTGTAACATCACCATCACCATC–3') and (5'–
GATGGTGATGGTGATGTTACACTTCACTGTCGGGG–3') (stop codon underlined). Each 
mutagenesis reaction was comprised of 100 ng of pGEX4T–PINIT parental plasmid template, 
2.5 µl of dimethyl sulfoxide (DMSO) 10 µl of 25 mM MgCl2, 1 µl of 10 mM dNTP mix , 125 
ng of the forward primer, 125 ng of the reverse primer, 5 µl of 10x Pfu DNA polymerase 
buffer (100 mM KCl, 100 mM (NH4)2SO4, 20 mM MgSO4, and 1 U of Pfu DNA polymerase 
and sterile distilled water to a final volume of 50 µl. Thermal cycling was allowed to proceed 
as follows: one cycle of denaturation (95°C for 30 seconds), 18 cycles of denaturation, 
annealing and extension (95°C for 30 seconds, 52°C for 60 seconds, 68°C for 5 minutes), one 
cycle of final extension (68°C for 7 minutes) and a 4°C hold at the end. Digestion of the 
parental pGEX4T–PINIT plasmid in the amplification product was achieved by the addition 
of 5U of DpnI restriction endonuclease to the reaction mixture and incubation at 37°C 
overnight. Pre– and post–DpnI samples were analysed by 0.8% TBE agarose gel 
electrophoresis. An aliquot of 10 µl of post–DpnI samples was transformed into E. coli 
JM109 supercompetent cells (Promega) for screening purposes. Plasmid DNA was isolated 
from the resulting colonies and screened for the desired mutation by DNA sequencing using 
the designed forward sequencing primer (Appendix H3). The fidelity of the construct was 
verified by automated direct sequencing (Rhodes University DNA sequencing unit, South 
Africa). 
4.2.4 Construction of PQE60–PINIT plasmid encoding PINIT–(His)6 protein 
The PINIT domain coding region was amplified form p513–flag–PIAS3 construct using the 
following primers: forward primer (5'– CCA TGG AGC CCC TGC CCT TCT ATG –3') 
(annealing temperature 63.5
o
C) with NcoI (underlined) and the reverse primer (5'– 
AGATCTTCACTGTCGGGGTCAGCGG –3') (annealing temperature 64.1oC) with a Bgl II 
site (underlined. The PINIT domain coding region was amplified using polymerase chain 
reaction (PCR) (stage1, 94
o
C for 2 minutes; Stage 2, 30 cycles of 94
o
C for 30 seconds, 55
o
C 
for 30 seconds and 72
o
C for 30 seconds; and Stage 3, 1 cycle at 72
o
C for 7 minutes). The 
PCR–amplified fragment was ligated into the pGEM–T–Easy vector to generate pGEM–T–
PINIT. The PINIT–encoding NcoI–BglII fragment was restricted from pGEM–T–PINIT and 
ligated upstream of the His–tag coding region of NcoI–BglII restricted pQE60 expression 
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vector to generate pQE60–PINIT. Restriction digestion using NcoI and BglII as well as 
automated direct sequencing was used to confirm the fidelity of the construct (Rhodes 
University DNA sequencing unit, South Africa).  
4.2.5 Construction of pQE2–PINIT plasmid encoding (His)7–PINIT protein  
The p513–Flag–PIAS3–WT plasmid was used as the template for amplification of the PINIT 
domain coding region. The polymerase chain reaction (PCR) amplification of the PINIT 
domain coding region was performed with the following primers: the forward primer, 5'–
CAT ATG AAG CCC CTG CCC TTC –3' (annealing temperature 58oC) with a NdeI site 
(underlined); and the reverse primer, 5'– AAG CTT ATTA CAC TTC ACT GTC GGG GTC 
3' (annealing temperature 60
o
C) with Hind III site (underlined). The PCR consisted of three 
stages: stage 1, 94°C for 5 min; stage 2, 25 cycles of 94°C for 30 seconds, 55°C for 30 
seconds and 72°C for 30 seconds; and stage 3, 1 cycle at 72°C for 5 min. The PCR–amplified 
fragment was purified after agarose gel electrophoresis and ligated into the pGEM–T–Easy 
vector to generate pGEM–T–PINIT that was transformed into E. coli JM109. The PINIT 
domain–encoding NdeI – HindIII fragment was restricted from pGEM–T–PINIT and purified 
after agarose gel electrophoresis before ligation downstream of His–tag coding sequence of 
NdeI–HindIII restricted pQE2 expression vector to generate pQE2–PINIT. The fidelity of the 
constructs and the mutants were verified by automated direct sequencing (Rhodes university 
DNA sequencing unit, South Africa). 
4.2.6 Expression of GST–PINIT–(His)6, GST–PINIT and PINIT–(His)6 proteins 
The plasmids constructs: pGEX4T–PINIT (GST–PINIT–(His)6); pGEX4T–PINIT (GST–
PINIT); pQE60–PINIT (PINIT–(His)6), where each transformed separately into various E 
coli expression strains (Table 4.1); E .coli BL21 (DE3), E .coli XLI Blue, E .coli M15 
[pREP4] and Rosetta. The cells were spread onto Luria Bertani (LB) agar plates containing 
100 µg/ml ampicillin. E .coli M15 [pREP4] transformed with the plasmid were spread onto 
LB plates containing 100 µg/ml ampicillin and 50 µg/ml kanamycin followed by incubation 
at 37
o
C for approximately 16 hours to select successful transformants. Starter cultures were 
prepared by inoculation of a single colony of each transformants into 25 ml Luria Bertani 
(LB) broth containing appropriate antibiotic (E .coli BL21 (DE3), E .coli XLI Blue and E 
.coli Rosetta transformants, ampicillin; E .coli M15 [pREP4] transformants, ampicillin and 
kanamycin) and incubated overnight at 37
o
C. The starter culture was inoculated into 225 ml 
fresh LB with 100 µg/ml appropriate antibiotic and grown for 2–3 hours at 37oC until A600 nm 
75 
 
of 0.4 to 0.45. Temperatures were adjusted as in Table 4.1 before inducing with isopropyl β–
D–1–thiogalactopyranoside (IPTG) at a final concentration of 0.8 mM. Six hourly samples 
and an overnight sample were collected and analysed by sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS–PAGE) (Laemmli, 1970). The presence of PINIT–
(His)6 and GST–PINIT–(His)6 proteins were determined by western blot analysis using 
mouse monoclonal anti–His primary antibody (1: 5000 dilution) and HRP–conjugated anti–
mouse IgG antibodies (1:5000 dilution). The presence of GST–PINIT was determined using 
mouse Anti–Glutathione–S–transferase (GST) monoclonal antibody (1:5000 dilution) and 
HRP–conjugated anti–mouse IgG antibodies (1:5000 dilution). Chemiluminescence–based 
protein detection was achieved using the ECL
TM
 western blotting kit (GE Healthcare) as per 
the manufacturer‟s instructions and captured with a Chemidoc chemiluminescence imaging 
system (BioRad, UK). 
4.2.7 Expression and batch purification of (His)7–PINIT protein by batch nickel 
affinity chromatography 
Starter cultures were prepared by inoculating of E. coli XL1 Blue [pQE2–PINIT] into 25 ml 
Luria Bertani (LB) broth containing 100 µg/ml ampicillin, and incubating overnight at 30°C. 
The starter culture was inoculated into 1 liter fresh LB with 100 µg/ml ampicillin, and grown 
for two hours at 37
o
C until A600 nm of 0.4 to 0.45 and switched the temperature to 20
o
C and 
inducing with isopropyl β–D–1–thiogalactopyranoside (IPTG) at final concentration of 0.8 
mM. After 4 hour post inductions cells were harvested by centrifugation at 4000 g for 20 
minutes. The protein was purified under native conditions using cells from a 1 liter (4 x 250 
ml) culture of E.coli XL1 Blue [pQE2–PINIT]. Cells were lysed under native conditions in 
lysis buffer (10 ml; 40 mM Tris–HCl pH 8.0, 100 mM NaCl, 10 mM imidazole), containing 
lysozyme (100 µg/ml), 1 mM phenylmethanesulphonyl fluoride (PMSF), aprotinin 800 nM, 
and pepstatin 0.8 µg/ml. The cells were stored at –80°C overnight and thawed the following 
morning. Sonication was carried out (3 X 15 sec) and the cell debris was removed by 
centrifugation at 4000xg for 25 minutes at 4
o
C. The supernatant was added to 50% (w/v) 
slurry of nickel–chelating sepharose beads (1ml) in lysis buffer and allowed to bind for 2 hrs 
at 4
o
C with gentle agitation. The beads were washed three times in native wash buffer (40 
mM Tris–HCl pH 8.0, 100 mM NaCl, and 50 mM imidazole) and the bound (His)7–PINIT 
protein eluted with native elution buffer (40mM Tris–HCl pH 7.5; 100 mM NaCl; 500 mM 
imidazole). The eluted protein was purified further and buffer exchanged by size exclusion 
chromatography (section 4.2.10) as the final step of purification. Protein concentrations were 
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determined using the Bradford method (Bradford, 1976). Protein purity was visualized by 
coomassie stained 12% SDS–PAGE gels (Laemmli, 1970). The presence of (His)7–PINIT 
was determined by western blot analysis using mouse monoclonal anti–His primary antibody 
(1:5000 dilution), HRP–conjugated anti–mouse IgG antibodies (1:5000 dilution). 
Chemiluminescence–based protein detection was achieved using the ECLTM western blotting 
kit (GE Healthcare) as per the manufacturer‟s instructions, and captured with a Chemidoc 
chemiluminescence imaging system (BioRad, UK). 
4.2.8 HisTrap nickel affinity column protein purification of (His)7–PINIT protein 
A 1 ml HisTrap nickel affinity column (GE healthcare) (dynamic binding capacity of 40 mg 
of His–tagged protein per ml of the medium) was washed with 10 column volume (CV) of 
distilled water to remove storage ethanol. The column was equilibrated with 5 CV of binding 
buffer (20 mM sodium phosphate, pH 7.4 containing 0.5 M NaCl). Protein samples were 
filtered through a 0.45 µm filter and 2 ml was applied to the column, followed by washing 
with 10 CV wash buffer (20 mM sodium phosphate buffer, pH 7.4 and 50 mM imidazole) at 
0.4 ml/min flow rate prior to elution. Bound protein was eluted with 10 CV of elution buffer 
(20 mM sodium phosphate, pH 7.4, containing 0.5 M NaCl and 0.5 M imidazole), using 
linear gradient from 0 to 100 % and followed by a further 5 CV 100 % elution buffer at 0.4 
ml/min flow rate. The HisTrap column purification procedure described above was 
performed using a ÄKTA (BASIC) FPLC system (Amersham Pharmacia Biotech, UK). 
Protein purity was visualized by coomassie stained 12% SDS–PAGE gels (Laemmli, 1970). 
The presence of (His)7–PINIT was determined by western blot analysis using mouse 
monoclonal anti–His primary antibody (1:5000 dilution), HRP–conjugated anti–mouse IgG 
antibodies (1:5000 dilution). Chemiluminescence–based protein detection was achieved using 
the ECL
TM
 western blotting kit (GE Healthcare) as per the manufacturer‟s instructions, and 
captured with a Chemidoc chemiluminescence imaging system (BioRad, UK). 
4.2.9 Expression and purification of STAT3 protein 
Mouse STAT3β was expressed and purified as described by Becker et al. (1998). Briefly, 
pET32–STAT3–tc vector was transformed into E. coli BL21 (DE3). Overnight starter 
cultures (25ml) in LB broth containing 200µg/ml amplicillin were inoculated into 975ml of 
LB broth (200µg/ml ampicillin) for expression. Cultures were grown to A600 nm of 0.3 at 37°C 
prior to a temperature change to 20°C until A600 nm of 0.5–0.6. Expression was induced with 
1mM IPTG for 5–6 hours at 20°C. Cells were pelleted by centrifugation at 4 000 g and 
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resuspended in ice–cold lysis buffer (20mM HEPES, pH 7.5, 150mM NaCl, 10% (v/v) 
Glycerol). Cells were lysed by lysozyme treatment at 37°C and sonication (3 x 1min pulses at 
50% power). Cell debris was pelleted by centrifugation at 27000g for 40min at 4°C. 
Supernatants were treated with 0.1% (v/v) polyethylimine (incubated on ice for 15minutes 
with gentle shaking) and further centrifugation at 27000g to remove nucleic acids followed 
by addition of 35% (w/v) powdered ammonium sulphate to precipitate soluble protein by 
centrifugation at 27000g (4°C) after 15 minute on ice with gentle agitation. Protein pellets 
were resuspended in 10ml dialysis buffer (20mM HEPES, pH 7.0, 200mM NaCl) and 
dialysed against 2 changes (2 hours each) of dialysis buffer at a ratio of 1:100 followed by a 
final exchange at 4°C overnight. STAT3 protein was further purified to homogeneity by gel 
filtration chromatography using Superdex 200pg 16/60HR on a ÄKTA (BASIC) FPLC 
system (Amersham Pharmacia Biotech, UK) system at 1ml/min. Fractions were collected, 
analysed by 12% SDS–PAGE and concentrated by AmiconR Ultra UltracelR (10K) 
Centrifugal Filters (Millipore, Ireland) into 10 mM HEPES, pH 7.4, 150 mM NaCl. Protein 
was quantified by Bradford method (Bradford, 1976).  
4.2.10   Molecular mass characterisation by size exclusion chromatography 
Size exclusion chromatography of (His)7–PINIT protein and (His)7–PINIT mutants was 
performed on ÄKTA (BASIC) FPLC system (Amersham Pharmacia Biotech, UK) with a 
Superdex 200 HR 10/30 column at 25
o
C. The mobile phase/elution buffer (20 mM HEPES 
buffer, pH 7.5 containing 150 mM NaCl) was used at a flow rate of 0.5 ml/min. Elution 
volumes of 1 ml were collected by peak detection at 280 nm absorbance. The molecular mass 
of the eluted proteins were calculated from a calibration curve using bovine serum albumin 
(BSA), 67 kDa, albumnin, 43 kDa, ferritin, 440 kDa, and lysozyme, 14.6 kDa as standards. 
Blue dextran was used to determine the void volume. All fractions were concentrated by 
Amicon
R
 Ultra Ultracel
R
 (10K) Centrifugal Filters (Millipore, Ireland) and analyzed by 12 % 
SDS–PAGE (laemmli, 1970). The presence of (His)7–PINIT was determined by western blot 
analysis using mouse monoclonal anti–His primary antibody (1:5000 dilution), HRP–
conjugated anti–mouse IgG antibodies (1:5000 dilution). Chemiluminescence–based protein 
detection was achieved using the ECL
TM
 western blotting kit (GE Healthcare) as per the 
manufacturer‟s instructions, and captured with a Chemidoc chemiluminescence imaging 
system (BioRad, UK). 
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4.2.11   Structural and folding analysis of (His)7–PINIT protein by FTIR spectroscopy 
The FTIR studies were conducted with a PerkinElmer Spectrum 100 FTIR spectrometer 
(PerkinElmer Inc.) and data acquisition by Spectrum version 6.3.5 software. The FTIR 
instrument scans automatically for 50 scans for one spectrum at 4 cm
–1
 spectral resolution. 
Subtraction of solvent contribution was performed by subtraction of blanking buffer HBS 
buffer (10 mM Hepes buffered saline, 150 mM NaCl, pH 7.4) spectra recorded under the 
same scanning conditions as the sample. The protein sample at 0.6 mg/ml in HBS buffer (10 
mM Hepes buffered saline, 150 mM NaCl, pH 7.4) and 10µl of protein sample was used for 
each spectrum scan. Hydrogen exchange was performed by incubation with 20% D2O 
overnight at 4°C before recording the spectra. 
4.2.12   FTIR data processing and analysis 
The amide I band of proteins consists of overlapping bands representing structural element 
such as α–helices, β–sheets, turns and non–ordered structures. Individual components were 
resolved by Fourier deconvolution procedure. This involved narrowing the widths of infrared 
bands, allowing increased separation of the overlapping components present within the broad 
band envelope (Kauppinen et al., 1981; Haris and Severcan, 1999). Bands revealed by this 
technique were used to identify the different structures present in a protein and also to detect 
conformational changes by monitoring alterations in the frequency and intensity of these 
bands (Haris et al., 1986; Surewicz Mantsch, 1988; Arrondo et al., 1993). The absorption 
associated with Amide I band leads to stretching vibrations of the C=O bond of the amide. 
Absorption associated with Amide II bands leads primarily to bending vibration of the N–H 
bending with a contribution from C–N stretching. Amide I bands in the spectral ranges from 
1620–1640 cm–1, with proteins is attributed from β–sheet structure. Experimental studies on 
proteins of known structure showed that α–helices conformation gave raises to infrared 
absorption in the range 1650–1658 cm–1. (Haris et al., 1986; Surewicz Mantsch, 1988; 
Arrondo et al., 1993; Surewicz and Mantsch, 1988; Susi and Byler, 1986; Tamm and 
Tatulian, 1997). In some cases, bands around 1655 cm
–1
 were attributed to large loop 
structures rather than to α–helices (Prestelski et al., 1991) (Appendix C1). Analysis of the 
peptide group vibration in the polypeptide system allowed assignment of the characteristic 
bands. Secondary structure quantification by measuring the relative areas of amide I band 
components was performed by Gaussian curve fitting in the amide I region using PeakFit ID 
(SySTAT Software Inc, USA). Bands were assigned to various elements of secondary 
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structure (α–helix, β–sheet and unordered motifs as (Fu et al., 1994; Griebenow et al., 1995; 
Singh et al., 1993). The frequencies of band centres were those obtained from the resolution 
enhanced spectra and Gaussian fitted curve.  
 
4.2.13   Biochemical function of (His)7–PINIT protein by dot blot association assay 
(His)7–PINIT–STAT3 binding studies were performed by dot blot association assay using 
chemiluminescence–based immunodetection for visualization. Recombinant mouse STAT3 
was expressed and purified as previously described using E.coli BL21 (DE3) as a host strain 
(Becker et al., 1998). STAT3 protein (50 µg, 100 µg, 200 µg, 400 µg and 500 µg,) was 
spotted on Hybond
TM–C Extra Nitrocellulose membrane in a Bio–Dot ST (BioRad, UK) 
apparatus connected to a vacuum pump. BSA (600 ng) was used as a negative control and 
(His)7–PINIT protein (40 µg) as a positive control. The membrane was blocked with 5% 
non–fat powdered milk in TBS (50 mM Tris, 150 mM NaCl, pH 7.5) for one hour at room 
temperature and overlayed with 100 ng/ml PINIT protein for two hours at 4
o
C. The 
membrane was washed twice for 10 minutes in TBST buffer (50 mM Tris–HCl, 150 mM 
NaCl, 1% Tween–20 (v/v) pH 7.5), before incubation for one hour in mouse monoclonal 
anti–His primary antibody (1:5000 dilution). The membrane was washed with TBST before 
incubation for one hour in HRP–conjugated goat anti–mouse antibody (1:5000 dilution). The 
membrane was washed with TBST before incubation with the chemiluminescence reagents 
(ECL, Amersham, UK), and detection of the signal using chemiluminescence–based protein 
detection. Chemiluminescence–based protein detection was achieved using the ECLTM 
western blotting kit (GE Healthcare, UK) as per the manufacturer‟s instructions, and captured 
with a Chemidoc chemiluminescence imaging system (BioRad, UK). 
 
4.3 RESULTS 
4.3.1 Design and construction strategy of PINIT protein expression plasmids 
 
The region coding for the PINIT domain was amplified from p513–flag–PIAS3 construct (a 
kind donation from Dr Hélène Boeuf, Université de Bordeaux, France) (Duval et al., 2003). 
The construct was confirmed by diagnostic restriction endonuclease analysis (Appendix B8) 
and further verified by automated direct sequencing (Rhodes University DNA sequencing 
unit, South Africa). The size of the PIAS3 construct was confirmed to be 2040 bp and direct 
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sequencing also confirmed the presence of full length PIAS3 coding region between NdeI and 
HindIII sites.  
 
Figure 4.1 Design strategy for construction of the expression plasmids. (A) Conserved domains in PIAS3 
showing the PINIT domain from amino acid position 85 to 272 (Accession No. AF034080). (B) Construction of 
the expression plasmids. The region encoding the PINIT domain (amino acids 85–272) was PCR amplified from 
p513–Flag–PIAS3 plasmid and ligated into pGEM–T–Easy to give pGEM–T–PINIT. The PINIT–encoding 
fragment was restricted from pGEM–T–PINIT and ligated on the multiple cloning sites (MCS) of the target 
expression vector to generate PINIT domain expression plasmids (pQE60–PINIT, pGEX4T–PINIT and pQE2–
PINIT). 
Bioinformatics tools were employed in chapter 2 to analyse the PIAS proteins and further 
analyse the conserved PINIT domain. The results were critical to define the choice of PINIT 
domain boundary. The knowledge of PINIT domain structure, sequence conservation pattern 
and prediction of the secondary structures or unfolded/ disordered regions were carefully 
considered to influence the expression and solubility of the PINIT domain. 
Furthermore, analysis of the nucleotide sequences of the PINIT domain revealed the 
existence of arginine (AGG/AGA) and proline (CCC) rare codons. This could result in 
problems of early translation termination and suitable expression strains that co–expresses the 
tRNA for these rare codons were used. Using PCR, the region encoding the PINIT domain 
was amplified and restriction sites were designed to facilitate excision and insertion into a 
selected target vector via pGEM–T (Figure 4.1) to yield a construct encoding a PINIT 
protein. 
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4.3.2 PINIT–(His)6 expression analysis 
C–terminal tags offer certain advantages that may contribute to their effectiveness. Because 
the His–tag is at the end of the protein, only full–length PINIT domain proteins will be 
tagged and any PINIT protein truncated by premature termination of translation will not be 
purified by the Ni–IMAC column. Such premature termination can occur because PIAS3 
protein is a mammalian protein with rare codons and is being expressed in a prokaryote 
system. The region encoding the PINIT domain of PIAS385–272 protein was amplified by PCR 
with NcoI and BgIII restriction sites to facilitate insertion into pQE60 (via a pGEM–T based 
strategy; Figure 4.1) to give pQE60–PINIT. The pQE60–PINIT construct (Figure 4.2A) 
encoding a PINIT–(His)6 protein was confirmed by diagnostic restriction endonuclease 
analysis (Figure 4.2B) and further verified by automated direct sequencing confirmed that 
PINIT domain was cloned in frame between NcoI and BgIII sites. 
 
Figure 4.2 Diagnostic restriction analysis of pQE60–PINIT. A) plasmid map of pQE60–PINIT rendered 
using Vector NTI Advance
TM
 software package (version 10.3; Invitrogen). The β–lactamase–encoding gene for 
ampicillin resistance (Amp
R
) is indicated. The position of the PINIT domain between NcoI and BglII restriction 
sites are indicated; the region encoding the C–terminal His tag segments is indicated downstream of the PINIT 
domain coding region. The origin of replication (ColE1 origin) is indicated. B) Restriction analysis of the 
pQE60–PINIT plasmid with NcoI and BglII restriction enzymes. DNA was loaded on 0.8% TBE agarose gel 
containing ethidium bromide in the following order: lane 1, lambda DNA molecular markers digested with Pst I; 
lane 2, undigested pQE60–PINIT; lane 3, pQE60–PINIT plasmid digested with BglII restriction enzyme; lane 4, 
pQE60–PINIT plasmid digested with NcoI and BglII restriction enzymes. Arrow indicates the position of the 
PINIT domain DNA fragment. The expected size of the PINIT domain DNA fragment  is 561 bp. 
 
The PINIT–(His)6 production in E. coli XL1 Blue [pQE60–PINIT] was observed one hour 
post induction on SDS–PAGE analysis and confirmed by western blot analysis ((Figure 4.3). 
Low expression levels were persistently observed despite optimisation of temperatures and 
use of different expression strains (Table 4.1). The low expression levels of PINIT–(His)6 
could be results of early translation termination or the protein being toxic to the expression 
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strain. Expression of the PINIT domain in a different expression vector and strain that could 
potentially improve the expression, folding and solubility was necessary.  
 
Figure 4.3 Heterologous expression levels of PINIT–(His)6 were low. A) 12% SDS–PAGE gel of the 
PINIT–(His)6 containing total protein extracts from E.coli XL1 Blue [pQE60–PINIT]: lane 1, molecular mass 
marker; lane 2, non–induced sample; lanes 3 – 5, IPTG induced samples 1, 3, 5 hour post induction; and lane 6, 
overnight post induction sample. . B) Western blot analysis for the detection of PINIT–(His)6 protein in E. coli 
XL1 Blue [pQE60–PINIT] total protein extracts prepared for the expression analysis in (A) using mouse 
monoclonal anti–His primary antibody and HRP–conjugated goat anti–mouse IgG antibodies. The arrow 
indicates the position of PINIT–(His)6. 
4.3.3 GST–PINIT–(His)6 expression analysis 
Double tagging the PINIT domain using N–terminal GST–tag and C–terminal His–tag was 
done to maximise the benefit of the tags. pGEX4T–1 expression vector was constructed as 
described in section 4.2.2. The primary advantage of GST–tag is it will potentially increase 
the solubility of insoluble or semi–soluble proteins expressed in E. coli and both tags 
facilitate purification. Therefore, the region encoding the PINIT domain of PIAS385–272 
protein was amplified by PCR with Nde I and SalI restriction sites to facilitate insertion into 
pGEX4T (via a pGEM–T based strategy; Figure 4.1) to give pGEX4T–PINIT. The reverse 
prime was designed with codons encoding for the His–tag upstream of the SalI restriction site 
to introduce a C–terminal His–tag. The pGEX4T–PINIT construct (Figure 4.4A) encoding a 
GST–PINIT–(His)6 protein was confirmed by diagnostic endonuclease restriction analysis 
(Figure 4.4B). The size of the PINIT domain encoding region was confirmed to be 561 bp 
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and automated direct sequencing (Rhodes University DNA sequencing unit, South Africa) 
confirmed that the PINIT domain coding region was inserted between Nde I and SalI sites 
and was in frame. 
 
Figure 4.4 Diagnostic restriction analysis of pGEX4T–PINIT. A) Plasmid map of pGEX4T–PINIT 
rendered using Vector NTI Advance
TM
 software package (version 10.3; Invitrogen). The plasmids confer 
ampicillin resistance to transformed E. coli cells as indicated (Amp
R; β–lactamase gene). The position of the 
PINIT domain between NdeI and SalI restriction sites is indicated; The region encoding the GST tag segments is 
indicated upstream of the PINIT domain coding region and the region encoding for the His Tag is indicated 
downstream of the PINIT domain coding region. The origin of replication (ColE1 origin) is indicated and 
regions coding for LacZ alpha, LacO genes and the thrombin cleavage site are indicated. B) Restriction analysis 
of the pGEX4T–PINIT plasmid with NdeI and SalI restriction enzymes. DNA was loaded on 0.8% TBE agarose 
gel containing ethidium bromide in the following order: Lane1, lambda DNA molecular markers digested with 
PstI; lane 2, undigested pGEX4T–PINIT; lane 3, pGEX4T–PINIT plasmid digested with NdeI restriction 
enzyme; lane 4, pGEX4T–PINIT plasmid digested with NdeI and SalI restriction enzymes. Arrow indicates the 
position of the PINIT domain DNA fragment. The expected size of the PINIT domain DNA fragment  is 561 bp. 
 
GST–PINIT–(His)6 protein was observed one hour after induction and the presence of the 
protein was confirmed by western blot analysis at 45 kDa molecular mass. Low level of 
protein expression was observed on SDS–PAGE (Figure 4.5). Western blot analysis was 
performed using mouse monoclonal anti–His primary antibody to detect the PINIT domain 
protein C–terminal His tag. Figure 4.5B showed that the full length GST–PINIT–(His)6 was 
expressed but at insufficient levels to be observed clearly on SDS–PAGE. Probably 
overexpression of the protein was affected by the disadvantages of the tags as discussed in 
section 4.1 and also the existence of the rare codons resulted in early translation termination. 
The existence of the arginine (AGG/AGA) and proline (CCC) rare codons in the PINIT 
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domain coding region cause early translation termination. Therefore E. coli BL21 (DE3) 
CodonPlus–RP expression strain that co–express the tRNA for these rare codons was used 
(Table 4.1). However, expression trials were performed at various expression temperatures 
and using various E. coli expression strain (Table 4.1) with no improved expression levels. 
 
Figure 4.5 GST–PINIT–(His)6 was expressed at low levels. A) 12% SDS–PAGE gel of the GST–PINIT–
(His)6 containing total protein extracts from E.coli BL21 (DE3) [pGEX4T–PINIT]: lane 1, molecular mass 
marker; lane 2, non–induced sample; lanes 3 – 7, induced samples using IPTG taken hourly; and Lane 8, 
overnight sample. B) Western blot analysis of GST–PINIT–(His)6 protein in E.coli BL21 (DE3) [pGEX4T–
PINIT] using mouse monoclonal anti–His primary antibody, HRP–conjugated goat anti–mouse IgG antibodies: 
lane 1, molecular mass marker; lane 2, induced samples using IPTG taken after one hour; lane 3, four hours 
induction; lane 4, overnight (16 hours) induction. The arrow indicated the position of the GST–PINIT–(His)6 
protein. The arrow indicates the position of GST–PINIT–(His)6 protein. 
 
Although the GST–PINIT–(His)6 protein was expressed, the low level of expression requires 
further optimisation of the expression condition. Possible reasons for low expression were 
straining of the PINIT protein folding resulting in possibly in a toxic protein due to the two 
tags. The existence of a C–terminal His–tag possibly resulted in a toxic protein fold. 
Removing the C–terminal His–tag would possibly improve the expression levels. 
4.3.4   GST–PINIT expression analysis  
A stop codon (TAA) was introduced by site directed mutagenesis upstream of the C–terminal 
His–tag coding region to express GST–PINIT protein. The verified construct was expressed 
in E. coli BL21 (DE3) [pGEX4T–PINIT–TAA–(His)6] and expression analysed by SDS–
PAGE and western blot. Low expression levels of GST–PINIT protein were observed one 
hour post induction (Figure 4.6A, lane 1). Molecular mass species at approximately 47 kDa 
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and 26 kDa were confirmed by western blot analysis to be a GST–PINIT and possible GST–
tag (Figure 4.6A and 4.6B). The expression analysis repeatedly showed consistent 
expression of the 47 kDa and 26 kDa species. 
 
Figure 4.6 GST–PINIT was expressed at low levels. A) 12% SDS–PAGE gel of the GST–PINIT containing 
total protein extracts from E.coli BL21 (DE3) [pGEX4T–PINIT–TAA–(His)6]: lane 1, molecular mass marker; 
lane 2, non–induced sample; lanes 3 – 7, induced samples using IPTG taken hourly; and Lane 8, overnight 
sample. B) Western blot analysis of GST–PINIT protein in E.coli BL21 (DE3) [pGEX4T–PINIT–TAA–(His)6] 
using mouse anti– GST monoclonal antibody and HRP–conjugated goat anti–mouse IgG antibody: lane 1, 
molecular mass marker; lane 2, non–induced sample; lane 3–6 induced samples using IPTG taken after 1, 2, 4 
and 6 hours induction; lane 7, overnight (16 hours) induction. The arrow indicated the position of the GST–
PINIT protein and the GST–tag protein. 
 
A possible reason for the low expression level was attributed to the folding of the GST–
PINIT protein. The molecular weight of the GST is 26 kDa and the PINIT domain is 
approximately of the same size, 23 kDa. Possibly the GST–tag alters the folding of the PINIT 
domain resulting in cleavage and degradation of the PINIT domain protein, hence the 
observed GST–tag protein on SDS–PAGE and by western blot analysis (Figure 4.6A and 
4.6B). An attempt to purify the GST–PINIT using a GST–Trap column (GE healthcare) 
resulted in degradation of the PINIT protein and eluted GST–tag protein only (data not 
shown). Further expression optimisation at different temperatures and use of various 
expression strains (Table 4.1) did not improve expression levels. 
4.3.5   (His)7–PINIT protein expression analysis 
The region encoding the PINIT domain of PIAS385–272 protein was amplified by PCR with 
Nde I and Hind III restriction sites to facilitate insertion into pQE2 (via a pGEM–T based 
strategy; Figure 4.7) to give pQE2–PINIT. The pQE2–PINIT construct encoding a (His)7–
PINIT protein was confirmed by diagnostic restriction endonuclease analysis and the PINIT 
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domain coding region of size 561 bp was confirmed (Figure 4.7) and further verified by 
automated direct sequencing to show that the coding region was inserted in–frame with Nde I 
and Hind III sites. 
 
 
Figure 4.7 Construction and diagnostic analysis of pQE2–PINIT plasmid. A). The region encoding the 
PINIT domain (amino acids 85–272) was PCR amplified from p513–Flag–PIAS3 plasmid and ligated into 
pGEM–T–Easy to give pGEM–T–PINIT. The PINIT–encoding fragment was restricted from pGEM–T–PINIT 
and ligated downstream of the His–tag coding sequence of NdeI–HindIII restricted pQE2 expression vector to 
generate pQE2–PINIT. B) Restriction analysis of the pQE2–PINIT plasmid with NdeI and HindIII restriction 
enzymes. DNA was loaded on 0.8% TBE agarose gel containing ethidium bromide in the following order: 
Lane1, lambda DNA molecular markers digested with PstI; lane 2, undigested pQE2–PINIT plasmid; lane 3, 
pQE2–PINIT plasmid digested with NdeI and HindIII restriction enzymes. Arrow indicates the position of the 
PINIT domain DNA fragment. The expected size of the PINIT domain DNA fragment  is 561 bp. (adapted from 
Mautsa et al., 2010). 
4.3.5  Expression optimisation of (His)7–PINIT protein in E. coli XL 1 Blue [pQE2–
PINIT] 
 (His)7–PINIT production in E. coli XL1 Blue [pQE2–PINIT] was evident as an over–
expressed protein one hour after induction, with the highest expression levels overnight post 
induction (Figure 4.8A, lane 8). Western blot analyses confirmed the expression of (His)7–
PINIT protein (Figure 4.8B). The predicted subunit molecular mass of the (His)7–PINIT 
protein is 23 kDa, and this correlated with its observed subunit molecular mass on a SDS–
PAGE gel (slightly below the 26 kDa marker; Figure 4.8A). Although the highest expression 
was evident on overnight post induction sample, higher order species of (His)7–PINIT were 
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observed by SDS-PAGE and western blot analysis of the whole cell lysates (data not shown) 
suggesting formation of protein aggregates. Therefore, all subsequent studies were conducted 
with a four hour post induction expressed (His)7–PINIT protein.  
 
 
Figure 4.8 Heterologous over-expression of (His)7-PINIT was successful. A) 12% SDS–PAGE analysis of 
the (His)7–PINIT–containing total protein extracts prepared from E. coli XL1 Blue [pQE2–PINIT] during 
expression analysis: Molecular mass markers are indicated on left hand side; lane 1,non–induced sample; lanes 
2–7, induced samples taken hourly; and lane 8, overnight induced sample. Arrow indicate the position of the 
(His)7–PINIT protein. B) Western blot analysis for the detection of (His)7–PINIT protein in E. coli XL1 Blue 
[pQE2–PINIT] total protein extracts prepared for the expression analysis in (A) using mouse monoclonal anti–
His primary antibody and HRP–conjugated goat anti–mouse IgG antibodies. The arrow indicates the position of 
(His)7–PINIT protein. (adapted from Mautsa et al., 2010). 
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Table 4. 1 Cloning vectors, expression strains and expression condition trials for 
optimum production of the PINIT domain fusion proteins. 
 
Expression 
vector 
Expressed 
protein 
E. coli 
Expression 
strains 
Temperature 
o
C 
IPTG  
mM 
Optimum expression 
conditions 
pQE60  PINIT–(His)6 XL 1 Blue; 
BL 21(DE3); 
M15 [pREP4] 
37; 30; 20 
 
0.8 ; 1.0  Low expression 
observed 
pGEX4–1  GST–PINIT–
(His)6 
XL 1 Blue; 
BL 21(DE3); 
Rosseta; 
M15[pREP4] 
37; 30; 20 0.8; 1.0 Expression at 20
o
C in 
BL21 (DE3) induced 
by 1 mM IPTG 
pGEX4T–1  GST–PINIT XL 1 Blue; 
BL 21(DE3); 
Rosseta; 
M15[pREP4] 
37 ; 30 ; 20 0.8 ; 1.0 Expression at 20
o
C in 
BL21 (DE3) induced 
with 1mM IPTG 
pQE2  (His)7–PINIT XL 1 Blue; 
BL 21(DE3) 
37; 30; 20 0.8; 1.0 Expression at 20
o
C in 
XL 1 Blue with 0.8 
1mM IPTG 
 
4.3.6 Solubility and batch purification studies of (His)7–PINIT protein by nickel 
affinity chromatography 
Both denaturing and native conditions were employed to investigate solubility and 
purification of (His)7–PINIT. Denaturing conditions were considered necessary in order to 
investigate the nature and condition of the higher order species detected by western blot 
analysis in whole cell lysates from SDS–PAGE gel. Cell lysis and purification was carried 
out in the presence of the 8 M urea based buffers. Analysis of the total, soluble and insoluble 
protein by SDS–PAGE showed the presence of an overexpressed (His)7–PINIT protein that 
was confirmed by western blot analysis (Figure 4.9A, 4.9B, 4.9C). The SDS–PAGE analysis 
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showed that the protein was soluble as most of the protein was found in the soluble fraction 
(Figure 4.9A, lane 6). However, the quantitative recovery of the protein in Figure 4.9B 
showed that the protein was not stable under denaturing purification conditions as shown by 
(His)7–PINIT degradation products below the 17 kDa marker (Figure 4.9C). Western blot 
analysis detected the presence of the monomeric species of (His)7–PINIT protein and not 
higher order species. However analysis of nickel affinity batch purified protein on a SDS–
PAGE gel revealed different molecular mass proteins at 45 kDa and 100 kDa (Figure 4.9B), 
possibly representing co–purifying E.coli chaperone proteins (Flynn et al., 1991; Blond–
Elgundi et al., 1993). Mass spectroscopy revealed that the species at 26 kDa, 45 kDa and 95 
kDa were (His)7–PINIT protein, elongation factor Tu (EFTU) and ClpB respectively.  
 
Figure 4.9 Solubility and batch nickel affinity purification studies under denaturing conditions of 
(His)7–PINIT. A) SDS–PAGE (12 %) gel of expression of (His)7–PINIT protein from E.coli XL1 
Blue[pQE2–PINIT]: Lane 1, molecular mass marker; lane 2, uninduced whole cell lysates; lane 3, whole cell 
lysates after 4 hours induction; lane 4, total protein lysates after sonication; lane 5, Insoluble protein; lane 6, 
soluble protein, supernatant after centrifugation of the cell lysates. B) SDS–PAGE (12 %) gel of purified 
(His)7–PINIT: lane 1, molecular mass marker; lane 2, first elution batch with 500mM imidazole; lane 3, second 
elution batch with 500mM Imidazole; lane 4, third elution batch with 500mM imidazole. C) Western blot 
analysis of the purified (His)7–PINIT from E.coli XL1 Blue [pQE2–PINIT]: Lane 1, molecular mass 
marker, lane 2, first elution batch with 500mM imidazole; lane 3, second elution batch with 500mM Imidazole; 
lane 4, third elution batch with 500mM imidazole. Arrows indicate the position of (His)7–PINIT protein. 
 
To biochemically characterize the protein, a soluble folded protein is necessary and therefore 
purification of the protein in its native state was performed using nickel affinity batch 
purification chromatography. Analysis of the purified protein by SDS–PAGE showed 
predominantly monomeric species of (His)7–PINIT indicated by the arrow (Figure 4.10A). 
The SDS–PAGE showed that (His)7–PINIT is soluble under native purification conditions as 
most of the protein was shown to be in the soluble fraction (Figure 4.10 A, lane 3) and not in 
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the insoluble fraction (Figure 4.10A, lane 4). The quantitative recovery of the protein shown 
on the SDS–PAGE gel showed that the protein was stable under native purification 
conditions compared to the denaturing purification condition. The western blot analysis 
indicated the presence of the purified (His)7–PINIT protein (Figure 4.10 B). However, co–
purifying E. coli species were observed at 55–72 kDa of the elution fractions and these 
corresponded to DnaK and GroEL molecular masses. Western blot analysis of the purified 
products with Anti-DnaK antibodies indicated that the contaminating species were different 
molecular mass species of E. coli DnaK (Appendix B6). 
 
Figure 4.10 Solubility and batch nickel affinity purification studies under native conditions of (His)7–
PINIT. A) SDS–PAGE (12 %) gel of expression and purification of (His)7–PINIT protein from E.coli XL1 
Blue [pQE2–PINIT]: Lane 1, molecular mass marker; lane 2, uninduced whole cell lysates; lane 3, soluble 
protein, supernatant after centrifugation of the cell lysates; lane 4, insoluble protein; lane 5, flow through; lane 6, 
first elution batch with 500 mM imidazole; lane 7, second elution batch with 500mM Imidazole. B) Western 
blot analysis of the purified (His)7–PINIT from E.coli XL1 Blue [pQE2–PINIT]: Lane 1, molecular mass 
marker; lane 2, first elution batch with 500 mM imidazole; lane 3, second elution batch with 500 mM Imidazole. 
Arrows indicate the position of (His)7–PINIT protein. 
4.3.7 HisTrap nickel affinity column purification of (His)7–PINIT protein  
A pre–packed HisTrap nickel affinity column was employed for the purification of (His)7–
PINIT protein. The column was connected to the FPLC and fast flow washes at 4ml/min with 
60 mM imidazole wash buffer was used to reduce non specific binding E. coli protein. The 
chromatogram (Figure 4.11A) showed the 5 ml peak of the non-specific E. coli proteins 
washed out with 60 mM imidazole wash buffer. The gradient elution was switched on after 
10 CV washes and (His)7–PINIT protein was eluted at 125 mM imidazole concentration at 14 
ml peak (Figure 4.11A). SDS–PAGE gel analysis of the 14 ml peak fraction showed (His)7–
PINIT protein as the major species (Figure 4.11B) at molecular mass below 26 kDa 
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consistent with the batch purification processes. The amount of E. coli protein contaminants 
co–purifying with the (His)7–PINIT were significantly less compared to batch nickel affinity 
purification.  
 
Figure 4.11 Column based nickel affinity purification of (His)7–PINIT. A) Chromatogram of (His)7–
PINIT purification from 1ml HisTrap Nickel affinity column using a ÄKTA (BASIC) FPLC system (Amersham 
Pharmacia Biotech, UK). The peak at 6 ml indicate protein washed out with 60 mM imidazole wash buffer and 
peak at 14 ml indicate (His)7–PINIT protein elution with 500 mM imidazole elution buffer. The blue line 
indicate the chromatogram trace at absorbance 280 nm and the green line indicate the gradient percentage 
increase of the imidazole concentration in the elution buffer. The complete purification process was performed 
at 4 ml/min flow rate B) SDS–PAGE (12 %) gel analysis of the peak fraction elution 14 ml. Lane 1, 
molecular mass marker; lane 2, elution volume fraction 14 ml. Arrow indicate the position (His)7–PINIT 
protein. 
4.3.8 Purification with Adenosine Tri–phosphate (ATP) based buffers 
Although (His)7–PINIT was successfully expressed at 20
o
C, the level of E–coli proteins co–
purifying required further purification or optimisation of the purification conditions. The 
quantitative recovery of these higher molecular mass species suggested that they were 
binding partners. Furthermore, mass spectroscopy and western blot analysis of the purified 
(His)7–PINIT protein samples revealed that these higher order contaminating species were 
EFTU, ClpB and DnaK respectively. Other possible proteins that could co–purify with the 
PINIT domain were GroEL and GroES. Owing to the distinct ability of DnaK chaperone to 
bind and release substrate in the presence of ADP/ATP, respectively (Rohman and Harrison-
Lavoie, 2000), pre–incubation of the protein solution with ATP prior to purification 
dissociates protein–DnaK complex (Amersham Pharmacia Biotech, The recombinant protein 
handbook, 18–1142–75, 2001). Also this is known to reduce but not completely remove the 
contaminating GroEL (Rohman and Harrison-Lavoie, 2000). 
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The total soluble protein was pre–incubated in binding buffer containing 5 mM ATP for 20 
minutes at room temperature before applying the sample to the HisTrap column equilibrated 
with binding buffer that contained 5 mM ATP. The elution fractions were analysed by SDS–
PAGE gel and showed decrease of the higher molecular species (Figure 4.12). Lower 
molecular weight species present on the SDS–PAGE could possibly have been degradation 
products from sample treatment or early translation termination products. 
 
Figure 4.12 Purification of (His)7–PINIT using ATP during column based nickel affinity 
chromatography. A) SDS–PAGE (12 %) analysis of (His)7–PINIT purified from E.coli XL1 Blue [pQE2–
PINIT]. Lane 1, molecular mass marker; lane 2 – 5, (His)7–PINIT elution fraction 13 to 16 ml respectively from 
the chromatogram of (His)7–PINIT (chromatogram not shown). Arrow indicate the position of the (His)7–
PINIT. 
4.3.9  (His)7–PINIT protein characterisation by size exclusion chromatography 
Characterisation of the size and determination of oligomeric state of the (His)7–PINIT 
domain protein in solution was performed by size exclusion chromatography. This method 
was also used to further purify protein after nickel affinity chromatography. The size 
exclusion column was calibrated using commercial standards. Blue dextran was used to 
determine the void volume. The molecular weight of the PINIT domain protein was 
calculated from the standard curve (Appendix B8 and B9). 
A two stage size exclusion chromatography was performed. First stage, partially purified 
(His)7–PINIT from column-based native nickel affinity chromatography in the presence of 
ATP was applied to the size exclusion column. The chromatogram (Figure 4.13A) showed 
multiple peaks of higher order species of E. coli contaminants shown on the SDS–PAGE 
(Figure 4.13B). However, the size exclusion column was equilibrated with ATP based buffer 
and the contaminants were separated from the (His)7–PINIT by size. SDS–PAGE and 
western blot analysis of the eluted fractions showed that the (His)7–PINIT protein eluted at 
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fractions 16 to 19 ml. Western blot analysis of the fractions indicated that bulk of the (His)7–
PINIT protein was eluted at fraction 16, 17 and 18 ml (Figure 4.13C). In the second stage, 
fractions 16 to 18 ml from the first size exclusion analysis were concentrated using Amicon
R
 
Ultra Ultracel
R
 (10K) Centrifugal Filters (Millipore, Ireland) and loaded into the size 
exclusion column. A single distinct peak was observed and found to contain (His)7–PINIT by 
western blot analysis (Figure 4.13D).  
 
Figure 4.13 Purification of (His)7–PINIT protein by two stage size exclusion chromatography. A) Size 
exclusion chromatography of (His)7–PINIT protein fraction eluted from HisTrap column based native 
purification with ATP. B) SDS–PAGE (12 %) gel analysis of size exclusion fractions 12 ml to19 ml; lane 1, 
molecular mass marker; lane 2–9, fraction 12 to 19 ml respectively from the size exclusion column. Arrow 
indicate the position of the (His)7–PINIT.C) Western blot analysis of fraction 13 to 18 ml resolved by SDS–
PAGE analysis. D) Stage two of size exclusion chromatography of concentrated (His)7–PINIT fractions (16 to 
19 ml) from first stage of size exclusion chromatography and western blot analysis of the peak fractions. E) 
Standard curve plot for (His)7–PINIT molecular mass determination. The molecular mass of the (His)7–PINIT 
peak fraction was found to be approximately 23 kDa. F) SDS–PAGE analysis of the size exclusion fractions 18 
and 19 ml. (adapted from Mautsa et al., 2010). 
 
The mobility of this peak indicated a species of molecular mass of approximately 23 kDa 
implying that the PINIT domain existed as a monomeric species in solution (Figure 4.13E). 
94 
 
The (His)7–PINIT protein was purified to homogeneity as shown by a single major protein 
band on SDS–PAGE (Figure 4.13F). The fractions under the peak were concentrated and the 
protein concentration quantified by Bradford assay to be approximately 0.6 mg per litre of 
original culture. 
4.3.10   Secondary structure analysis of (His)7–PINIT protein by FTIR spectroscopy 
The PINIT domain protein was analysed in an H2O environment and in 20 % D2O based HBS 
buffer (Figure 4.14). Amide I band arises mainly from the overlapping of stretching 
vibrations of the C=O bonds of the protein backbone (Susi and Byler, 1986) and Amide II 
bands arises from vibration in NH side chains. Comparison of the PINIT domain in H2O 
environment and in the D2O environment (Figure 4.14) reflected spectral shift as a 
consequence of the isotropic replacement of the exchangeable hydrogen of the PINIT domain 
amino groups.  
 
Figure 4.14 FTIR analysis of purified (His)7–PINIT. Infrared spectrum of the PINIT domain protein in 
H2O solution (blue continuous trace) and in 20 % D2O solution (red dashed trace) Difference spectra after 
digital subtraction of the buffer spectrum. Amide I, 1600−1690 cm–1 arises from C=O stretching; Amide II, 
1480−1575cm–1 arises from CN stretching and NH bending (Miyazawa et al., 1956; Krimm and Bandekar, 
1986). Amide II frequencies shift for PINIT domain in D2O is due to deuterated exchange. 
 
In a well–defined folded three–dimensional structure protein, many of the amide hydrogen 
were buried in the interior of the protein and this resulted in marked decrease in the rate of 
amide hydrogen to water molecules. However, with time they eventually exchanged since 
proteins are flexible. Previous researchers have used hydrogen isotope exchange to show 
protein fold (Kunihiro et al., 1984). The addition of heavy water affected the vibration 
frequencies of Amide I and Amide II bands of the infrared spectrum of the protein. 
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Superimposition of the spectrums over different times of deuterium exchange showed the 
change of the Amide II band (Figure 4.14). 
Peaks centred at 1625, 1634.7,1644 cm
–1
 for PINIT protein in the H2O environment (Figure 
4.15) were inside the region which was a characteristic of the Amide group implicated in β–
sheets (Byler and Susi, 1986; Susi and Byler, 1986; Surewicz and Mantsch, 1988). The bands 
around 1625 cm
–1
 and 1691 cm
–1
 reflected a particular β–structure which involved stronger 
hydrogen bonding. Bands at 1653 cm
–1
 in H2O environment can in principle be assigned to 
α–helical and 1662.9 cm–1 can be assigned to 310 α–helix (Krimm and Bandekar, 1986; Susi 
and Byler, 1986; Dong et al., 1990) even though this structure is rarely observed in proteins. 
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Figure 4.15 Secondary structure analysis of (His)7–PINIT protein in H2O environment. The Amide 1 
region of the infrared spectra of PINIT domain protein in H2O environment was deconvoluted and the peaks 
fitted with the Gaussian curve. Gaussian bands are shown as symmetrical peaks underneath the deconvolved 
infrared (IR) spectra. The peak wavelength numbers are shown at the top of each peak. 
The PINIT protein in the D2O environment had overlapping bands arising from deuterated 
and the unexchanged population of the different extended structures, resulting in exposure of 
hidden bands at 1637 cm
–1
 (Figure 4.16). The observed Amide I bands within 1672 cm
–1
 to 
1681 cm
–1
 in H2O could be assigned to β–turns (Byler and Susi, 1986; Krimm and Bandekar, 
1986). Large vibration frequency shifts were predicted for a given type of β–turn as dihedral 
angles can vary (Krimm and Bandekar, 1986). Bands at 1655 cm–1 and 1646 cm–1 could be 
assigned to the deuterated α–helix and random segments or loops, respectively. 
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Figure 4.16 Secondary structure analysis of (His)7–PINIT protein in D2O environment. Amide I region 
infrared spectra of (His)7–PINIT protein in D2O environment was deconvoluted and the peaks fitted with the 
Gaussian curve Gaussian bands are shown as symmetrical peaks underneath the deconvolved IR spectra. The 
peak wavelength numbers are shown on each peak.  
 
Table 4.2 Fractional band areas (% Area), Frequencies (wave number) and band 
assignments of FTIR Amide I component bands of native PINIT domain protein in H2O 
and 20 % D2O environment. 
 
The fractional areas of the Amide I component bands are directly proportional to the relative 
content of the secondary structure types yielding them (Byler and Susi, 1986). The positions 
and the percentage of band areas for the different fitted bands from the Gaussian curve fit 
results in H2O and D2O (Table 4.2). The PINIT domain in H2O solution; 49 % of the amide 
C=O groups are involved in β–sheets, 29 % α–helical, 14 % in β–turns and 8 % should be 
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random or unordered and irregular structures. Quantification in D2O yields more realistic 
results because of deuteration shifts allowing identification of other structures. The β–sheets 
are estimated to 66 %, and α–helical are quantified to be 20.4 % and 13.6 % β–turns. 
The generated PINIT model (Figure 4.17A) and its systematic representation of the 
secondary structures (Figure 4.17B) showed that the bulk part of the secondary structure 
features are β–sheets and the D2O results (Table 4.2) indicated that 66 % of the amide C=O 
groups are involved in β–sheets. 
 
Figure 4.17 Cartoon representation of the PINIT domain model and the systematic secondary structure 
representation. A) The model of the PINIT domain generated from the X–ray structure of the PINIT domain of 
Siz1 (PDB ID: 3i2D) showing the two antiparallel β sheets; one includes β1, β2, β4, and β7, and the other 
includes β3, β5, and β6. The β sheets are connected by protruding loops (L1, L2, and L3) that join strands β2–3, 
β4–5, and β6–7 at one end of the molecule, while β3–4 and β5–7 are connected by a helix α1 and a loop, 
respectively, on the opposite surface. B) The systematic representation of the flow of the secondary structure 
features of the generated PINIT domain model. 
4.3.11     Preliminary characterisation of the PINIT–STAT3 interaction 
Preliminary characterisation of PINIT–STAT3 interaction was performed by dot blot 
association assay before employing sensitive methods like SPR. The (His)7–PINIT protein 
was found to interact with varying amounts of recombinant STAT3 (50 µg – 500 µg) blotted 
onto nitrocellulose membrane. The interaction was concentration dependent as indicated by 
the increasing intensity of the signal (Figure 4.18). When the signal intensity was plotted 
against the amount of STAT3, a typical saturation curve was generated, suggesting that 
interaction was potentially specific. The saturation point was reached at 200 µg of STAT3 
(S3), with no further PINIT protein binding evident with increasing STAT3. The absence of 
any detectable interaction of PINIT with BSA protein also suggested that PINIT bound to 
STAT3 in a specific manner.  
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Figure 4.18 (His)7–PINIT interaction with STAT3 protein at increasing concentration of STAT3. A) 
Dots blot assay; STAT3 was vacum blotted onto a nitrocellulose membrane, incubated with (His)7–PINIT (100 
µg/ml), and the bound (His)7–PINIT detected by western blot analysis using mouse monoclonal anti–His 
primary antibody and HRP–conjugated goat anti–mouse IgG antibodies; P, (His)7–PINIT (40 µg); STAT3: S1 = 
50 µg; S2 = 100 µg; S3 = 200 µg; S4 = 400 µg; S5 = 500 µg; and BSA = 600 µg. B) Graphical representation of 
the dot blot assay; the intensity of (His)7–PINIT bound to STAT3 detected by western blot analysis was plotted 
against increasing amounts of STAT3 on the nitrocellulose membrane. This experiment was repeated three 
times giving similar results; a typical example is shown here. 
 
4.4 DISCUSSION AND CONCLUSION 
The successful expression and purification of (His)7–PINIT protein from E.coli XL1 Blue 
[pQE2–PINIT] was achieved. Also, (His)7–PINIT protein size and secondary structure 
content were characterised and preliminary functional investigation showed that the (His)7–
PINIT is folded and functional as it was capable of associating with STAT3. 
Expression of the PINIT domain of a mammalian PIAS3 protein in a prokaryote system 
required a carefully designed strategy. This was because of the existence of rare codons that 
were likely to cause early translation termination and or misfolding of the protein. The 
problem was overcome through trying various expression vectors and combination of fusion 
tags and expression strains that co–express the tRNA for those rare codons (Table 4.2). 
Although GST–tag was suggested to improve the protein folding (Kaplan et al., 1997) the 
folding of the PINIT domain was affected by the GST–tag. Two species of the GST–tagged 
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protein were observed suggesting PINIT protein degradation. The double tagging of the 
protein was suggested to improve the protein yield and enhances its solubility as well as 
facilitating its purification (Pryor and Leiting, 1997). However, the GST–tag and His–tag did 
not successfully over–expressed GST–PINIT–(His)6 protein. Probably, the size of the PINIT 
domain greatly affected the folding because GST–tag and PINIT domain had molecular mass 
of 26 kDa and 23 kDa respectively. His–tag is small and was suggested to enhance protein 
expression. Although the expression was successful, the position of the His–tag was critical 
for the expression of the PINIT protein. pQE expression vector systems with T5 promoter 
containing two lac operator sequences for tight regulation were used. The difference was that 
pQE2 had the N–terminal His–tag and pQE60 had a C–terminal His–tag. Successful 
overexpression was achieved by use of the pQE2 vector with an N–terminal His–tag. 
ATP based nickel affinity column and a two stage size exclusion chromatography was 
determined as the standard (His)7–PINIT purification procedure to achieve high protein 
purity. E. coli contaminating proteins which were persistently co–purifying with (His)7–
PINIT were identified by mass spectroscopy and western blot analysis as E. coli chaperone 
proteins which have higher affinity for ATP. The use of ATP based buffers in nickel affinity 
column purification eliminated most of the contaminating proteins. Also, size exclusion 
chromatography with ATP based buffers further facilitated the separation of the remaining 
contaminating protein. A second stage of the size exclusion was necessary to characterise the 
size and further purify the (His)7–PINIT protein. Due to the rigorous purification stages, 
(His)7–PINIT protein degraded to a low yield (0.6 mg per litre of original culture). For 
structural elucidation by either NMR or X–ray crystallography, uniformly purified protein of 
at least 10 mg was required. 
However, FTIR was used to characterise the secondary structure features of the PINIT 
domain and determined its folding state by hydrogen–deuterium exchange. Approximately 66 
% of the secondary structure features of (His)7–PINIT domain were β–sheets consistent with 
the homology model generated from the PINIT domain of Siz1 (Figure 4.17A and 4.17B). 
Hydrogen–deuterium exchange of the amide bonds showed that the protein was folded 
because a large reduction in the intensity of the Amide II band in D2O due to the hydrogen–
deuterium exchange of the amide bonds resulted in the shift of the amide II band towards 
lower frequencies (approximately 1455 cm
–1
). This was because buried hydrophobic pockets 
of β–sheets amino acids in Amide I band were not easily accessible by D2O for deuterium 
exchange compared to amide II bands primarily from N–H stretching vibrations (Figure 
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4.14). Furthermore, the folding of the (His)7–PINIT was confirmed by its ability to associate 
with STAT3. Dot blot association assay revealed that the purified protein can bind 
specifically to STAT3 protein and saturate the STAT3 binding site or in a concentration 
dependent manner (Figure 4.18). 
To conclude, the PINIT domain of the PIAS3 was successfully heterologously over-
expressed at 20
o
C in E. coli XL 1 Blue expression strain. The expression and purification was 
achieved by use of the N–terminal (His)7–tag and the purity of the (His)7–PINIT protein was 
improved by use of ATP containing washbuffer to remove contaminating proteins of E.coli 
origin. Furthermore, biophysical and biochemical techniques were employed to characterise 
the size, secondary structure content and its association with STAT3 protein. The results 
showed successful production of a functional and folded protein and this set a platform for 
further investigation of PINIT–STAT3 interaction. 
 
 
 
101 
 
 
 
 
CHAPTER 5 
 
THE IN VITRO ANALYSIS OF THE PIAS3–STAT3 INTERACTION: ROLE OF THE 
PINIT DOMAIN 
 
Protein–protein interactions are essential for the functioning of living cells. Biomolecular 
interactions can be visualised in real time, using the principle of surface plasmon resonance 
spectroscopy on a BIAcore instrument, and kinetic rate and affinity constants can be 
determined. In this study SPR spectroscopy has been applied to the interaction of the PINIT 
domain with recombinant STAT3 protein to determine kinetic and affinity constants. Based 
on previous studies and structural bioinformatic analysis (Chapter 2), mutants were 
generated of the PINIT domain which were further characterised based on molecular mass 
and structural integrity. Furthermore, the significance of the replaced residues in PINIT 
mutants was evaluated by PINIT mutant–STAT3 interaction analysis. 
 
 
 
 
 
 
 
 
 
102 
 
 
5.1 INTRODUCTION 
The basic concept of SPR is the detection of biospecific adsorption of an analyte due to 
changes in reflective index close to the chip surface, in continuous flow, to an immobilized 
ligand at the same spot and at the same time as it occurs, i.e. real–time interaction kinetics 
(Liedberg et al., 1983). SPR technology is an efficient and sensitive method to analyse 
binding kinetics of an interaction (Rich and Myzka, 2000; 2004). It allows the measurement 
of analyte association rate (kon) and dissociation rate (koff), which are indicators for the degree 
of recognition and binding stability of the ligand–analyte interaction. The ratio of the two is a 
measure of the affinity or binding strength of the analyte for the ligand ( onoffD kkK / ) 
meaning that a high affinity can be caused by a high association rate or slow dissociation rate 
(Jönsson et al., 1991; Myszka, 1997). The basic multistep protocol for examining molecular 
interactions may be described by the following four steps: (1) immobilisation or capture of a 
ligand; (2) injection of the test analyte and real–time recording of an interaction curve; (3) 
step 2 is repeated with increasing concentrations of test analyte; and (4) the data fit is 
performed on the collected sensorgrams for determination of rate constants (Beseničar et al., 
2006). The association and dissociation of the analyte to the immobilised ligand are followed 
in real–time and presented in collected sensorgrams of response versus time. The response 
signal from the SPR detector is proportional to the mass of protein per surface area (Stenberg 
et al., 1991). The advantages of SPR over other techniques are: direct and rapid 
determination of association and dissociation rates of the binding process; no need for 
labelling of protein; and small amount of sample used in the assay (often nanomolar 
concentrations of protein) (Beseničar et al., 2006). Assay types performed using the BIAcore 
are: binding specificity, i.e. qualitative studies to confirm the specificity of interactions; and 
quantitative measurements for determination of affinity and kinetic rate constant evaluation. 
While kinetic association (ka) and dissociation (kd) rate constants from real–time 
measurements of binding interactions provide information regarding complex formation and 
complex stability, the rate constants provide a link between protein function and structure 
through the evaluation of the impact of amino acid substitution.  
Characterisation of the PIAS3–STAT3 interaction by direct biophysical techniques such as 
SPR has not been done. Studies of protein–protein interaction using biophysical techniques 
are dependent on the production of folded, biologically active protein. In the previous chapter 
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(Chapter 4), the production of folded and functional wildtype PINIT domain was described. 
Here, the direct interaction with recombinant STAT3 will be shown in real–time by 
quantitative SPR spectroscopy for determination of kinetic association and dissociation rate 
constants based on the concentration dependency of interaction. Furthermore, mutant PINIT 
proteins were characterised by FTIR and used in a qualitative SPR assay to evaluate the 
significance of the substituted amino acids in the PINIT–STAT3 interaction. 
 
5.2 METHODS  
5.2.1 Preconcentration of STAT3 to determine optimal immobilization conditions 
STAT3β used in this study was expressed and purified as previously described (section 
4.2.9). Preconcentration analysis of STAT3β was performed at a flow rate of 10µl/min. 
Recombinant STAT3β (20µg/ml) was diluted in 10 mM sodium acetate buffer solutions at 
four pH values (pH 4.0, pH 4.5, pH 5.0, pH5.5) to determine a suitable pH for 
immobilisation. The optimal pH for immobilization should be 1 unit below the estimated pI 
of STAT3 in order to ensure that the immobilised ligand protein has a net positive charge. 
The pI and molecular mass of the protein were estimated using the pI/MW tool found at 
http://au.expasy.org/tools/pi_tool.html (Appendix F1). The pH that resulted in the maximum 
surface retention was used for immobilization. 
5.2.2 Immobilisation of STAT3 on CM5 sensor chip 
SPR was performed using a BIAcore X instrument (GE Healthcare, Sweden). STAT3β was 
immobilized on flow cell one (Fc1) of a primed CM5 sensor chip at approximately 8500 RU 
using amine coupling. The CM5 dextran matrix on the sensor chip surface was first activated 
with a 1:1 mixture of 0.1 M N–hydroxysuccinimide (NHS) and 0.4 M 1–ethyl–3–
[dimethylaminopropyl] carbodiimide (EDC) to create reactive succinimide esters. Hepes–
buffered saline (HBS; 10 mM HEPES, 150 mM NaCl, pH 7.4) was used as the running buffer 
at 25°C. Flow cells were activated for 7 minutes by injecting 35 µl of 1:1 NHS/EDC (0.1 M 
NHS and 0.4 M EDC). An aliquot of 10 µl of 20 µg/ml STAT3 protein in 10 mM sodium 
acetate, pH 4.5 was injected at a constant flow rate of 5 µl/min, followed by a 70 µl injection 
of ethanolamine (1.0 M; pH 8.5) to block any remaining activated groups on the surface. This 
method resulted in approximately 8 500 RU STAT3 immobilised. Flow cell two (FC2) was 
blocked with ethanolamine after NHS/EDC activation and used as an inline reference cell. 
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5.2.3 Quantitative analysis of PINIT–STAT3 protein binding by SPR spectroscopy 
Injections of 10 µl of (His)7–PINIT (5–25 µM) and the (His)7–PINIT mutants were 
performed at a flow rate of 10 µl/min using HBS buffer as the running buffer for 60 s 
association and 60 s dissociation. All sensorgrams were collected at 25°C. Triplicate 
injections of (His)7–PINIT were performed for each concentration to account for statistical 
variability. Kinetic evaluation of the data was performed based on the 1:1 Langmuir 
association for determination of the observed rate constant, kobs and Req, the steady state 
binding level. Rate constants were calculated following linear regression fitting of kobs versus 
concentration of analyte ([(His)7–PINIT]) plots according to the equation, kobs = ka.Concanalyte 
+ kd. The affinity constant (KD) was calculated from the ratio of the dissociation (kd) and the 
association rate constants (ka), (i.e. KD = kd/ka). Data and statistical analysis were performed 
using BIAevaluation 3.2 (BIAcore, Sweden) and Prism 5.03 software (Graphpad Software, 
USA). 
5.2.4 Mutagenesis, expression and purification of the (His)7–PINIT mutants  
Site–directed mutagenesis was performed using the double stranded whole plasmid linear 
non–PCR amplification procedure (QuikChange mutagenesis kit; Stratagene). 
Complementary mutagenesis primers were designed for the introduction of single point 
mutations at L97A, R99N and R99Q mutation into the PINIT domain coding sequence 
(Appendix G2). The primers were synthesised by Integrated DNA Technologies (USA). 
Each mutagenesis reaction was comprised of 100 ng of pQE2–PINIT parental plasmid 
template, 2.5 µl of dimethyl sulfoxide (DMSO), 10 µl of 25 mM MgCl2, 1 µl of 10 mM 
dNTP mix , 125 ng of the forward primer, 125 ng of the reverse primer, 5 µl of 10x Pfu DNA 
polymerase buffer (200 mM Tris–HCl [pH 8.8], 100 mM KCl, 100 mM (NH4)2SO4, 20 mM 
MgSO4), and 1 U of Pfu DNA Polymerase and sterile distilled water to a final volume of 50 
µl. Thermal cycling was allowed to proceed as follows: one cycle of denaturation (95°C for 
30 seconds), 18 cycles of denaturation, annealing and extension (95°C for 30 seconds, 52°C 
for 60 seconds, 68°C for 5 minutes), one cycle of final extension (68°C for 7 minutes) and a 
4°C hold at the end. Digestion of the parental pQE2–PINIT plasmid in the amplification 
product was achieved by the addition of 5U of DpnI restriction endonuclease to the reaction 
mixture and incubation at 37°C overnight. Pre– and post–DpnI samples were analysed by 
0.8% TBE agarose gel electrophoresis (Appendix D4). An aliquot of 10 µl of post–DpnI 
samples was transformed into E. coli JM109 supercompetent cells (Promega) for screening 
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purposes. Plasmid DNA was isolated from the resulting colonies and screened for the desired 
mutation by DNA sequencing (Appendix D7) using the designed forward sequencing primer 
(Appendix H3). The expression and purification of the (His)7–PINIT domain mutants were 
performed as previously described (Chapter 4 section 4.2.7 and 4.2.8).  
5.2.5 Molecular mass characterisation of the (His)7–PINIT mutants by size exclusion 
chromatography 
Size exclusion chromatography of the (His)7–PINIT mutants were performed as previously 
described in section 4.2.10. 
5.2.6 Structural and folding analysis of (His)7–PINIT mutants by FTIR spectroscopy 
Structural and folding analysis of the (His)7–PINIT mutants and the FTIR spectra data 
processing and analysis were performed as previously described (Chapter 4, section 4.2.11 
and 4.2.12). 
5.2.7 Assessment of the importance of in silico predicted R97 and R99 residues by SPR 
SPR was performed using BIAcore X (GE Healthcare, Sweden) as previously described 
(section 5.2.3) using 20 µM of each (His)7–PINIT mutant. (His)7–PINIT mutants were 
expressed, purified and quantified as previously described (Chapter 4). 
5.3 RESULTS 
5.3.1  Immobilisation of the STAT3 on CM5 sensor chip 
Immobilization of STAT3 via covalent amine coupling was performed in sodium acetate pH 
4.5. Although pH 4 resulted in a sharper gradient for preconcentration, pH 4.5 was selected to 
avoid any deleterious effects to STAT3 tertiary structure at low pH (Figure 5.1). Typically, 
the optimal immobilization pH is one unit below the pI; the predicted theoretical STAT3 pI 
was determined to be 6.85 (http://expasy.org/tools/pitool.html) (Gasteiger et al., 2005). Under 
these conditions the ligand displays a positive charge and is effectively preconcentrated into 
the negatively charged carboxymethyl dextran matrix. The unreacted esters are “blocked” 
with ethanolamine. Inline reference surfaces are prepared in the same manner, except that all 
carboxyls are blocked and no ligand was added. The final immobilisation level of STAT3 
was calculated by subtracting the reference cell (Fc2) from Fc1; STAT3 was immobilised at 
8511 RU (27045.2–18534.1 = 8511) (Figure 5.2A and 5.2B). 
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Figure 5.1 STAT3 preconcentration test to determine the optimum pH and concentration needed to 
reach a targeted level of response. STAT3 (20 µg/ml) in 10 mM sodium acetate buffer solution at pH 4.0 
pH4.5 pH5.0 pH5.5 was passed over CM5 sensor chip at flow rate of 5 µl/minutes. The surface was regenerated 
by passing over 10 µl of glycine pH 1.5 followed by 20 µl of 0.05 % SDS at 5 µl/minute flow rate. (RU, 
response units). 
 
Figure 5.2 The immobilisation of STAT3 on the surface of the sensor chip. A) The immobilization of 
STAT3 was performed by activation of carboxymethyl groups on a dextran–coated chip by reaction with N–
hydroxysuccinimide. This was followed by covalent bonding of STAT3 to the chip surface via amide linkages 
and excess activated carboxyls were blockaged with ethanolamine. The surface was regenerated with 10 mM 
glycine pH 1.5. B) The reference surface was prepared by activating the carboxymethyl groups by reacting with 
N–hydroxysuccinimide or 1–ethyl–3–(3–dimethylamino–propyl) carbodimide hydrochloride but no STAT3 was 
added and all carboxyls were blocked with ethanolamine. The x on the graph represents the injection points. 
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5.3.2 Quantitative analysis of PINIT–STAT3 interaction 
Real time interaction analysis of (His)7–PINIT binding to STAT3 was determined by 
injection of varying concentrations of (His)7–PINIT (5 µM to 25 µM) over immobilised 
STAT3 (Figure 5.3A). The chip surface was regenerated by removal of (His)7–PINIT with 
regeneration buffer (10 mM glycine, pH 1.5). Curve fits were performed under the 
assumption of an ABBA   binding model to calculate association kinetics ( A , represents 
the analyte; B , represents the immobilised ligand and AB , represents ligand–analyte 
complexes). The binding responses revealed a concentration dependency for the interaction 
of (His)7–PINIT with STAT3 (Figure 5.3A).  
 
Figure 5.3 SPR analysis of (His)7–PINIT–STAT3 interaction. A) SPR analysis of (His)7–PINIT 
interaction with immobilised STAT3. Representative sensorgrams were obtained by injecting 10 µl of (His)7–
PINIT (5, 10, 15, 20 and 25 µM) at a flow rate of 10 µl/min. B) Linear plot of kobs vs [(His)7–PINIT] allowed for 
determination (see text for details) of kinetic rate and affinity constants, ka (2.97 × 10
3
 ± 268.9 M
–1
.s
–1
) and kd 
(0.046 ± 0.0045.s
–1
) and KD (15.7 ± 0.2 µM). The inset shows that the binding follows 1:1 Langmuir binding 
kinetics after data transformation via Scatchard plot. (adapted from Mautsa et al., 2010). 
108 
 
The apparent affinity constant (KD) for (His)7–PINIT–STAT3 interaction was found to be 
15.7 ± 0.2 µM (n=3) as calculated from ka and kd values obtained from plotting kobs vs 
[(His)7–PINIT] (see Figure 5.3B). Linear transformation of data and analysis via Scatchard 
plot (see Figure 5.3B INSET, Bound/Free vs Bound, where Bound is Req and Free is [(His)7–
PINIT]) confirmed (His)7–PINIT–STAT3 interaction follows 1:1 Langmuir binding kinetics. 
Also, the linear association kinetics and the concentration range of the analyte (His)7–PINIT 
strongly suggest that the simple binding model is applicable to describe the interaction 
between PINIT and STAT3. 
5.3.3 Expression and purification of the (His)7–PINIT mutants  
The PINIT domain mutants were produced to elucidate the function of highly conserved 
residues (L97 and R99). Based on previous knowledge of conserved residues, homology 
modeling, and previous mutational studies (Duval et al., 2003; Levy et al., 2006; Yagil et al., 
2009), mutants of (His)7–PINIT were generated by substitutions as described in the 
methodology (section 5.2.3). Expression studies were performed at the same conditions as the 
(His)7–PINIT protein. (His)7–PINIT–L97A, (His)7–PINIT–R99N and (His)7–PINIT–R99Q 
mutant proteins production in E. coli XL1 Blue [pQE2–PINIT] was evident one hour post 
induction with the maximum expression levels at overnight post induction (Figure 5.4, A–
C). Although the highest expression levels were observed overnight, SDS–resistant higher 
order molecular mass species of (His)7–PINIT were evident on western blot analysis (data not 
shown). Therefore a four hour post induction expression was considered for purification and 
characterisation because single species of (His)7–PINIT protein was observed and the 
expression level was considered sufficient. The expressions of (His)7–PINIT domain mutants 
were consistent with the wild type (His)7–PINIT domain. PINIT domain mutants were 
purified in the same manner as the wildtype PINIT domain by ATP based nickel affinity 
column and a two stage size exclusion chromatography. The size exclusion chromatogram of 
the mutants showed protein elution at 17 to 19 ml elution volume (Appendix B9). Elution 
fractions of individual mutant (His)7–PINIT after the second size exclusion were 
concentrated by Amicon
R
 Ultra Ultracel
R
 (10K) Centrifugal Filters (Millipore, Ireland) and 
analysed by 12% SDS–PAGE (Figure 5.4D). The protein yield of the mutants, cultured in 
one litre of LB broth, respectively, was determined: (His)7–PINIT–L97A, 0.71 mg/litre of 
original culture; (His)7–PINIT–R99N, 0.66 mg/litre of original culture; and (His)7–PINIT–
R99Q, 0.76 mg/litre of original culture. 
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Figure 5.4 Production of recombinant PINIT domain mutants. A) upper panel, 12 % SDS–PAGE gel 
analysis of (His)7–PINIT–L97A containing total protein extracts prepared from E. coli XL1 Blue[pQE2–
PINIT–L97A]: Molecular mass markers are indicated on left hand side M; lane 1, non–induced sample; lanes 2 
– 7, induced samples using IPTG taken hourly; and Lane 8, overnight 16 hours induction sample. Lower panel, 
Western blot analysis of (His)7–PINIT–L97A corresponding to the lanes of the upper panel (His)7–PINIT–L97A 
was detected by western blot analysis using mouse monoclonal anti–His primary antibodies (GE Healthcare) 
and HRP–conjugated anti–mouse secondary antibodies. B) upper panel, 12 % SDS–PAGE gel analysis of 
(His)7–PINIT–R99N containing total protein extracts prepared from E. coli XL1 Blue[pQE2–PINIT–
R99N]: Molecular mass markers are indicated on left hand side M; lane 1, non–induced sample; lanes 2 – 7, 
induced samples using IPTG taken hourly; and Lane 8, overnight 16 hours induction sample. Lower panel, 
Western blot analysis of (His)7–PINIT–R99N corresponding to the lanes of the upper panel (His)7–PINIT–R99N 
was detected by western blot analysis using mouse monoclonal anti–His primary antibodies (GE Healthcare) 
and HRP–conjugated anti–mouse secondary antibodies. C) upper panel, 12 % SDS–PAGE gel analysis of 
(His)7–PINIT–R99Q containing total protein extracts prepared from E. coli XL1 Blue[pQE2–PINIT–
R99Q]: Molecular mass markers are indicated on left hand side M; lane 1, non–induced sample; lanes 2 – 7, 
induced samples using IPTG taken hourly; and Lane 8, overnight 16 hours induction sample. Lower panel, 
Western blot analysis of (His)7–PINIT–R99Q corresponding to the lanes of the upper panel (His)7–PINIT–R99Q 
was detected by western blot analysis using mouse monoclonal anti–His primary antibodies (GE Healthcare) 
and HRP–conjugated anti–mouse secondary antibodies. D) Upper panel–12 % SDS–PAGE gel analysis of 
purified mutants of (His)7–PINIT: Molecular mass markers are indicated on left hand side M; lane1 (His)7–
PINIT–L97A; lane 2, (His)7–PINIT–R99N; lane 3, (His)7–PINIT–R99Q. Lower panel, Western blot analysis of 
mutants of (His)7–PINIT corresponding to the lanes of the upper panel were detected by western blot analysis 
using mouse monoclonal anti–His primary antibodies (GE Healthcare) and HRP–conjugated anti–mouse 
secondary antibodies. Arrows indicate the position of the mutants of (His)7–PINIT. 
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5.3.4 Structural and folding analysis of mutant (His)7–PINIT proteins by FTIR 
spectroscopy 
FTIR analysis of the mutants (His)7–PINIT in comparison with the wildtype (His)–PINIT 
revealed similar secondary structure features. The percentage areas occupied by specific 
secondary structure features were the same as in all mutants of (His)7–PINIT (Appendix C3), 
furthermore, infrared spectra of the wild type (His)7–PINIT and mutants, ((His)7–PINIT–
L97A, (His)7–PINIT–R99N and (His)7–PINIT–R99Q) (Figure 5.5) revealed similar folds 
and peaks. Assignment of the frequencies showed that the three proteins had similar wave 
numbers and assignments and the percentage area occupied by β–sheets was approximately 
the same (Appendix C2). The data on percentage of areas occupied by the secondary 
structure features did not suggest conformational changes caused by the substitution 
mutations. The FTIR data revealed no shift in areas occupied by β–sheets and α–helices in 
both wildtype PINIT domain and the mutant PINIT domains.  
 
Figure 5.5 Spectra analysis of the mutants (His)7–PINIT. Absorbance spectra comparison of wildtype 
(His)7–PINIT and its mutant derivates. The spectra similarity showed similar fold and secondary structure 
contents between the wildtype and mutants of (His)7–PINIT. All spectra were recorded under the same 
conditions and settings. 
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5.3.5 The importance of L97 and R99 residues of the PINIT domain on PINIT–
STAT3 interactions  
STAT3 was immobilized on the sensor chip and wild type (His)7–PINIT and its mutants were 
passed over the chip at the same concentration (20 µM). Comparison of the response curves 
for the mutant domains versus the wild type domain indicated that there was limited binding 
by PINIT–R99N and PINIT–L97A mutants and no binding, but rather an apparent bulk shift 
response for the PINIT–R99Q mutant (Figure 5.6). Fourier transform infra–red spectroscopy 
indicated that the three mutants and the wild type (His)7–PINIT had superimposable spectra, 
and therefore were structurally similar (Figure 5.5). The in silico analysis of these residues 
showed that the R99 residue was surface exposed (Chapter 2 Figure 2.8C) whereas the L97 
residue was buried in the hydrophobic pocket (Chapter 2 Figure 2.8C). The sequence 
conservation and structural analysis revealed the potential involvement of these residues in 
protein–protein interaction. In vitro analysis of these mutant proteins by SPR revealed that 
these residues were potentially critical for interaction of the PIAS3 PINIT domain with 
STAT3. 
 
Figure 5.6 SPR analysis of the interaction of wildtype (His)7–PINIT and (His)7–PINIT mutants with 
STAT3. SPR analysis of the interaction of wild type (His)7–PINIT and its mutant derivatives (PINIT–R99N, 
PINIT–R99Q and PINIT–L97A) with immobilized STAT3. The curves for a single concentration of the (His)7–
PINIT proteins (20 µM) are shown. The residues L97 and R99 are critical for the ability of the PINIT domain to 
interact with STAT3. 
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5.4 DISCUSSION AND CONCLUSION 
A quantitative assessment of the kinetics of PINIT–STAT3 interaction provided evidence for 
the function of the PINIT domain in the interaction mechanism of PIAS3 with STAT3 
protein. The study showed that biomolecular interaction analysis using SPR was a suitable 
technique for the analytical description of PINIT–STAT3 interaction. The binding kinetics 
observed strongly suggest that the interaction at the sensor surface can be sufficiently 
described by a 1:1 molar interaction model as shown by the Scatchard linear plot (Figure 
5.3B). The SPR analysis confirmed the preliminary evidence of the biochemical function of 
the purified (His)7–PINIT performed by dot blot association assay (Chapter 4). Both 
experiments revealed the concentration dependency of the PINIT–STAT3 interaction. 
Using rational site directed mutagenesis, mutant PINIT proteins were produced, quantified 
and biochemically characterised in the same manner as wild type (His)7–PINIT (Chapter 4). 
The expression of the mutant (His)7–PINIT protein (Figure 5.4) and the yield per litre of 
culture was in the range of 0.6 to 0.7 mg, which was consistent with the wild type (His)7–
PINIT (0.6 mg/litre of culture).  
An investigation of conformational changes in the mutant (His)7–PINIT proteins in aqueous 
solution revealed predominantly β–sheet proteins and peak assignments consistent with that 
of wild type (His)7–PINIT. If there was significant conformational change due to mutation, 
evidence of drastic reduction of the β–sheet content would be detected by change in 
percentage area occupied by the β–sheet. FTIR of the PINIT domain and its mutants in H2O 
environment revealed that the protein had approximately 45 % β–sheet content (Appendix 
C3). Mutations performed were on the loop between the β1 and β2 sheet (Chapter 2. Figure 
2.8C) and spectra analysis showed no effect on the sheet content. Structural analysis (chapter 
2) and FTIR analysis found that the L97A, R99N and R99Q mutations did not disrupt the 
overall tertiary structure of the PINIT domain, suggesting that any functional effects of the 
mutations were not an indirect effect of misfolding. 
SPR analysis of the predicted residues on PINIT–STAT3 interaction revealed that the L97A, 
R99N and R99Q mutations resulted in abrogation of PINIT domain binding to STAT3 
suggesting that L97 and R99 were directly involved in binding. The abrogation of PINIT–
R99N and PINIT–R99Q interaction with STAT3 was possibly due to the reduced bulk and 
lack of charge on the Asn and Gln residues compared to Arg. Loss of functionality for 
PINIT–L97A mutant was possibly due to substitution with Ala, a small residue compared to 
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Leu which resulted in a more compact packing conformation causing a change in orientation 
of the neighbouring R99 residue. 
In silico analysis of the PINIT domain was described in Chapter 2 and revealed that L97 and 
R99 residues were highly conserved and indicated potential importance in PIAS3 structure 
and function contributed to PINIT–STAT3 interaction. Furthermore, the homology model of 
the PINIT domain showed that the positively charged R99 residue of the PINIT domain was 
predicted to be surface exposed (Chapter 2 Figure 2.8C), and thus potentially able to form 
electrostatic contacts with, as of yet unidentified, negatively charge residues on STAT3.  
Previous mutational studies within the same region, in particular, PIAS3–Y94P mutant 
protein, has been found to not associate with STAT3 (Levy et al., 2006). However, its 
functional effects were probably the result of disruption in secondary structure and hence 
misfolding of PIAS3. The Tyr residue is shown on the β–sheet (Figure 2.8C) and therefore, 
its substitution with Pro may results in secondary structure disruption possible because Pro 
does not fit into the regular part of either helix or sheet structures due to its lack of backbone–
NH.  
PINIT–STAT3 interaction using SPR has been shown for the first time and these data 
validated the previous in vivo findings that the PINIT domain alone can interact with STAT3 
(Levy et al., 2006; Yagil et al., 2009). Furthermore, structure function analysis using point 
mutations suggest that the PINIT domain (PIAS385–272) is potentially a major determinant in 
PIAS3–STAT3 interaction. In particular the N–terminal region β1–loop–β2 region of PINIT 
domain (Chapter 2, Figure 2.8) which was also a major focus by previous researchers.  
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CHAPTER 6 
 
CONCLUSIONS AND FUTURE PROSPECTS 
 
The study attempted to address the knowledge gap of PIAS3–STAT3 interaction. The work 
presented here focused on a previously identified critical domain, PINIT, that was capable of 
performing the same function as the full length PIAS3 and attempted to address an essential 
question of the requirements of the PIAS3 interface for PIAS3–STAT3 interaction. This 
chapter critically discusses the in silico; in vivo and in vitro findings of PIAS3–STAT3 
interaction described in previous chapters and suggests future prospects for study.  
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6.1 CONCLUSIONS 
The research findings detailed in this study have for the first time shown the following: a 
PINIT domain homology model based on the PINIT domain structure; the heterologous 
overexpression and purification of a folded functional recombinant PINIT domain; 
biophysical characterisation of the PINIT-STAT3 interactions using SPR; and the mutation of 
some of the residues critical for PINIT-STAT3 interaction and potentially PIAS3-STAT3 
interaction (Mautsa et al., 2010). Furthermore, this study has shown for the first time the 
localisation effect of the critical residues that determine the PINIT-STAT3 interaction on the 
full length PIAS3 and also the localisation effect of the individual domains of PIAS3. 
The work presented here focused on the structural and functional characterisation of PIAS3 
in silico, in vivo and in vitro. In silico PIAS3 analysis and the key findings were used to guide 
the experimental design strategies. In particular, the determination of PINIT domain (M85–
V272) boundaries based on the conserved regions and predicted secondary structure features. 
The predicted PINIT domain homology model showed the orientation of residues in three–
dimensional space. Of particular interest was the N–terminus β–sheet–loop–β–sheet peptide 
(Figure 2.8C) of the generated PINIT domain model. The region was previously suggested 
as the minimum fragment that could perform the same function as the PIAS3 (Levy et al., 
2006; Yagil et al., 2009). Based on the in silico analysis discussed in Chapter 2, L97 and R99 
residues were predicted to be critical for PIAS3 structure and function. It should be noted that 
this prediction was based on the model that was generated using low target–template 
sequence identity (PINIT domain of PIAS3 and Siz1 respectively). Nevertheless, the 
secondary structure prediction showed that the fold was conserved across species, in this case 
mammalian (target) and yeast (template). Also, L97A, R99N and R99Q mutations were 
predicted to have no structural effect on the PINIT domain. Therefore, the model was 
validated and adopted for further in vivo and in vitro structure–function analysis. The in silico 
predictions were first evaluated in vivo using HeLa human cervical cancer cells. The 
localisation effect of individual domains in comparison to the full length was evaluated under 
IL–6 stimulation. PIAS3 was completely localised in the nucleus in all cells while the PINIT 
domain was predominantly perinuclear and nuclear localised in most cells with some in the 
cytoplasm in all cells. The acidic domain was predominantly perinuclear localised in all cells 
and also found in the cytoplasm. Comparison of the localisation differences of full length 
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PIAS3 with PINIT and acidic domains suggested a degree of functional disruption; hinting at 
an undefined or incomplete (i.e. a multidomain NLS) nuclear localisation signal. 
It has been suggested previously that the PINIT motif is necessary for nuclear localisation of 
the PIAS3 protein (Duval et al., 2003). However, the localisation differences of the PIAS3 
and the PINIT domain in HeLa cells (Figure 3.3 and Figure 3.4) suggests that the conserved 
PINIT motif may possibly be critical for structural stability of the PIAS3 protein. Co–
localisation analysis of PIAS3, PINIT and acidic domains with STAT3 suggested good co–
localisation of PIAS3 and PINIT domain with STAT3 compared to acidic domain co–
localisation with STAT3. These findings were not conclusive because only a single cell line 
was used; also, HeLa cells were shown to constitutively express IL–6(Maleczyk et al., 1991, 
Eustace et al., 1993) suggesting autocrine activation of the JAK–STAT3 pathway. Use of an 
IL–6 inducible cell line would allow for a more dynamic picture of PIAS3–STAT3 
association and trafficking as opposed to the largely static results obtained from the HeLa 
cells. Furthermore, it may be necessary to perform the study in a normal cell line in 
comparison to the cancer cell line because of differences in STAT3 regulation and PIAS3 
expression levels.  
Observed differences of localisation between the mutants (PIAS3–L97 and PIAS3–R99) and 
the wildtype PIAS3 suggested possible functional disruption due to the mutations. These 
residues were predicted to be directly involved in PIAS3–STAT3 interaction. The mutations 
potentially resulted in a loss of the non covalent contacts involved in the association of 
PIAS3 with STAT3. However, taken together, the in silico and in vivo findings, suggested the 
necessity to further investigate the PINIT domain and the residues L97 and R99 within the 
PINIT domain. 
Guided by these findings, the main study focused on the heterologous over–production of the 
PINIT domain in a bacterial system. Previous approaches involved production of PIAS3 
peptides in mammalian and yeast cells (Chung et al 1997; Levy et al., 2003; Yagil et al., 
2009; Borghouts et al., 2010). Heterologous over–production of the PINIT domain in 
sufficient quantities allowed application of biophysical techniques to characterise the protein 
in terms of structure and function. Size exclusion chromatography showed that the protein 
existed as a monomer in solution. Although the PINIT domain protein was successful 
expressed, the yield typical for a one litre culture was low due to the number of purification 
stages performed to get a pure protein. Nevertheless, the protein yield was sufficient for the 
biophysical and biochemical functional characterisation. The over–expression was dependent 
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on the (His)7–tag because other tags (GST-tag and His-tag) were attempted with no 
successful over–expression. PIAS3 structural determination by X–ray crystallography or 
NMR spectroscopy was limited by production of the protein, and in this study the production 
of the protein for structural study was limited by the loss of the protein due to rigorous 
purification stages. However, secondary structural content characterisation with FTIR was in 
agreement with the generated PINIT model in that, 66 % of the secondary structures were β–
sheets.  
Preliminary investigation of the purified PINIT domain protein showed that the protein was 
able to bind STAT3 in a specific concentration dependent manner. These findings formed the 
basis for further investigation of the PINIT–STAT3 interaction using SPR and also the 
evaluation of the importance of L97 and R99 residues on PINIT–STAT3 interaction. The 
quantitative assessment of the kinetics from SPR data suggested a strong PINIT–STAT3 
interaction which followed 1:1 Langmuir binding kinetics. This suggested that the PINIT 
domain followed a typical mechanism of a classic biochemical inhibitor, i.e. binding to a 
single site on STAT3. PINIT–L97A, PINIT–R99N and PINIT–R99Q mutants were expressed 
and purified in the same manner as the wildtype PINIT domain. The mutations performed 
were predicted in silico and validated by FTIR to have no apparent structural effect on the 
PINIT domain. Therefore, it was expected that any loss of function was as a result of direct 
involvement of the L97 and R99 residues. The L97 and R99 residues were determined to be 
directly involved in the PIAS3–STAT3 interaction due to abrogation of PINIT–STAT3 
interaction when mutated. 
The research findings in this study, in the context of finding of others (Chung et al., 1997; 
Borghouts et al., 2010), suggested that two separate domains of PIAS3 (PINIT and acidic 
domains) possibly contribute to STAT3 binding. Nevertheless, it has been suggested that 
protein domain contributions to binding are often additive (Prinsloo et al., 2009). But this can 
only be addressed by conducting studies on holo–PIAS3–STAT3. Previous studies showed 
that mutation of the PINIT domain within full–length PIAS3 abrogated PIAS3–STAT3 
interaction (Levy et al., 2006). This evidence was consistent with data from this study and 
also suggests that the PINIT domain is an important determinant of PIAS3–STAT3 
interaction. Furthermore, this study was performed with unphosphorylated monomeric 
STAT3 and provided experimental evidence that the association of the PINIT domain of 
PIAS3 was not dependent on phosphorylation of STAT3. This calls for the evaluation of the 
notion that PIAS3 protein binds to phosphorylated STAT3 and translocates to the nucleus as 
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a complex where it dephosphorylates STAT3 and returns to the cytoplasm (Dabir et al., 
2009).  
The interaction of PIAS3 with STAT3 is critical in the regulation of aberrant activation of 
STAT3. To date, PIAS3 protein or PIAS family member structures have not been determined. 
In silico predictions which depend on the existence of appropriate template structures allow 
for in silico investigation of PIAS3 structure. The existence of the structure was critical to 
guide the design of in vivo and in vitro experiments. These studies were performed using 
generally similar molecular approaches of indirect interaction of PIAS3–STAT3. Also there 
was limited structural analysis and application of in silico tools to analyse PIAS3 structural 
functions. Although mutations performed resulted in loss of PIAS3 function, these mutations 
were based on random conserved residues in the full length PIAS3 rather than based on 
specified individual domains. Hence, various random binding site of PIAS3 were suggested 
by individual researchers (Levy et al., 2006; Yagil et al., 2009; Borghouts et al., 2010). The 
findings in this study could form the basis of chemotherapeutic drug design to inhibit STAT3 
aberrant activation. 
 
6.2 FUTURE PROSPECTS 
If multiple domains of PIAS3 are involved in PIAS3–STAT3 interaction, detailed in vitro and 
in vivo studies on individual domains are required to elucidate the multiple molecular 
determinants of PIAS3 regulation of STAT3. It is important to assess the efficacy of the 
PINIT domain on suppression of STAT3 transcriptional activity in comparison to full length 
PIAS3. Also this would allow for the validation of L97 and R99 residues and the role they 
may play in PIAS3–STAT3 interaction. Furthermore, in vivo analysis of the functional effects 
of mutating L97 and R99 in the negative regulation of STAT3 could be assessed by 
performing luciferase promoter reporter assays. The luciferase reporter plasmid containing 
STAT3 promoter region could be co-transfected with the expression plasmid containing 
either PIAS3, mutant PIAS3 (L97, R99), PINIT or acidic domains and then measure the 
luciferase activity. Furthermore the effect of expression of the mutants PIAS3 and the PINIT 
and acidic domain on the cell cycle could be determined by analysis of DNA content using 
propidium iodide staining (Gazitt and Hu, 1998) and analysis by flow cytometry. These may 
answer questions of the sufficiency of the PINIT domain alone in regulation of STAT3.  
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Although localisation studies performed in the current study have shown a degree of 
perturbation on PIAS3 function by mutation of L97 and R99, immunoprecipitation studies 
could be performed to investigate the extent of the effect of the mutations on the perturbation 
of PIAS3-STAT3 interaction. Localisation studies would be more effective to assess the 
effect mutation or individual domains and PIAS3 full length if stable transfectants were 
generated.  
Also, of interest, would be the comparison of the binding affinity of the phoshorylated and 
unphosphorylated STAT3 for the PINIT domain and full–length PIAS3. For example, 
performing SPR studies using a STAT3 Y705E mutant (i.e. a phospho–mimic) will verify the 
importance of this residue in the PIAS3–STAT3 interaction. When these questions are fully 
addressed and taken together with the knowledge of the PINIT domain binding interface 
shown in this study, it is necessary to investigate the STAT3 binding interface. In silico 
PINIT–STAT3 docking and mutational analysis of STAT3 identified residues using SPR can 
be employed. While the mutational analysis of the PINIT domain have been shown to 
abrogate the PINIT-STAT3 interaction. There are more conserved residues that could be 
mutated to determine the number of PINIT interacting surfaces and assess the importance of 
the L97 and R99 residues in the PINIT-STAT3 interaction. 
Although the expression and purification of the PINIT domain was successful, other 
expression strategies and expression systems (e.g. pET vector system) could be employed in 
order to produce sufficient quantities for structural determination by X-ray crystallography 
and NMR. Co–crystallisation of the PINIT–STAT3 complex to elucidate the complex using 
X–ray crystallography will contribute significantly to the mechanism of interaction, 
potentially revealing distinct contact points. Also, the NMR solution structure of the PINIT 
domain structure would allow for PINIT–STAT3 interaction studies by NMR titration 
experiments. This method will further identify other residues that can potentially interact with 
STAT3 in solution and these residues can be mapped into the PINIT domain model to gain 
insight of their orientation in three-dimensional space.  
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APPENDICES 
APPENDIX A: AMINO ACID AND NUCLEOTIDE NOMENCLATURE 
 
One and three-letter codes were used to represent amino acids, and single letter codes were 
used to represent nucleotides as set forward by the Joint Commission of Biochemical 
Nomenclature (JBNC) of IUPAC (International Union of Pure and Applied Chemistry) and 
the IUBMB (International Union of Biochemistry and Molecular Biology): 
 
NUCLEOTIDE    SINGLE-LETTER CODE 
 
Adenine     A 
Cytosine     C 
Guanine     G 
Thymine     T 
Uracil      U 
Any Nucleotide    (A, C, G, T or U) N 
 
 
AMINO ACID  1-LETTER CODE  3-LETTER CODE    DNA CODONS 
 
Alanine       A    Ala   GCT, GCC, GCA, GCG 
Arginine     R    Arg  CGT, CGC, CGA, CGG, AGA, AGG 
Asparagine     N    Asn   AAT, AAC 
Aspartic acid     D    Asp   GAT, GAC 
Cysteine     C    Cys   TGT, TGC 
Glutamine     Q    Gln   CAA, CAG 
Glutamic acid     E    Glu   GAA, GAG 
Glycine     G     Gly   GGT, GGC, GGA, GGG 
Histidine     H    His   CAT, CAC 
Isoleucine     I    Ile   ATT, ATC, ATA 
Leucine    L    Leu  CTT, CTC, CTA, CTG, TTA, TTG 
Lysine      K    Lys   AAA, AAG 
Methionine     M    Met   ATG 
Phenylalanine     F    Phe   TTT, TTC 
Proline      P    Pro  CCT, CCC, CCA, CCG 
Serine      S       Ser  TCT, TCC, TCA, TCG, AGT, AGC 
Threonine     T    Thr  ACT, ACC, ACA, ACG 
Tryptophan     W    Trp   TGG 
Tyrosine     Y    Tyr   TAT, TAC 
Valine      V    Val  GTT, GTC, GTA, GTG 
Stop      -     -  TAA, TAG, TGA 
Any Amino Acid    X       -      - 
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APPENDIX B: SUPPLEMENTARY FIGURES 
 
 
 
Figure B1 Restriction endonuclease analysis of PINIT and acidic domain constructs. A) Restriction map 
of p513–flag–PINIT. The regions on the plasmids encoding for PINIT domain, the N–terminal flag–tag 
encoding segments are indicated by red. B) Restriction map of p513–flag–Acidic plasmid. The regions on the 
plasmids encoding for Acidic domain and the N–terminal flag–tag encoding segments are indicated. C) 
Ethidium bromide stain of 0.8% TBE agarose gels electrophoresis. Restriction analysis of p513–flag–PINIT 
and p513–flag–Acidic plasmids with NdeI and HindIII restriction enzymes. DNA was loaded on 0.8% TBE 
agarose gel containing ethidium bromide in the following order: Lane1, lambda DNA molecular markers 
digested with PstI; lane 2, a cocktail of PCR amplified fragments encoding for the PINIT and Acidic domains; 
lane 3, p513–flag–Acidic plasmid digested with NdeI and HindIII restriction enzyme; lane 4, p513–flag–PINIT 
plasmid digested with NdeI and HindIII restriction enzyme. The expected sizes of the PINIT and acidic domain 
DNA fragments are 561 and 375 bp respectively. 
 
 
136 
 
 
 
 
 
 
 
Figure B2 Co–localisation analysis of PINIT domain with STAT3 in HeLa cells. A) HeLa cells grown on 
glass cover slips were transiently transfected for 48 hours with a p513–flag–PIAS3 plasmid. Cells were starved 
for 12 hours and stimulated for 30 minutes with IL–6 before fixing as described in section 3.2.3. 
Immunofluorescent labeling was performed with mouse anti–FLAG M2 monoclonal antibodies followed by one 
hour incubation with Alexa Fluor
R
 488 donkey anti–mouse IgG (green). Cell nuclei (blue) were directly labelled 
with Hoescht 33258. The endogenous STAT3 was stained with STAT3 rabbit polyclonal IgG antibodies and 
followed by one hour incubation Alexa Fluor 546 chicken anti–rabbit IgG. The immunofluoresence images were 
captured using a confocal fluorescence microscopy on a laser–scanning Zeiss LSM 510 confocal microscope. 
Merged images were automatically created by merging the green image with nuclei hoescht staining image and 
STAT3 (red) image using Zeiss LSM Image Browser software (Carl Zeiss GmbH Jena). 
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Figure B3 Quantitative co–localisation analysis of the PIAS3, PINIT, and acidic domains and STAT3. 
A) Frequency scatter plots of PIAS3 and STAT3 and the PIAS3–STAT3 scatter plot. PIAS3–STAT3 scatter 
plot, the intensity of a given pixel in PIAS3 (green) image was used as the x–coordinate of the scatter plot and 
the intensity of the corresponding pixel in STAT3 (red) image as the y–coordinate. B) Frequency scatter plots 
of PINIT and STAT3 and the PINIT–STAT3 scatter plot. PINIT–STAT3 scatter plot, The intensity of a 
given pixel in PINIT domain (green) image was used as the x–coordinate of the scatter plot and the intensity of 
the corresponding pixel in STAT3 (red) image as the y–coordinate. C) Frequency scatter plots of Acidic 
domain and STAT3 and the scatter plot of Acidic–STAT3. Acidic–STAT3 scatter plot, The intensity of a 
given pixel in Acidic domain (green) image was used as the x–coordinate of the scatter plot and the intensity of 
the corresponding pixel in STAT3 (red) image as the y–coordinate. D) Comparison of Pearson‟s correlation 
coefficient (Pearson‟s corr. coeff.) calculated for PIAS3, PINIT and Acidic domains. Co–localization results 
shown in a pixel distribution along a straight line whose slope will depend on the fluorescence ratio between the 
two channels and whose spread is quantified by the Pearson‟s correlation coefficient (PCC) which is close to 1 
as red and green channel intensity distributions are linked. Co–localisation analysis was performed using 
MacBiophotonics ImageJ software (MBF–ImageJ; http://www.macbiophotonics.ca). PCC: PIAS3–STAT3 was 
0.638; PINIT–STAT3 was 0.732; Acidic–STAT3 was 0.574. 
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Figure B4 Restriction endonuclease analysis of p513–flag–PIAS3, p513–flag–PIAS3L, pQE2–PIAS3, 
pQE2–PIAS3L. DNA was loaded on 0.8% TBE agarose gel containing ethidium bromide in the following 
order. Lane 1, lambda DNA molecular markers digested with PstI; lane 2, p513–flag–PIAS3 construct digested 
with NdeI and HindIII; lane 3, undigested p513–flag–PIAS3; lane 4, p513–flag–PIAS3 digested with Hind III; 
lane 5, p513–flag–PIAS3L digested with NdeI and HindIII; lane 6, p513–flag–PIAS3L digested with HindIII; 
lane 7, undigested p513–flag–PIAS3L.  
 
 
Figure B4 The plasmid map of the pGEX4T–PINIT–TAA–(His)6. B5 Plasmid rendered using Vector NTI 
Advance
TM
 software package (version 10.3; Invitrogen). The plasmids confer ampicillin resistance to 
transformed E. coli cells as indicated (Amp
R; β–lactamase gene). The position of the PINIT domain between 
NdeI and SalI restriction sites is indicated; the plasmid has a stop codon (TAA) between the PINIT coding 
region and the His–tag coding region. The region encoding the GST tag segments is indicated upstream of the 
PINIT domain coding region and the region encoding for the His-tag is indicated downstream of the PINIT 
domain coding region after the TAA stop codon. The origin of replication (ColE1 origin) is indicated and 
regions coding for LacZ alpha, LacO genes and the thrombin cleavage site are indicated. 
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Figure B6 Western blot analysis of DnaK contaminants in purified (His)7–PINIT protein. Western blot 
analysis of DnaK using mouse anti–DnaK monoclonal antibody and HRP–conjugated goat anti–mouse IgG 
antibodies: lane 1, molecular mass marker; lane 2 first elution batch of (His)7–PINIT; lane 2, second elution 
batch of (His)7–PINIT. The western blot analysis showed multiple species of contaminating DnaK protein in the 
purified (His)7–PINIT. 
 
 
Figure B7 Bradford standard curve for protein concentration determination. Bradford standard curve for 
protein concentation determination prepared using varying BSA concentartion and Bradford reagents. 
Absorbance of the samples was read at 595 nm in a PowerWave
TM
 Microplate spectrophotometer (Biotek). The 
curve is represented by the linear equation: y = 0.0035x – 0.0405; R2 = 0.9885. 
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Figure B8 Size exclusion chromatography of the protein standards. A) gel filtration chromatography 
traces of lysozyme, carbonic anhydrase, BSA, and Blue dextran for standard curve plot to determine the 
molecular mass of the PINIT domain protein. (B) Protein standard curve plot of log molecular weight of the 
proteins in Figure (3A) against their retention volume for (His)7–PINIT molecular mass determination. The 
molecular mass of the (His)7–PINIT peak fraction was found to be approximately 23 kDa.  
 
 
Figure B9 Size exclusion chromatography of PINIT domain mutants. A) Size exclusion chromatography 
of (His)7–PINIT–L97A, (His)7–PINIT–R99N and (His)7–PINIT–R99Q proteins proteins. All mutants were 
eluted at the same elution volumes under the second peak indicated by a bracket. B) Standard curve plot used 
for molecular mass determination of the eluted mutant proteins. The molecular mass of the mutant (His)7–PINIT 
proteins were determied as approximately 23 kDa. C) 12 % SDS–PAGE analysis of the concentrated fractions 
18 and 19 ml of the mutant proteins. M, molecular mass marker; lane 1, (His)7–PINIT–R99N; lane 2, (His)7–
PINIT–L97A; lane 3, (His)7–PINIT–R99Q. 
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Figure B10 Secondary structure analysis of (His)7–PINIT–L97A protein in H2O environment. Amide I 
region infrared spectra of (His)7–PINIT–L97A protein in H2O environment was deconvoluted and the peaks 
fitted with the Gaussian curve Gaussian bands are shown as symmetrical peaks underneath the deconvolved IR 
spectra. The peak wavelength numbers are shown at the on each peak. 
 
 
Figure B11 Secondary structure analysis of (His)7–PINIT–R99N protein in H2O environment. Amide I 
region infrared spectra of (His)7–PINIT–R99N protein in H2O environment was deconvoluted and the peaks 
fitted with the Gaussian curve Gaussian bands are shown as symmetrical peaks underneath the deconvolved IR 
spectra. The peak wavelength numbers are shown at the on each peak. 
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Figure B12 Secondary structure analysis of (His)7–PINIT–R99Q protein in H2O environment. Amide I 
region infrared spectra of (His)7–PINIT–R99Q protein in H2O environment was deconvoluted and the peaks 
fitted with the Gaussian curve Gaussian bands are shown as symmetrical peaks underneath the deconvolved IR 
spectra. The peak wavelength numbers are shown at the on each peak. 
 
 
Figure B14 Size exclusion chromatography of ammonium sulphate purified STAT3β protein. A) Size 
exclusion chromatography of STAT3β protein fraction purified by ammonium sulphate precipitation. Western 
blot analysies to detect STAT3β was performed usisng mouse monoclonal anti-STAT3 IgG antibodies and HRP 
conjugated goat anti-mouse IgG antibodies. B) SDS-PAGE analysis of purified STAT3β and size exclusion 
fractions; molecular mass markers are indicated on the left side; lane 1, STAT3β purified by ammonium 
sulphate precipitation as decdribed in section 4.2.9; line 2–5, fraction 68, 70, 72 and 74 ml respectively 
respectively from the size exclusion column. 
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APPENDIX C:  SUPPLEMENTARY TABLES 
 
Table C1 Deconvoluted amide I band frequencies and assignments to secondary 
structure for protein in D2O and H2O media. Data adapted form Dong et al. (1992); Susi 
et al. (1986). 
 
 
Table C2 Fractional band areas (% Area), frequencies (wave number) and band 
assignments of FTIR Amide I component bands of PINIT mutants; PINIT–L97A, 
PINIT–R99N, PINIT–R99Q and the native PINIT domain protein in H2O. 
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Table C3 Relative content of secondary structures quantified from fractional band 
areas (% Area) of FTIR amide I secondary structure features of the PINIT domain, 
PINIT–L97A, PINIT–R99N and PINIT–R99Q in H2O solution. 
 
  
 β–sheet 
(% Area) 
α–helix 
(% Area) 
PINIT–L97A 45.4 15.3 
PINIT–R99N 45.3 16 
PINIT–R99Q 45.5 17 
PINIT 45.2 16 
145 
 
APPENDIX D: GENERAL EXPERIMENTAL PROCEDURES OF STANDARD 
MOLECULAR BIOLOGY TECHNIQUES 
 
D1: ISOLATION OF PLASMID DNA 
The protocol for isolation of plasmid DNA was adapted from that described QIAprep 
Miniprep handbook (QIAGEN) plasmid isolation kit. In brief, E. coli cells transformed with 
the plasmid of interest were grown overnight at suitable temperature and in 5 ml cultures of 
LB media (1% tryptone, 0.5% yeast extract, 1% NaCl) supplemented with the appropriate 
antibiotic for plasmid selection at concentration of 100 μg/ml. The cells were harvested in a 
microcentrifuge (~17900 x g for 1 minute) and the cell pellet was resuspended in 250 μl of 
resuspension buffer (P1). Lysis buffer 250 μl (LyseBlue reagent P2) was added and mixed by 
inverting the tube 4–6 times, and subsequently 350 μl of neutralisation buffer (N3) was 
added. This was followed by centrifugation ((~17900 x g for 10 minutes) and the supernatant 
was applied to the QIAprep spin column by pipetting and centrifuged for 30–60 seconds and 
discard the flow through. The column was washed with by adding 500 µl of wash buffer (PB) 
and centrifuging for 30–60 seconds and discards the flow–through. The second was 
performed by adding 750 µl buffer (PE) and centrifuging for 30–60 seconds. The flow–
through was discarded and centrifuged for an additional 1 minute to remove residual wash 
buffer. The DNA was eluted in a clean 1.5 ml microcentrifuge tube by adding 50 µl elution 
buffer (EB) or water to the centre of the QIAprep spin column and let it stand for 1 minute 
and centrifuge for 1 minute at ~17900 x g. 
D2: ISOLATION OF ENDOTOXIN FREE PLASMID DNA FROM E. COLI FOR 
TRANSFECTION IN MAMMALIAN CELLS 
The protocol for isolation of endotoxin free plasmid DNA was adapted from that described in 
the GenElute
TM
 Endotoxin–free plasmid Midiprep kit (Sigma Aldrich). In brief, pellet 40 µl 
of overnight recombinant E. coli culture by centrifugation at 5 000 x g. The bacterial pellet 
was resuspended to homogenous with 1.2 ml of resuspension solution. The resuspended cells 
are lysed by adding 1.2 ml of lysis solution and immediately mix the contents by gentle 
inversion 6–8 times. The debris were precipitated by adding 0.8 ml of neutralization solution 
and contents were immediately mixed thoroughly by gentle inversion followed by 
centrifuging at ≥15 000 x g for 15 minutes at 2–8oC. The supernatant was transferred to clean 
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tube. The removal of endotoxin was performed by adding 300 µl of endotoxin removal 
solution to the supernatant and thoroughly mixed by inversion for 1 minute followed by 
incubation on ice for ≥5 minutes; with 1–2 times mixing during the ice incubation. The tube 
was then warmed at 37°C in water bath for 5 minutes followed by centrifugation at 3 000–
5 000 x g for 5 minutes at room temperature. The clear upper phase which contains plasmid 
DNA was transferred to the clean tube and the process repeated. The clear upper phase was 
transferred to a clean tube and 0.8 ml of DNA binding solution was added and mixed 
thoroughly by inversion or by votexing and transferred to a GenElute Midprep binding 
column in a collection tube and centrifuged at 3 000–5 000 x g for 1–2 minutes. The flow 
through was discarded and washed by 2 ml of optional was solution by centrifuging at 3 000–
5 000 x g for 2 minutes followed by a 3 ml was with washing solution concentrate at 3 000–
5 000 x g and discard the flow through and spin for an extra 1 minutes to remove residual 
wash solution. The DNA was eluted by transferring the column to a clean collection tube and 
adding 0.8 ml of pre–warmed (at 65oC) endotoxin–free water directly to the binding filter 
allowing the water to soak for 10 minutes before centrifuging at 3 000–5 000 x g for 3 – 5 
minutes to elute the DNA. 
D3: DNA DIGESTION WITH RESTRICTION ENZYMES 
Plasmid DNA was digested with the appropriate restriction endonuclease(s) for three hours at 
the 37°C in a digestion reaction comprising: 200 – 500 ng of plasmid DNA, 1X restriction 
buffer and 1 – 2 U of restriction endonuclease enzyme and distilled water to a final volume of 
20 μl. The digested DNA was resolved by agarose gel electrophoresis. Restriction buffers for 
single and double restriction enzyme digestions were selected as per the supplier‟s 
recommendations. PstI–digested λDNA marker was prepared by the digestion of 20 μl of 526 
μg.ml–1 λDNA (Promega) for three hours at 37°C in a reaction containing 5 U of PstI 
restriction enzyme (Fermentas), 20 μl of the appropriate 10x restriction enzyme buffer 
(Fermentas) and distilled water to a final volume of 200 μl. The digested λDNA was treated 
with 6x DNA gel loading buffer (0.25% (w/v) bromophenol blue, 30% (v/v) glycerol) for use 
in subsequent agarose gel electrophoresis. 
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D4: AGAROSE GEL ELECTROPHORESIS 
Agarose gels were prepared by melting molecular grade agarose (0.8 % or 1 % (w/v)) in TBE 
Buffer (45 mM Borate, 1 mM EDTA, 45 mM Tris–Cl, pH 8.3) and supplementing ethidium 
bromide to a final concentration of 0.5 μg/ml on cooling prior to casting. DNA samples for 
electrophoresis were treated with 6x DNA gel loading buffer (0.25% (w/v) bromophenol 
blue, 30% (v/v) glycerol) and loaded onto the gel with an appropriate marker of PstI–digested 
λDNA. The samples were resolved at 100 V and visualised under ultra–violet light with a 
Chemidoc Imaging System (Bio–Rad).  
D5: EXTRACTION AND PURIFICATION OF DNA FROM AN AGAROSE GEL 
Resolved DNA fragments were isolated subsequent to agarose gel electrophoresis using the 
Zymoclean Gel DNA recovery kit (ZYMO RESARCH) as per the manufacturer‟s 
instructions. In brief, the DNA fragment of interest was identified by brief exposure to long–
wave UV light, excised from the gel using a sterile razor blade and transferred to a 1.5 ml 
microcentrifuge tube. To the microcentrifuge tube, 3 volumes of ADB buffer to each volume 
of agarose excised from the gel was added and incubated at 55°C for 10 minutes until the gel 
slice was completely dissolved. The melted agarose solution was transferred to a Zymo–spin 
column in a collection tube. This was centrifuged at ≥10 000 x g for 30 – 60 seconds and the 
flow–through was discarded. The column was washed twice with was buffer and centrifuged 
at ≥ 10 000 x g. The flow–through was discarded and centrifuged for an additional 1 minute 
to remove residual wash buffer. Water or elution buffer ≥ 6 µl was added directly to the 
column matrix and placed into a 1.5 ml tube and centrifuged at ≥10 000 x g for 30 – 60 
seconds to elute DNA. 
D6: LIGATION OF DNA FRAGMENTS 
DNA fragments intended for ligation (typically 500 ng of insert fragment to 100 ng of target 
plasmid) were incubated overnight at 4°C in a ligation reaction comprising 1 μl of 10x 
ligation buffer (Roche Applied Sciences), 1 U of T4 DNA Ligase (Roche Applied Sciences) 
and distilled water to a final volume of 10 μl. The ligation reaction was transformed into 
competent E. coli cells. 
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D7: DNA SEQUENCING 
Plasmid DNA was isolated for DNA sequencing using the QiaPrep
R
 Miniprep Kit (Qiagen) 
as per the manufacturer‟s instructions (APPENDIX). Sequencing reactions comprised the 
plasmid DNA (350 ng), 3.2 pmol of primer (forward or reverse primer), 2 μl of 5 x Big DyeR 
Terminator Sequencing Buffer (Big Dye Terminator Cycle Sequencing Kit version 3.1, 
Applied Biosystems), 4 μl of Big Dye Terminator (Applied Biosystems) and distilled water to 
a final volume of 10 μl. Thermal cycling was perfomed in a GeneAmp PCR System 9700 
(version 3.05; Applied Biosystems) as follows: one cycle of denaturation (96 °C, 2 minutes), 
30 cycles of denaturation, annealing and extension (96 °C for 30 seconds, appropriate 
annealing temperature for 30 seconds, and 72°C for 30 seconds) and a final elongation at 
72
o
C for 7 minutes. Purification of the amplification product from unincorporated big dye 
terminators was achieved with Zymo–Spin I TM columns (Zymo Research) as per the 
manufacturer‟s instructions. The DNA was eluted in 15 ul of water and vacumm dried. The 
purified DNA resuspended in Hi–Di buffer for sequencing in ABIPRISM 3100 Genetic 
Analyser (Applied Biosystems, USA) and analysed by capillary electrophoresis. DNA 
sequencing results were analysed using BioEdit Sequence Alignment Editor (version 7.0.4.1). 
D8: DNA CLEAN AND CONCENTRATOR 
DNA cleaning up and concentration was performed using a DNA clean and Concentrator–
5
TM
 kit (ZYMO RESEARCH) as per the manufacturer‟s instructions. In brief, in 1.5 ml 
microcentrifuge tube 2 volumes of DNA binding buffer to each volume of DNA was added 
and mixed briefly by votexing. The mixture is then transferred to a Zymo–spinTM column in a 
collection tube and centrifuged at ≥ 10 000 rpm for 30 seconds and the discard the flow–
through. The column was washed twice with 200 µl Wash buffer, centrifuging at ≥ 10 000 
rpm for 30 seconds. The DNA was eluted by adding 6–10 µl of water directly to the column 
matrix and transfer the column to the 1.5 ml microcentrifuge and centrifuged at ≥ 10 000 rpm 
for 30 seconds to elute the DNA. 
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D9:  NICKEL AFFINITY COLUMN STRIPPING AND RECHARGING 
The column was stripped by washing with at least 5–10 column volumes of stripping buffer 
(20 mM sodium phosphate, 0.5 M NaCl, 50 mM EDTA, pH 7.4) followed by 5 –10 column 
volumes of distilled water before recharging the column. The column is recharged by loading 
0.5 ml or 2.5 ml of 0.1 M NiSO4 in distilled water on HisTrap HP 1 ml and 5 ml column, 
respectively. The column is then washed with 5 column volumes of distilled water and 5 
columns of binding buffer (20 mM sodium phosphate, 0.5 NaCl, 20–40 mM imidazole, pH 
7.4) (to adjust the pH) before storage in 20 % ethanol. 
D10: PREPARATION OF COMPETENT E. COLI CELLS 
The strain of interest was grown overnight at 37°C in 5 ml of LB media (1% tryptone, 0.5% 
yeast extract, 1% NaCl). The resulting overnight culture was diluted into 50 ml of LB media 
to an A600 of 0.1 and allowed to grow until early log phase (A600 of 0.3 – 0.6). The cells were 
harvested by centrifugation at 5000 x g for 5 minutes at 4°C and resuspended in 50 ml of ice–
cold 0.1 M MgCl2 and incubated on ice for 2 minutes. The cells were then pelleted by 
centrifugation as before and resuspended in 25 ml of ice–cold 0.1 M CaCl2 and incubated on 
ice for one hour. The cells were centrifugation as before and resuspended in 5 ml of 0.1 M 
CaCl2 and 5 ml of 30% (v/v) glycerol. The competent cells were aliquoted in 300 µl volumes 
in microcentrifuge tubes and stored at –80°C prior to use. 
D11: TRANSFORMATION OF COMPETENT E. COLI CELLS 
Competent E. coli cells 300 μl were incubated with 100 ng of the plasmid DNA of interest 1–
2 μl of ligation product at 4°C for 30 minutes, followed by heat shock at 42°C for 45 seconds 
and incubation on ice for 5 minutes. The cells were diluted with 700 µl of LB media (1% 
tryptone, 0.5% yeast extract, 1% NaCl) and incubated at 37°C for one hour with shaking. 
Transformed cells are pelleted by centrifugation and dicard the supernatant and resuspend the 
pellet in 100 µl fresh LB media. The bacterial suspension (100 μl) was plated onto 1.5% agar 
in LB media supplemented with the appropriate antibiotics at desired concentration. The 
plates were incubated overnight at 37°C. Transformation controls included a sterile control 
with sterile distilled water replacing the plasmid DNA in the incubation mixture, and a 
competence control with plasmid DNA of known concentration (10 ng of plasmid pUC18; 
Promega) transformed into the E. coli cells.  
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D12: PROTEIN CONCENTRATION DETERMINATION BY BRADFORD’S 
ASSAY 
Protein concentration determination was performed by Bradford‟s assay (Bradford, 1976). A 
volume of 200 μl of Bradford‟s reagent (Bio–Rad; diluted 1:4 with distilled water) was added 
to 10 μl of undiluted, 1:10 and 1:100 diluted protein samples of unknown concentration. 
Following incubation at room temperature for 10 minutes, the Absorbance of the samples was 
read at 595 nm in a PowerWave
TM
 Microplate spectrophotometer (Biotek). Protein 
concentration was determined with the corresponding 0 – 250 μg.ml–1 Bovine Serum  
D13: BRADFORD ASSAY FOR PROTEIN CONCENTRATION 
DETERMINATION 
Protein concentrations were determined by Bradford assay method (Bradford 1976). Bovine 
serum albumen (BSA) was used as the standard contain a range of 20 to 300 µg/ml 
concentration to volume of 100 µl and 100 µl of Bradford reagent was added the protein 
samples were prepared in the same manner. Standards were prepared in triplicate and 
incubated at room temperature for 5 minutes and absorbance was read at 595 nm using a 
PowerWave (PowerWave
TM
 Microplate spectrophotometer (Biotek)).  
D14: SDS–PAGE 
Protein samples were treated with 5x SDS–PAGE sample buffer (10% glycerol, 2% SDS, 5% 
β–mercaptoethanol, 0.05% bromophenol blue, 0.0625 M Tris, pH 6.8) in a ratio of 4:1 
respectively and loaded onto a polyacrylamide gel constituted by a resolving gel (10–12% 
(w/v) acrylamide, 0.1% (w/v) SDS, 0.05% (w/v) ammonium persulphate (APS), 0.005% 
(v/v) N,N,N‟,N‟–tetramethylethylenediamine (TEMED), 0.375 M Tris, pH 8.8) and a 
stacking gel (4% (w/v) acrylamide, 0.1% (w/v) SDS, 0.05% (w/v) APS, 0.005% (v/v) 
TEMED, 0.125 M Tris, pH 6.8). The gel was resolved in a Mini Protean
R
 II system (Bio–
Rad) at 160 V for one hour and stained or used for Western blot analysis. Staining of the 
SDS–PAGE gel was performed using Coomassie Blue stain (40% (v/v) methanol, 7% (v/v) 
acetic acid, 0.25% (w/v) Coomassie Blue R250 in distilled water) for one hour and destained 
for two hours using destaining solution (40% (v/v) methanol, 7% (v/v) acetic acid in distilled 
water).  
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D15: PROTEIN DETECTION BY WESTERN BLOT ANALYSIS 
The protocol for the detection of proteins by Western blot analysis was adapted from 
Amersham ECL Advanced Western blotting detection Kit (GE Healthcare). Proteins were 
resolved by SDS–PAGE and transferred onto nitrocellulose membrane (Hybond C–extra; GE 
Healthcare) in transfer buffer (20% (v/v) methanol, 192 mM glycine, 25 mM Tris) at 100 V 
for two hours in a PowerPack western transfer blotting system (BioRad). Protein transfer was 
verified with Ponceau stain; (0.5 % (w/v) Ponceau, 1% (v/v) glacial acetic acid). The 
membrane was subsequently destained with distilled water and blocked overnight at 4°C in 
blocking solution (5% (w/v) fat–free milk powder in Tris Buffered Saline (TBS; 50 mM Tris, 
150 mM NaCl, pH 7.5). The membrane was incubated with appropriate primary antibody (at 
desired dilution ration ranging from 1: 500–5 000) for one hour at room temperature or 
overnight at 4
o
C. The membrane was washed three times with Tris Buffered Saline–Tween 
buffer (TBS–T; TBS containing 0.1% (v/v) Tween 20) and incubated with the appropriate 
horse–radish peroxidise (HRP)–conjugated secondary antibody (1:5000 in blocking solution) 
for one hour at room temperature and washed three times for 15 minutes each wash with 
TBS–T. The protein was detected by chemiluminescence–based protein detection ECL 
Western blotting kit (GE Healthcare) following manufacturer‟s instructions, and images were 
captured with a Chemidoc chemiluminescence imaging system (BioRad, UK). 
D16: MEMBRANE STRIPPING AND REPROBING 
The protocol for membrane stripping and reprobing for proteins by Western blot analysis was 
adapted from Amersham ECL Advanced Western blotting detection Kit (GE Healthcare). In 
brief, the membrane is submerged in stripping buffer (100 mM 2–mercaptoethanol, 2 % (w/v) 
SDS, 62.5 mM Tris–HCl pH 6.7) and incubates at 50oC for 30 minutes with occasional 
agitation. The membrane was washed twice for 10 minutes in PBS–T (1 M Tris HCl, pH 7.6; 
100 mM NaCl, 0.1 % (v/v) Tween 20) at room temperature. The membrane was blocked in 
blocking solution (5 % (w/v) no–fat powder milk and PBS–T) for one hour at room 
temperature. The immunodetection was carried on as described in Appendix C14. 
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APPENDIX E:  LIST OF MATERIALS AND SPECIALISED REAGENTS 
 
 
ANTIBODIES      SUPPLIER 
Alexa Fluor
R
 488 donkey anti–mouse   Invitrogen, USA 
Alexa Fluor
R
 488 chicken anti–rabbit  Invitrogen, USA 
Alexa Fluor
R
 546 donkey anti–mouse  Invitrogen, USA 
HRP–goat anti–mouse IgG    GE Healthcare, UK    
HRP–conjugated sheep anti–mouse    GE Healthcare, UK 
HRP–conjugated donkey anti–rabbit    GE Healthcare, UK 
Mouse anti–GST monoclonal antibody  Santa Cruz biotechnology, USA 
Mouse anti–FLAG M2 monoclonal antibodies Sigma–Aldrich, USA 
Mouse monoclonal anti–His primary antibody GE Healthcare, UK 
Mouse Anti–DnaK Monoclonal Antibody  Sigma–Aldrich, USA 
mouse monoclonal ant-PIAS3 IgG   Santa Cruz biotechnology, USA 
mouse monoclonal anti-STAT3 IgG antibody Santa Cruz biotechnology, USA 
rabbit polyclonal anti-STAT3 IgG   Santa Cruz biotechnology, USA 
 
 
REAGENT       SUPPLIER 
β–mercaptoethanol      Merck, Germany 
λDNA        Promega, USA 
Acetic Acid       Saarchem, South Africa 
Adenosine triphosphate (disodium salt)   Sigma–Aldrich, USA 
Agar (Bacteriological)     Biolab Diagnostics, South Africa 
Agarose       Hispanagar, Spain 
Ammonium per sulphate     Saarchem, South Africa 
Ampicillin       Fisher Scientific, UK 
30% Bis–Acrylamide      Bio–Rad, US 
Bovine Serum Albumin     Sigma–Aldrich, USA 
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Boric Acid       Saarchem, South Africa 
Bradford‟s Reagent      Bio–Rad, USA 
Bromophenol Blue      Sigma–Aldrich, Germany 
Calcium chloride      Saarchem, South Africa 
Amicon
R
 Ultra Ultracel
R
 Centrifugal Filters   Millipore, Ireland    
Coomassie Brilliant Blue R250    Sigma–Aldrich, Germany 
Hoescht       Invitrogen, USA 
dNTP mix       Roche Applied Sciences, Germany 
EDTA, sodium salt      Saarchem, South Africa 
Ethanol       Saarchem, South Africa 
Ethidium bromide      Sigma–Aldrich, Germany 
Glacial acetic acid      Saarchem, South Africa 
Glycerol       EMD Chemicals, USA 
 
REAGENT        SUPPLIER 
Glycine       Sigma–Aldrich, Germany 
HEPES       Fisher Scientific, UK 
Hybond C–extra      GE Healthcare, UK 
Hydrochloric Acid      Saarchem, South Africa 
Imidazole       Sigma–Aldrich, Germany 
Isopropyl–1–thio–β–D–galactopyranoside   Roche Applied Sciences, Germany 
Kanamycin sulphate      Roche Applied Sciences, Germany 
Lysozyme       Sigma–Aldrich, USA 
Methanol       Saarchem, South Africa 
Pepstatin A       Sigma–Aldrich, USA 
Phenylmethylsulphonyl fluoride (PMSF)   Sigma–Aldrich, USA 
Polyacrylamide      Bio–Rad, USA 
Ponceau S       Sigma–Aldrich, Germany 
Potassium chloride (KCl)     Saarchem, South Africa 
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Potassium hydroxide (KOH)     Saarchem, South Africa 
Potassium phosphate (K2HPO4)    Merck, Germany 
Potassium dihydrogen phosphate (KH2PO4)   Merck, Germany 
Protein A/G PLUS Agarose     Santa Cruz Biotechnology, USA 
 
REAGENT        SUPPLIER 
Q–Sepharose Fast FlowTM     Sigma–Aldrich, USA 
Sepharose Fast Flow
TM
     GE Healthcare, UK 
Sodium chloride (NaCl)     Saarchem, South Africa 
Sodium dodecyl sulphate (SDS)    Sigma–Aldrich, USA 
Sodium phosphate (NaH2PO4 / Na2HPO4)   Saarchem, South Africa 
Sodium hydroxide (NaOH)     Saarchem, South Africa 
Snakeskin
TM
 dialysis tubing     Thermo Scientific, USA 
TEMED (N,N,N‟,N‟–tetramethylethylenediamine)  Sigma–Aldrich, Germany 
Tris (Tris–2–amino–2–hydroxymethyl–1,3–propanol) Sigma–Aldrich, Germany 
Tryptone       Oxoid, UK 
Tween 20       Saarchem, South Africa 
Urea        Sigma–Aldrich, Germany 
Yeast extract       Oxoid, UK 
 
RESTRICTION ENZYMES    SUPPLIER 
BamHI        Fermentas, Lithuania 
BglII         Promega, USA 
DpnI         Promega, USA 
HindIII        Fermentas, Lithuania 
Nde I         Promega, USA 
NheI         GE Healthcare, UK 
PstI         Fermentas, Lithuania 
SalI         Fermentas, Lithuania 
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E. COLI STRAINS      SUPPLIER 
E. coli BL21(DE3)      Promega, USA 
E. coli JM109       Promega, UK 
E. coli Rosetta
 
      Novagen, USA 
E. coli XL1–Blue       Stratagene, USA 
E. coli M15[pREP4]       Qiagen (USA)  
 
PLASMIDS       SUPPLIER 
pGEM–T EasyR       Promega, USA 
pQE2        Qiagen, USA 
pQE60        Qiagen, USA 
pGEX4T–N1       Promega, USA 
 
ENZYMES       SUPPLIER 
Expand High Fidelity Taq Polymerase   Roche Applied Sciences, Germany 
10x Buffer       Roche Applied Sciences, Germany 
T4 DNA Ligase      Roche Applied Sciences, Germany 
Ligation buffer     Roche Applied Sciences, Germany 
Pfu Dna Polymerase and 10x Buffer    Promega, USA 
 
COMMERCIAL KITS     SUPPLIER 
Big Dye
TM
 Terminator Cycle Sequencing Kit  Applied Biosciences, UK 
ECL Western Blotting Kit     GE Healthcare, UK 
Zymoclean
TM
 Gel DNA Recovery Kit   Zymo Research,USA 
DNA Clean & Concentrator–5TM   Zymo Research, USA 
GenElute
TM
 Endotoxin–free Plsmid MidiPrep Kit Sigma–Aldrich, USA 
QIAPrep
R
 Miniprep Kit     Qiagen, USA 
HisTrap HP      GE Healthcare, UK 
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PROTEIN MARKERS    SUPPLIER 
Pageruler
TM
 Protein Ladder     Fermentas, USA 
Protein marker II peqGold    Fermentas, USA 
Protein marker IV pre–stained   Invitrogen, USA 
 PRIMERS 
All primers were synthesised by :Integrated DNA Technologies (IDT, USA) through 
WhiteSci, South Africa. 
:Inqaba Biotechnology, South Africa  
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APPENDIX F: WEB BASED BIOINFORMATICS ANALYSIS TOOLS AND 
PYTHON SCRIPTS. 
 
F1: WEB BASED BIOINFORMATIC ANALYSIS TOOLS 
http://expasy.org/tools/pi_tool.html– Compute the theoretical isoelectric point (pI) and 
molecular weight (Mw) from a UniProt Knowledgebase entry or 
for a user sequence 
http://blast.ncbi.nlm.nih.gov/Blast.cgi– Search protein database using a protein query 
Algorithms: blastp, psi–blast, phi–blast 
http://toolkit.tuebingen.mpg.de/hhpred– Homology detection & structure prediction by 
HMM–HMM comparison 
http://toolkit.tuebingen.mpg.de/clustalw– ClustalW is a general purpose multiple 
alignment program for DNA or proteins. 
http://bioinf.cs.ucl.ac.uk/psipred/psiform.html– Secondary structure prediction using 
neural networks. PSIPRED is one of the most popular and accurate 
methods around.  
http://toolkit.tuebingen.mpg.de/psi_blast– Search with an amino acid sequence against 
protein databases for locally similar sequences 
https://genesilico.pl/toolkit/unimod?method=MetaMQAPII– MetaMQAPII is a 
metaserver for quality assessment of protein structures optimized 
for theoretical models 
https://genesilico.pl/toolkit/unimod?method=Verify3D– David Eisenberg's Verify3D 
method for the assessment of protein models with three–
dimensional profiles." 
https://genesilico.pl/toolkit/unimod?method=Prosa– Knowladge based mean fields based 
method.  
http://www.pymol.org/– a highly extensible program for interactive visualization and 
analysis of molecular structures 
http://www.cgl.ucsf.edu/chimera/– UCSF Chimera is a highly extensible program for 
interactive visualization and analysis of molecular structures 
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F2: PYTHON SCRIPT USED IN MODELLER 9V3 
 
Python script to generate 100 models from the template structure  
 
# Homology modeling by the automodel class 
 
from modeller.automodel import *  # Load the automodel class 
 
log.verbose()     # request verbose output 
env = environ()# create a new MODELLER environment to build this model in 
 
# directories for input atom files 
env.io.atom_files_directory = './:./atom_files' 
 
 
a = automodel(env, 
 alnfile = 'alignment_hhpred.pir',     # alignment filename 
 knowns = ('3i2D'), # codes of the templates 
  sequence = 'PIAS3_PINIT_domain', assess_methods=(assess.DOPE, 
assess.GA341)) # code of the target 
a.starting_model= 1 # index of the first model  
a.ending_model = 100 # index of the last model 
 # (determines how many models to calculate) 
a.final_malign3d = True    # generate superimposed templatesand 
model (*_fit.pdb files) 
a.make() # do the actual homology modeling 
ok_models = filter(lambda x: x['failure'] is None, a.outputs)   
 # Get a list of all successfully built models from a.outputs 
key = 'DOPE score'    # Rank the models by DOPE score 
ok_models.sort(lambda a,b: cmp(a[key], b[key])) 
m = ok_models[0]     # Get top model 
print "1st top model: %s (DOPE score %.3f)" % (m['name'], m[key]) 
ms = ok_models[1]   # Get 2nd top model 
print "2nd top model: %s (DOPE score %.3f)" % (ms['name'], ms[key]) 
mss = ok_models[2]    # Get 3rd top model 
print "3rd top model: %s (DOPE score %.3f)" % (mss['name'], mss[key]) 
 
 
Python script to calculate Zdope scores 
import subprocess 
 
ofile = open("zdope_scores.txt","w") 
ofile.write("z–DOPE–score filename\n") 
ofile.close() 
models = [] 
for model in open("modellist").readlines(): 
 models.append(model.strip()) 
for model in models: 
 subprocess.call("mod9v7 zdope_single.py "+model,shell=True) 
 subprocess.call("mv zdope_single.log zdope."+model[:–4],shell=True) 
exit 
#print models 
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Python script to sort the calculated Zdope scores  
 
ifile=open("zdope_scores.txt") 
lines = ifile.readlines() 
ifile.close() 
scores = [] 
for line in lines: 
 scores.append(line.rsplit()) 
 
scores.sort() 
ofile=open("sorted_zdope_scores.csv","w") 
for line in scores: 
 ofile.write(str(line[0])+","+line[1]+",\n") 
 
 
Python script for loop refinement of the existing model 
# Loop refinement of an existing model 
from modeller import * 
from modeller.automodel import * 
 
log.verbose() 
env = environ() 
 
# directories for input atom files 
env.io.atom_files_directory = 'Model_HHpred' 
 
# Create a new class based on 'loopmodel' so that we can redefine 
# select_loop_atoms (necessary) 
class MyLoop(loopmodel): 
 # This routine picks the residues to be refined by loop modeling 
 def select_loop_atoms(self): 
 # 10 residue insertion  
 return selection(self.residue_range('70', '79')) 
 
m = MyLoop(env, 
 inimodel='PIAS3_PINIT_domain.B99990046.pdb', # initial model of the 
target 
 sequence='PINIT_46') # code of the target 
 
m.loop.starting_model= 1 # index of the first loop model  
m.loop.ending_model = 50 # index of the last loop model 
m.loop.md_level = refine.very_slow # loop refinement method; this 
yields 
 # models quickly but of low quality; 
 # use refine.slow for better models 
 
m.make() 
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APPENDIX G: PROTEIN AND NUCLEOTIDE SEQUENCES 
 
G1: NUCLEOTIDE SEQUENCES  
>PIAS3 coding sequence  
ATGGCGGAACTGGGCGAACTGAAACATATGGTGATGAGCTTTCGCGTGAGCGAACTGCAGGTGCTGCT
GGGCTTTGCGGGCCGCAACAAAAGCGGCCGCAAACATGAACTGCTGGCGAAAGCGCTGCATCTGCTGA
AAAGCAGCTGCGCGCCGAGCGTGCAGATGAAAATTAAAGAACTGTATCGCCGCCGCTTTCCGCGCAAA
ACCCTGGGCCCGAGCGATCTGAGCCTGCTGAGCCTGCCGCCGGGCACCAGCCCGGTGGGCAGCCCGGG
CCCGCTGGCGCCGATTCCGCCGACCCTGCTGACCCCGGGCACCCTGCTGGGCCCGAAACGCGAAGTGG
ATATGCATCCGCCGCTGCCGCAGCCGGTGCATCCGGATGTGACCATGAAACCGCTGCCGTTTTATGAA
GTGTATGGCGAACTGATTCGCCCGACCACCCTGGCGAGCACCAGCAGCCAGCGCTTTGAAGAAGCGCA
TTTTACCTTTGCGCTGACCCCGCAGCAGCTGCAGCAGATTCTGACCAGCCGCGAAGTGCTGCCGGGCG
CGAAATGCGATTATACCATTCAGGTGCAGCTGCGCTTTTGCCTGTGCGAAACCAGCTGCCCGCAGGAA
GATTATTTTCCGCCGAACCTGTTTGTGAAAGTGAACGGCAAACTGTGCCCGCTGCCGGGCTATCTGCC
GCCGACCAAAAACGGCGCGGAACCGAAACGCCCGAGCCGCCCGATTAACATTACCCCGCTGGCGCGCC
TGAGCGCGACCGTGCCGAACACCATTGTGGTGAACTGGAGCAGCGAATTTGGCCGCAACTATAGCCTG
AGCGTGTATCTGGTGCGCCAGCTGACCGCGGGCACCCTGCTGCAGAAACTGCGCGCGAAAGGCATTCG
CAACCCGGATCATAGCCGCGCGCTGATTAAAGAAAAACTGACCGCGGATCCGGATAGCGAAGTGGCGA
CCACCAGCCTGCGCGTGAGCCTGATGTGCCCGCTGGGCAAAATGCGCCTGACCGTGCCGTGCCGCGCG
CTGACCTGCGCGCATCTGCAGAGCTTTGATGCGGCGCTGTATCTGCAGATGAACGAAAAAAAACCGAC
CTGGACCTGCCCGGTGTGCGATAAAAAAGCGCCGTATGAAAGCCTGATTATTGATGGCCTGTTTATGG
AAATTCTGAACAGCTGCAGCGATTGCGATGAAATTCAGTTTATGGAAGATGGCAGCTGGTGCCCGATG
AAACCGAAAAAAGAAGCGAGCGAAGTGTGCCCGCCGCCGGGCTATGGCCTGGATGGCCTGCAGTATAG
CGCGGTGCAGGAAGGCATTCAGCCGGAAAGCAAAAAACGCGTGGAAGTGATTGATCTGACCATTGAAA
GCAGCAGCGATGAAGAAGATCTGCCGCCGACCAAAAAACATTGCCCGGTGACCAGCGCGGCGATTCCG
GCGCTGCCGGGCAGCAAAGGCGCGCTGACCAGCGGCCATCAGCCGAGCAGCGTGCTGCGCAGCCCGGC
GATGGGCACCCTGGGCAGCGATTTTCTGAGCAGCCTGCCGCTGCATGAATATCCGCCGGCGTTTCCGC
TGGGCGCGGATATTCAGGGCCTGGATCTGTTTAGCTTTCTGCAGACCGAAAGCCAGCATTATGGCCCG
AGCGTGATTACCAGCCTGGATGAACAGGATACCCTGGGCCATTTTTTTCAGTATCGCGGCACCCCGAG
CCATTTTCTGGGCCCGCTGGCGCCGACCCTGGGCAGCAGCCATCGCAGCAGCACCCCGGCGCCGCCGC
CGGGCCGCGTGAGCAGCATTGTGGCGCCGGGCAGCAGCCTGCGCGAAGGCCATGGCGGCCCGCTGCCG
AGCGGCCCGAGCCTGACCGGCTGCCGCAGCGATGTGATTAGCCTGGAT 
 
>PINIT domain coding sequence (PIAS3) 
ATGAAACCGCTGCCGTTTTATGAAGTGTATGGCGAACTGATTCGCCCGACCACCCTGGCGAGCACCAG
CAGCCAGCGCTTTGAAGAAGCGCATTTTACCTTTGCGCTGACCCCGCAGCAGCTGCAGCAGATTCTGA
CCAGCCGCGAAGTGCTGCCGGGCGCGAAATGCGATTATACCATTCAGGTGCAGCTGCGCTTTTGCCTG
TGCGAAACCAGCTGCCCGCAGGAAGATTATTTTCCGCCGAACCTGTTTGTGAAAGTGAACGGCAAACT
GTGCCCGCTGCCGGGCTATCTGCCGCCGACCAAAAACGGCGCGGAACCGAAACGCCCGAGCCGCCCGA
TTAACATTACCCCGCTGGCGCGCCTGAGCGCGACCGTGCCGAACACCATTGTGGTGAACTGGAGCAGC
GAATTTGGCCGCAACTATAGCCTGAGCGTGTATCTGGTGCGCCAGCTGACCGCGGGCACCCTGCTGCA
GAAACTGCGCGCGAAAGGCATTCGCAACCCGGATCATAGCCGCGCGCTGATTAAAGAAAAACTGACCG
CGGATCCGGATAGCGAAGTG 
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>Acidic domain coding sequence (PIAS3) 
ATGGAAGATGGCAGCTGGTGCCCGATGAAACCGAAAAAAGAAGCGAGCGAAGTGTGCCCGCCGCCGGG
CTATGGCCTGGATGGCCTGCAGTATAGCGCGGTGCAGGAAGGCATTCAGCCGGAAAGCAAAAAACGCG
TGGAAGTGATTGATCTGACCATTGAAAGCAGCAGCGATGAAGAAGATCTGCCGCCGACCAAAAAACAT
TGCCCGGTGACCAGCGCGGCGATTCCGGCGCTGCCGGGCAGCAAAGGCGCGCTGACCAGCGGCCATCA
GCCGAGCAGCGTGCTGCGCAGCCCGGCGATGGGCACCCTGGGCAGCGATTTTCTGAGCAGCCTGCCGC
TGCATGAATATCCG 
 
G2: PROTEIN SEQUENCES  
>PIAS3 mouse 
MAELGELKHMVMSFRVSELQVLLGFAGRNKSGRKHELLAKALHLLKSSCAPSVQMKIKEL 
YRRRFPRKTLGPSDLSLLSLPPGTSPVGSPGPLAPIPPTLLTPGTLLGPKREVDMHPPLP 
QPVHPDVTMKPLPFYEVYGELIRPTTLASTSSQRFEEAHFTFALTPQQLQQILTSREVLP 
GAKCDYTIQVQLRFCLCETSCPQEDYFPPNLFVKVNGKLCPLPGYLPPTKNGAEPKRPSR 
PINITPLARLSATVPNTIVVNWSSEFGRNYSLSVYLVRQLTAGTLLQKLRAKGIRNPDHS 
RALIKEKLTADPDSEVATTSLRVSLMCPLGKMRLTVPCRALTCAHLQSFDAALYLQMNEK 
KPTWTCPVCDKKAPYESLIIDGLFMEILNSCSDCDEIQFMEDGSWCPMKPKKEASEVCPP 
PGYGLDGLQYSAVQEGIQPESKKRVEVIDLTIESSSDEEDLPPTKKHCPVTSAAIPALPG 
SKGALTSGHQPSSVLRSPAMGTLGSDFLSSLPLHEYPPAFPLGADIQGLDLFSFLQTESQ 
HYGPSVITSLDEQDTLGHFFQYRGTPSHFLGPLAPTLGSSHRSSTPAPPPGRVSSIVAPG 
SSLREGHGGPLPSGPSLTGCRSDVISLD 
 
> PINIT domain (PIAS3)  
MKPLPFYEVYGELIRPTTLASTSSQRFEEAHFTFALTPQQLQQILTSREVLPGAKCDYTIQVQLRFCL
CETSCPQEDYFPPNLFVKVNGKLCPLPGYLPPTKNGAEPKRPSRPINITPLARLSATVPNTIVVNWSS
EFGRNYSLSVYLVRQLTAGTLLQKLRAKGIRNPDHSRALIKEKLTADPDSEV 
 
>Acidic domain (PIAS3) 
MEDGSWCPMKPKKEASEVCPPPGYGLDGLQYSAVQEGIQPESKKRVEVIDLTIESSSDEEDLPPTKKH
CPVTSAAIPALPGSKGALTSGHQPSSVLRSPAMGTLGSDFLSSLPLHEYP 
> PINIT domain (Siz1) 
FAVPTIHFKESPFYKIQRLIPELVMNVEVTGGRGMCSAKFKLSKADYNLLSNPNSKHRLYLFSGMINP
LGSRGNEPIQFPFPNELRCNNVQIKDNIRGFKSKPGTAKPADLTPHLKPYTQQNNVELIYAFTTKEYK
LFGYIVEMI 
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APPENDIX H:  SEQUENCES OF PRIMERS USED IN PCR, MUTAGENESIS, 
AND DNA SEQUENCING 
 
H1: PCR PRIMERS USED TO AMPLIFY THE PIAS3 DOMAINS CODING SEQUENCE 
VECTOR DOMAIN PRIMER NAME    SEQUENCE (5’ TO 3’) 
pQE2  PINIT  PIAS3_132_F   CATATGAAGCCCCTGCCCTTC 
pQE2  PINIT  PIAS3_132–R  AAGCTTATTACACTTCACTGTCGGGGTC 
pGEX4T PINIT  pGEX4T–PINIT–F CATATGAAGCCCCT CCCTTCTA GAAGTCTATGGG 
pGEX4T PINIT  pGEX4T–PINIT–R GTCGACTTAGTGATGGTGATGGTGATGCACTTCACTG 
pQE60   PINIT  pQE60–PINIT–F CCATGGAGCCCCTGCCCTTCTATG 
pQE60  PINIT  pQE60–PINIT–R AGATCTTCACTGTCGGGGTCAGCGG 
pEGFP–PIAS3  EGF–PIAS3–F   GCTAGCATGGCGGAGCTG  
pEGFP–PIAS3  EGFP–PIAS3–R   GACGTCATTTCCTTGGACAAGCTT   
pEGFP–PINIT  PINIT–F  GCTAGCATGAAGCCACTGCC 
pEGFP–PINIT  PINIT–R   CCCCGACAGTGAAGTGAAGCT T 
p513–flag –acidic PIAS3–C–F  CATATGGAAGATGGATCCTGGTGTC 
p513–flag-acidic PIAS3–C–R  AAGCTTTAAGCCCCCAGTGG   
 
H2: PRIMERS USED IN MUTAGENESIS 
MUTATION   PRIMER PRIMER NAME   PRIMER SEQUENCE (5’ to 3’) 
PIAS3 R99Q Sense  R99Q-sense   GGGGAGCTCATCCAACCCACCACCCTT 
 Antisense    R99Q-antisense    AAGGGTGGTGGGTTGGATGAGCTCCCC 
PIAS3 R99N Sense  R99N-sense    TCTATGGGGAGCTCATCAATCCCACCACCCTTGCGTC 
 Antisense    R99N-antisense   GACGCAAGGGTGGTGGGATTGATGAGCTCCCCATAGA 
PIAS3 L97A Sense  L97A-sense   GAAGTCTATGGGGAGGCCATCCGACCCACCAC 
  Antisense   L97A-antisense    GTGGTGGGTCGGATGGCCTCCCCATAGACTTC 
PINIT-TAA-(His)6 Sense  PINIT-TAA-F   CCCCGACAGTGAAGTGTAACATCACCATCACCATC 
  Antisense    PINIT-TAA-R    GATGGTGATGGTGATGTTACACTTCACTGTCGGGG 
(P513-flag)NdeI Sense  p513-NdeI-sense    CCATTTCCTTGGACCATATGTAAGCTTCCTAGGTC 
   Antisense  p513-NdeI-anti   GACCTAGGAAGCTTACATATGGTCCAAGGAAATGG 
163 
 
 
H3: PRIMERS USED IN DNA SEQUENSES 
TARGET PRIMER NAME   PRIMER SEQUENCE (5’ to 3’) 
pQE2  pQE2–F    CCCGAAAAGTGCCACC 
pQE2  pQE2–R    TTAGCTCCTGAAAATCTCG 
pQE60  pQE60–F   GACCGCTGACCCCGACAGTAGATCTCATCA 
PQE60  pQE60–R   TGATGAGATCTACTGTCGGGGTCAGCGGTC 
p513  p513–PIAS3–F   GCATTGTGGCTCCTGGGAGC 
p513–flag p513–flag–F   CCT CTG CTA ACC ATG TTC ATG CC 
 
    
